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1.1. English Summary 
 
Background: Ten years ago, stage IV melanoma carried a dismal prognosis, with very 
short survival. The therapies available then, namely dacarbazine, temozolomide, and 
other chemotherapies, alone or in combination with surgery and/or radiotherapy, were 
unable to provide clinically significant benefit. In the last decade, the medical community 
testified a revolution in the treatment of advanced melanoma with the introduction of 
immune checkpoint inhibitors, and targeted therapy with mitogen-activated protein ki-
nase inhibitors (MAPKi). Both therapies were able to provide sustainable overall survival 
benefits in stage IV melanoma. Here, we aimed to investigate whether the survival ad-
vantages seen in phase II, and III clinical trials investigating the afore mentioned thera-
pies, were reproducible or not in a real-world setting.  
 
Patients and methods: In this retrospective, multicentric analysis, we included stage IV 
melanoma patients, diagnosed between 2011 and 2018, treated in the skin cancer center 
in Tuebingen, or in other German centers, and prospectively documented in the German 
Central Malignant Melanoma Registry (CMMR).  
The following patients’ and tumor data were collected from the CMMR: year of birth, 
gender, date of primary tumor diagnosis, type of melanoma, localization, tumor thick-
ness, Clark level, presence of ulceration, presence of regression, date of sentinel lymph 
node biopsy (if applicable), presence of lymph node metastases, stage at first diagnosis 
and date and localization of recurrence. The following variables were further included, 
based on patients’ clinical chart review: date and type of local and systemic therapy in 





Criteria in Solid Tumors version 1.1 (RECIST 1.1), date of progressive disease, date of 
last contact, cause of death, and death date. Patients included had a minimum follow-up 
of three months. Progression free survival (PFS) was defined as the time between date 
of stage IV diagnosis, start date of systemic therapy, or date of melanoma brain metas-
tases (MBM) diagnosis, depending on the type of population evaluated, and date of pro-
gressive disease, or last contact or death, for the patients that didn’t progress. Overall 
survival (OS) was defined as the time between stage IV diagnosis, start date of systemic 
therapy, or date of MBM diagnosis, depending on the type of population evaluated, and 
date of last contact or death.  
Kaplan-Meier estimates were used for the calculation of PFS and OS. Differences be-
tween groups were assessed using the log-rank test. When applicable, hazard ratios 
(HR) with 95% confidence intervals (CI) were calculated to quantify the impact on sur-
vival. Multivariate logistic regression models were used to examine associations be-
tween variables, when appropriate. Results were reported as two-sided p values with 
95% CIs. All p-values presented are two-sided tests of statistical significance at 0.05. 
For the indirect comparison between MAPKi, the Bucher method was used. All analyses 
were submitted to and approved by the local Ethics Committee. 
 
Results: Six publications reporting data from 3143 stage IV melanoma patients were 
included in this thesis. The 3-years (3-y) OS rate for patients treated with first-line chem-
otherapy, the most used systemic therapy in 2011-2014 was 15.9% (95% CI: 8.8-23). 
For patients treated with first-line immunotherapy in the same period, the 3-y OS rate 
was 37.4% (95% CI: 16.6-58.2). In the period of 2015-2018, the 3-y OS rate for patients 
treated with first-line immunotherapy almost duplicated compared to the 2011-2014 pe-





partial response (PR) or stable disease (SD). For patients achieving a CR, the 3-y OS 
rate was 87.7% (95% CI: 70.8–100). 
In patients harboring a BRAFV600 mutation, and with presence of worse prognostic fac-
tors, namely elevated baseline lactate dehydrogenase (LDH), worse Eastern Coopera-
tive Oncology Group Performance Status (ECOG PS) and higher tumor volume, the 
combination of vemurafenib plus cobimetinib showed a non-significant lower risk for pro-
gression or death, compared to dabrafenib plus trametinib, and encorafenib plus 
binimetinib. 
Compared to cutaneous melanoma, patients with uveal melanoma derived less benefit 
from systemic therapy, even when treated with combined immunotherapy. The median 
OS (mOS) was only 16.1 months (95% CI: 12.9–19.3), but still higher than those reported 
for both chemotherapy and programmed cell death protein 1 (PD-1) monotherapy in this 
sub-group. 
The benefit observed in intracerebral disease was similar to the benefit in extracerebral 
disease, when combined immunotherapy (nivolumab plus ipilimumab) was used. The 
mOS in patients with MBM was 19 months (95% CI: 15.9-22.0). For the whole collective 
of patients receiving nivolumab plus ipilimumab, the 3-y OS rate was 30.1% (95% CI: 
22.2-37.9). For patients achieving a CR, the 2-y OS rate was 85.6% (95%CI: 69.3-100), 
very similar to other stage IV patients. Patients receiving combined immunotherapy and 
local therapy (surgery or stereotactic radiotherapy) had a better outcome when com-
pared to patients that didn’t receive local therapy – the 2-y OS rate was 49.5% versus 
40.9 % (95%CI: 40.9-58.1 and 26.6-55.2). This benefit was observed regardless the tim-
ing of local therapy, i.e., before or after starting nivolumab plus ipilimumab. 
 
Conclusions: Our real-world data confirmed the improvement of survival outcomes in 





MAPKi in the last decade. Results show that, currently, PD-1 based immunotherapy 
should be offered as first-line therapy in stage IV melanoma. In patients with BRAFV600 
mutation and worse prognostic features, first-line systemic therapy with MAPKi could be 
considered. In patients with MBM, combination of systemic immunotherapy and local 
therapy should be offered, when feasible. 
 






1.2. Portuguese summary 
 
Contexto prévio: Há cerca de dez anos, os doentes diagnosticados com melanoma em 
estadio IV tinham um prognóstico reservado e uma sobrevivência muito curta. As tera-
pêuticas então disponíveis, nomeadamente dacarbazina, temozolomida e outros citotó-
xicos, isoladamente ou em combinação com cirurgia e/ou radioterapia, não proporcio-
navam benefícios clínicos significativos. Na última década, a comunidade médica e ci-
entífica testemunhou uma revolução no tratamento do melanoma em estadio IV com a 
introdução da imunoterapia, particularmente dos inibidores de checkpoint, e das tera-
pêuticas alvo, nomeadamente dos inibidores da via da mitogen-activated protein cinase 
(MAPKi). Ambas as terapêuticas demonstraram benefícios sustentados em termos de 
sobrevivência global em doentes com melanoma metastizado. Nesta análise, pretende-
mos investigar se o aumento de sobrevivência global observado nos ensaios clínicos de 
fase II e III que levaram à aprovação destas terapêuticas, podem ou não ser reproduzi-
dos em contexto de prática clínica diária.   
 
População incluída: Nesta análise retrospectiva, multicêntrica, incluímos doentes di-
agnosticados com melanoma estadio IV entre 2011 e 2018, e tratados no centro onco-
lógico de Tuebingen, ou noutros centros da Alemanha, e documentados prospectiva-
mente no Registo Central de Melanoma Maligno (CMMR) alemão.  
Os seguintes dados foram obtidos através do CMMR: ano de nascimento, sexo, data de 
diagnóstico do tumor primário, tipo histológico, localização anatómica, espessura, nível 
de clark, presença de ulceração, presença de regressão, data da biópsia do gânglio 
sentinela (se aplicável), presença de metástases no gânglio sentinela, estadio à data do 
primeiro diagnóstico, e data e localização da recidiva. Outros dados foram posterior-





sistémica em estadio IV e respectivas datas de início e fim, melhor resposta à terapêu-
tica e respectiva data, de acordo com os critérios RECIST 1.1, data de progressão da 
doença, data do último contacto, e causa e data da morte. Todos os doentes incluídos 
foram seguidos durante, pelo menos, três meses. 
 
Análise estatística: A sobrevivência livre de progressão (PFS) foi definida como o 
tempo entre a data de diagnóstico em estadio IV, data de início da terapia sistémica, ou 
data do diagnóstico de metástases cerebrais, dependendo do tipo de população avali-
ada, e data de progressão da doença, data do último contacto ou data de óbito no caso 
dos doentes que não tiveram progressão. A sobrevivência global (OS) foi definida como 
o tempo entre a data do diagnóstico em estadio IV, data de início da terapia sistémica, 
ou data do diagnóstico de metástases cerebrais, dependendo do tipo de população ava-
liada, e data do último contacto ou data de óbito.  
Usámos estimativas de Kaplan-Meier para o cálculo da PFS e OS. As diferenças entre 
grupos foram avaliadas utilizando o teste de log-rank. Quando aplicável, foram calcula-
dos hazard ratios (HR) com intervalos de confiança de 95% (95% IC) para quantificar o 
impacto na sobrevivência. Quando aplicável, foram também utilizados modelos de re-
gressão logística multivariada para avaliar associações entre variáveis. As associações 
entre variáveis foram consideradas estatisticamente significativas para valores de p < 
0.05. Para a comparação indirecta entre os MAPKi, foi usado o método de Bucher. To-
das as análises foram submetidas e aprovadas pelas Comissões de Ética locais. 
 
Resultados: Seis publicações incluindo dados de 3143 doentes diagnosticados com 
melanoma em estadio IV foram compiladas para a elaboração da presente tese. A taxa 
de OS aos 3 anos (3-y OS rate) para doentes tratados com quimioterapia em primeira 





23); para doentes tratados com imunoterapia em primeira linha no mesmo período, a 3-
y OS rate foi de 37.4% (95% CI: 16.6-58.2). No período entre 2015-2018, a 3-y OS rate 
para doentes tratados com imunoterapia em primeira linha, quase que duplicou em com-
paração com o período de 2011-2014, e foi de 64.6% (95% CI: 53.2-76) para doentes 
com resposta completa, resposta parcial ou doença estável. Para doentes com resposta 
completa, a 3-y OS rate foi de 87.7% (95%CI: 70.8-100). 
Em doentes com mutação BRAFV600 e presença de factores de pior prognóstico, no-
meadamente valores elevados de LDH à data de início de tratamento, ECOG PS redu-
zido e maior volume tumoral, a combinação vemurafenib/cobimetinib demostrou uma 
redução não significativa do risco de progressão ou morte em comparação com dabra-
fenib/trametinib, e encorafenib/binimetinib. 
Em comparação com o melanoma cutâneo, os doentes com melanoma ocular benefici-
aram menos da terapia sistémica, mesmo quando tratados com nivolumab/ipilimumab. 
A sobrevivência global média (mOS) foi de apenas 16.1 meses (95% CI: 12.9-19.3), 
ainda assim mais elevada do que a reportada em doentes tratados com quimioterapia 
ou monoterapia com anti-PD-1. 
Em termos de sobrevivência global, o benefício da imunoterapia e das terapêuticas alvo 
na doença intracerebral foi semelhante ao observado na doença extracerebral. Isto foi 
particularmente verdade em doentes tratados com nivolumab/ipilimumab. A mOS foi de 
19 meses (95% CI: 15.9-22.0) e a 3-y OS rate foi de 30.1% (95% CI: 22.2-37.9) Para os 
doentes com resposta completa, a 2-y OS rate foi de 85.6% (95% CI: 69.3-100), muito 
semelhante às taxas de sobrevivência observadas em outros doentes em estadio IV, 
sem metastização cerebral. Os doentes que receberam nivolumab/ipilimumab e tera-
pêutica local (radiocirugia ou cirurgia) beneficiaram mais em comparação com os doen-
tes que não receberam terapêutica local - a 2-y OS rate foi de 49.5% versus 40.9% (95% 





em que os doentes receberam terapêutica local, i.e., antes ou depois de iniciar nivolu-
mab/ipilimumab. 
 
Conclusões: Os nossos dados da prática clínica diária confirmam uma melhoria em 
termos de sobrevivência global em doentes com melanoma em estadio IV, diagnostica-
dos e tratados entre 2011-2019. Estes benefícios deveram-se à introdução de novas 
opções terapêuticas, nomeadamente imunoterapia com inibidores de checkpoint e tera-
pêuticas alvo com MAKi. Os nossos resultados mostraram que actualmente, a imunote-
rapia com inibidores de checkpoint, deve ser oferecida em primeira linha em todos os 
doentes com melanoma em estadio IV. Em doentes com mutação BRAFV600 e com 
presença de factores de pior prognóstico, terapêutica com MAPKi pode igualmente ser 
considerada em primeira linha metastática. Em doentes com metastização cerebral, a 
combinação de terapia sistémica e local deve ser discutida e ponderada, em primeira 
linha ou posteriormente, sempre que viável. 
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1.4. Abbreviation list 
AE Adverse Events 
AJCC American Joint Committee on Cancer 
ALM Acral Lentigo Melanoma 
APC Antigen Presenting Cells 
ASCO American Society of Clinical Oncology 
BRAF B-Raf Proto-Oncogene 
v-Raf murine Sarcoma Viral Oncogene Homolog B 
irAE Immune Related Adverse Events 
IARC International Agency of Research on Cancer 
CI Confidence Interval 
CMMR German Central Malignant Melanoma Registry 
CTCAE Common Terminology Criteria for Adverse Events 
CTLA-4 Cytotoxic T-lymphocyte-associated protein 4 
CR Complete Response 
DCR Disease Control Rate 
EMA European Medicines Agency 
ECOG PS Eastern Cooperative Oncology Group Performance Status 
EORTC European Organisation for Research and Treatment of Cancer 
ESMO European Society of Medical Oncology 
FDA Food and Drug Administration 
HLA Human Leukocyte Antigen 
HR Hazard Ratio 
ICI Immune Checkpoint Inhibitors  
LDH Lactate Dehydrogenase 
LMM Lentigo Melanoma 
MAPKi Mitogen-activated Protein Kinase Kinase inhibitors 
MBM Melanoma Brain Metastases 
MEK Mitogen-activated Protein Kinase Kinase 
NM Nodular Melanoma 
ORR Overall Response Rate 
OS Overall Survival 
mOS Median Overall Survival 





PD-L1 Programmed Cell Death Ligand 1 
PD Progressive Disease 
PFS Progression Free Survival 
PR Partial Response 
RECIST 1.1 Response Evaluation Criteria in Solid Tumors version 1.1 
SD Stable Disease 
SIRT Selective Internal Radiotherapy 
SOC Standard of Care 
SPO Sociedade Portuguesa de Oncologia 
SSM Superficial Spreading Melanoma 
TACE Trans-arterial Chemoembolization 
TCR T-cell receptors 
ULN Upper Limit Normal 
UV Ultraviolet 










2.1. Incidence and prevalence of melanoma 
In recent years, there was a worldwide increase of melanoma incidence. 1 By 2020, the 
number of newly diagnosed melanomas worldwide is expected to reach 279,938, and it 
is estimated that about 67,809 people will die from this disease. The numbers are from 
the International Agency for Research on Cancer (IARC). 2 Other national reports pro-
vided similar data, showing that the increased incidence rate of melanoma is a global 
issue. 3-5 The incidence rate of cutaneous melanoma is higher in white populations com-
pared to Spanish, Afro-American, Indian and Asian. 6 The mean annually age-adjusted 
incidence of melanoma in whites per 100 000 persons is 18.4 and in Spanish, Afro-
Americans, Indians and Asians it is 2.3, 0.8, 1.6 and 1.0, respectively. 
In most European countries, the melanoma incidence rate almost doubled between 1990 
and 2005, increasing between + 2% and + 10% annually. 7 In 2012, melanoma was the 
fifth most frequent solid tumor entity in Germany. The incidence rate according to the 
age-standardization rose from 12.4/100,000 to 19.2/100,000 between 1999 and 2012, 
representing an increase of approximately 55%. 3 In this publication we reported an in-
crease in incidence of melanoma from 12.7/100,000 to 19.2/100,000 in men and from 
12.1/100,000 to 19.2/100,000 in women, which represents an average annual increase 
of +3.1% and +3.5% in men and women, respectively. There was a marked annual in-
crease of 10.9% for both sexes between 2006 and 2009, that coincided with the period 
when the nationwide skin cancer screening program was introduced. 3 An extrapolation 
of the data until 2030 shows that the age-standardized incidence rates will continue to 
increase. In Germany, the expected incidence rates are 31/100,000 and 30/100,000 for 





The last IARC report shows that in 2018 in Portugal, the age-standardized incidence rate 
(World) per 100,000 for both sexes, all ages and for all cancers was 259,5. 8 For mela-
noma, the rate was 6.4 compared to 21.6 in Germany, in the same report. 
2.2. Biology of melanoma  
 
2.2.1. Melanoma subtypes  
 
2.2.1.1. Cutaneous Melanoma 
The two most common subtypes of cutaneous melanoma concern the 1) superficial 
spreading melanoma (SSM) in about 57% of cases, and the 2) nodular melanoma (NM) 
in about 21% of cases. Other less frequent melanoma subtypes are 3) the lentigo ma-
ligna melanoma (LMM) in about 9% of cases, occurring mainly in chronically sun-ex-
posed skin of older patients, and the 4) acral-lentiginous melanoma (ALM) in about 4% 
of cases, which can be located in fingers, toes, palms and soles, and is associated with 
a poorer prognosis. 9-12 
There is robust evidence that cutaneous melanoma is associated with the intermittent 
exposure to ultraviolet (UV) radiation and history of sunburns early in life, namely 
throughout childhood and adolescence; however, the risk appears to be present regard-
less the age group. 13-15 The change in leisure and holiday patterns in the later decades, 
and also the change on the type of protective clothes used while sunbathing, resulted in 
significantly increase to UV exposure. This is the main reason for the global increase of 
this tumor entity. 16,17 
Approximately 6% of all diagnosed melanomas occur in body regions that have little ex-





regions frequently or intermittently exposed to UV radiation, such as the face, chest, 
back, arms and legs. 9,18  
The development of melanomas as its correlation with UV exposure has been shown 
previously by several groups. In 2010 the whole spectrum of somatic mutations in the 
entire genome of a melanoma metastasis was catalogued for the first time. 19 It was 
shown that about 70% of the detected single base substitutions were of the type C-T and 
also around 70% of the dinucleotide substitutions were of the type CC-TT. It is largely 
known that these are "signature mutations" for exposure to UV radiation, and therefore, 
this finding represents an important proof of the connection between the development of 
melanoma and UV radiation exposure. 
Due to this relation between UV radiation exposure and cutaneous melanoma, this sub-
type of melanoma belongs to the human malignancies with the highest tumor mutational 
burden. 20 The high tumor mutational burden has been associated with response to im-
munotherapy in melanoma and other solid tumors. 21,22 
 
2.2.1.2. Mucosal Melanoma 
About 55% of the mucosal melanomas are diagnosed in the head and neck area, 24% 
the anorectal region and 21% the genital tract. 23-27 This type of melanoma is usually 
diagnosed in later stages, which might contribute to the less favorable prognosis. The 
lower expression of the programmed death ligand 1 (PD-L1) and overall lower tumor 
mutational burden, may also contribute to the lower response rates to immune check-





2.2.1.3. Uveal Melanoma 
Uveal melanomas have a different metastatic pattern from cutaneous melanomas. Since 
the eye has no lymphatic system, almost all uveal melanoma metastases are found di-
rectly in the liver via hematogenic spread. This particular pattern of metastatic spread 
turns these patients into perfect candidates for liver directed therapeutic approaches in-
cluding surgical resection, trans-arterial chemoembolization (TACE), 32-35 and selective 
internal radiotherapy (SIRT). 36-38 Both methods, TACE and SIRT, achieve good re-
sponse rates of up to 57% and 63%, respectively. Similar to mucosal melanoma, the 
response rates to immune checkpoint inhibitors are considerably lower than for cutane-
ous melanoma. 39-42 However, combined immunotherapy has been shown to be a safe 
and more effective therapeutic option for these patients, when compared to chemother-
apy or PD-1 monotherapy. 43   
2.3. The 8th edition of the AJCC classification 
Melanoma, like other solid tumors, is staged according to the TNM classification. The 
new TNM classification was published in 2017 by the American Joint Committee on Can-
cer (AJCC). 44 The changes introduced affected mostly the classification of stage III mel-
anoma with a new sub-stage IIID. Considering that adjuvant therapy has become avail-
able and approved in stage III as well, a very short discussion on the implications of 
these new classification is of importance. 
The 8th edition of the AJCC melanoma classification displays what can be defined as a 
very favorable outcome for stage III patients. In fact, with these outcomes, the discussion 
arose whether there was the need to treat all stage III patients. It was particularly striking 
that stage IIC had worse prognosis than stage IIIA. Several authors addressed this as-





untreated stage III patients, i.e., patients from the placebo arm of the European Organi-
sation for Research and Treatment of Cancer (EORTC) 18991 and 18071 trials, and 
from a Tuebingen cohort, we have discussed and pointed out that, the survival rates 
presented in the new AJCC classification might be overrated. 48 This has implications in 
both trials’ design and in indication for systemic treatment. We advocated that all stage 
IIIB and IIIC patients should receive systemic therapy, and that for stage IIIA patients, 
the decision should be individualized. There were not many stage IIIA patients included 
in the clinical trials evaluating systemic therapy, and the prognosis is considerably favor-
able.  
As for stage IV, a new substage - M1d - was introduced for patients with brain metasta-
ses, recognizing that these patients, when left untreated, have a different and worse 
prognosis compared with other stage IV patients. The M1d substage includes patients 
with brain metastases with or without metastases in other organs. The M1c category no 
longer includes patients with brain metastases, and elevated lactate dehydrogenase 
(LDH) no longer defines M1c category. LDH level is defined by using a suffix next to the 
M category: normal LDH is identified as 0 (zero) and elevated LDH is identified as 1 
(one). No suffix is used if the LDH value is not recorded or is unspecified. The particular 
subgroup of M1d patients is one of the focus of this thesis (Manuscripts 5 and 6). Table 






Table 1: Overview of the TNM classification for cutaneous melanoma 
Stage Criteria 
I Tumor thickness up to 2mm without ulceration  
no metastases 
II Tumor thickness > 1mm up to 2mm with ulceration 
 
Any tumor with a tumor thickness of more than 2mm 
no metastases 
III Any tumor thickness with metastases in nearby skin areas or lymph 
nodes 
IV Any tumor thickness with metastases in distant skin areas, lymph 
nodes or organs (e.g. liver, lung, brain, ...) 
 
 
2.4. Systemic therapy of advanced melanoma 
 
The landscape of the systemic therapy in melanoma has changed considerably in the 
last 10 years. For decades, different combinations of chemotherapy have been investi-
gated in advanced melanoma, but these therapies produced very marginal benefits. 49 
Until the introduction of immune checkpoint inhibitors (ipilimumab, nivolumab and pem-
brolizumab), and targeted therapies with BRAF and MEK inhibitors (vemurafenib plus 
cobimetinib, dabrafenib plus trametinib and encorafenib plus binimetinib) in the thera-
peutic arsenal, there was no effective therapy for patients diagnosed with advanced mel-
anoma. Targeted therapies can be offered to patients whose melanomas carry a 
BRAFV600 mutation, and immune checkpoint inhibitors can be used to treated both 
BRAFV600 mutated and BRAF wild-type melanomas. 
Figure 1 depict a simplified timeline of the systemic therapies currently available and 








Figure 1: Timing of re-imbursement for systemic therapies in stage IV melanoma, in 
Portugal (top) and Germany (bottom) 
 
2.4.1. Immunotherapy with CTLA-4 and PD1/PDL-1 inhibitors 
 
Cancer immunotherapies aim to harness the anti-cancer response of the immune system 
to selectively destroy cancer cells while leaving normal tissues unharmed. In the last 
years, immune checkpoint inhibitors have been established as a potent novel cancer 
immunotherapy showing unparalleled anti-tumor effects in previously difficult to treat ma-
lignancies like metastatic melanoma and lung cancer, among others. Importantly, im-
mune checkpoint inhibitors were primarily investigated in patients with cutaneous mela-
noma, due to its high immunogenicity and immune responsiveness. 50-52 As previously 
mentioned, it is now widely accepted that a high tumor mutational burden, observed in 
tumors like cutaneous melanoma, is associated with a large number of potent ne-
oepitopes being presented on the cancer cell surface, and being directly responsible for 
the immune recognition of such tumors and efficacy of immune checkpoint inhibitors. 53,54  


















Encorafenib + Binimetinib 





Ipilimumab, an immune checkpoint inhibitor targeting cytotoxic T-lymphocyte-associated 
protein 4 (CTLA-4) was the first developed, and was followed by the programmed cell 
death-1 (PD-1) inhibitors, nivolumab and pembrolizumab, and PD-Ligand 1 (PD-L1) an-
tibodies (e.g. atezolizumab). 55 These antibodies block the interaction between the inhib-
itory T lymphocyte receptors CTLA-4 or PD-1 with their natural ligands CD80/CD86 or 
PD-L1/PD-L2, respectively. In a normal setting, ligand binding leads to a deactivation of 
T cells limiting the immune response to a stimulus, and thereby protecting from an over-
shooting immune response. However, some tumors express PD-L1 on their surface lead-
ing to PD-1 mediated deactivation of tumor-infiltrating T cells and immune evasion. An-
tibodies blocking the interaction of PD-1 on T cells with its ligand PD-L1 on tumor cells 
lead to the suppression release of tumor-specific T cells. These T-cells are now enabled 
to efficiently recognize and kill tumor cells. Importantly, efficacy of PD-1/PD-L1 blocking 
antibodies relies on pre-existing tumor-reactive T cells recognizing tumor-specific 
epitopes like neoepitopes on the tumor cell surface.  
On the other hand, blockade of CTLA-4 on T cells primarily supports their activation 
(priming). Key for T cell priming are antigen presenting cells (APC) taking up extracellular 
antigens from pathogens or tumors, and presenting these via HLA class I and II mole-
cules on their surface. These complexes of antigens, and either HLA class I or II mole-
cules can be recognized by matching T-cell receptors (TCR) of CD8+ or CD4+ T cells, 
respectively, leading to the activation of antigen-specific lymphocytes only. However, for 
efficient T cell activation, APC also need to display co-stimulatory factors like CD80 and 
CD86 being recognized by the activating receptor CD28 on T cells. Upon stimulation, T 
cells express the inhibitory receptor CTLA-4, which has a higher affinity to the APC sur-
face molecules CD80/CD86 than CD28 competing for their binding. Upon ligand bind-
ing CTLA-4 can also directly inhibit TCR-driven intracellular signaling. 56 As a net effect 





blocking antibodies therefore enhance priming and effector activity of antigen-specific T 
cells and inhibit immune suppression mediated by a specific group of CD4+ T cells, the 
regulatory T cells (Tregs).  
Figure 2 and  




Figure 2: The priming phase and CTLA-4 blockade 
 
Antigen presenting cells (APC) activate naïve T-cells using two different ligands: MHC-I<>TCR and CD80/86 
<> CD28. After this initial priming and activation, CTLA-4 is upregulated and expressed in the T-cell mem-
brane. CTLA-4 has a higher affinity to CD80/86 than CD28 and displaces the initial ligation. When CTLA-4 
binds to CD80/86, it blocks further T-cell activation, and limits the T-cell activation induced by APC’s. CTLA-





inhibitory signals, prolonging T-cell activation. APC: antigen presenting cells; MHC-I: major histocompatibility 




Figure 3: The effector phase and the PD-1/PD-L1/2 blockade 
 
PD-1 is expressed by T-cells that acts as an inhibitory molecule when binding to the two identified ligands: 
PD-L1 and PD-L2. Binding of PD-1 to PD-L1/2 inhibits tumor cell apoptosis, promotes T-cell exhaustion and 
prevents an active antitumor response. Therapy with PD-1 inhibitors (pembrolizumab and nivolumab) will 
stop the negative regulation, and preclude T-cell exhaustion and deactivation, reestablishing antitumor im-






2.4.1.1. Anti- CTLA4 – ipilimumab 
The antibody ipilimumab was the first one to be investigated in the treatment of meta-
static melanoma patients. The first trials evaluating ipilimumab in stage IV melanoma did 
so by comparing ipilimumab 3 mg/kg, plus a gp100 peptide vaccine, ipilimumab plus 
gp100 placebo, and gp100 plus ipilimumab placebo, all administered once every 3 weeks 
for four treatments, in patients that have already received and progressed under sys-
temic therapy. 52 Results showed that ipilimumab, with or without a gp100 peptide vac-
cine, as compared with gp100 alone, improved overall survival (OS) in this population of 
patients.  
The results of these first trials, led to further investigation comparing ipilimumab with the 
standard of care (SOC) at that time for stage IV melanoma, which was chemotherapy. A 
phase III trial evaluated the combination of ipilimumab 10mg/kg plus dacarbazine versus 
dacarbazine alone in treatment naïve patients. 58 The results showed that ipilimumab in 
combination with dacarbazine, as compared with dacarbazine plus placebo, improved 
OS in this population.  
Further studies evaluating ipilimumab monotherapy in previously treated and treatment 
naïve patients showed that, for the first time in advanced melanoma, systemic therapy 
was able to induce long-term responses in this population. 59-63 In 2015, a pooled analysis 
of long-term survival data from phase II and III trials of ipilimumab in unresectable or 
metastatic melanoma was published. 64 With a follow-up of up to 10 years, the authors 
showed that a plateau in the survival curve can be recognized at approximately 3 years. 
This plateau was independent of prior therapy or ipilimumab dose investigated. These 
data once again confirmed that with ipilimumab monotherapy, long-term responses can 





Based on the previously results, ipilimumab was approved by the FDA and the EMA for 
the treatment of advanced melanoma. 65 Patients are treated with four cycles of ipili-
mumab 3 mg/kg, every three weeks. 
 
2.4.1.2. Anti-PD-1 – nivolumab and pembrolizumab 
The investigation of immunotherapy for the treatment of advanced melanoma advanced 
with further research on anti-PD-1 inhibitors, namely nivolumab and pembrolizumab. The 
mechanism of action of these two molecules is slightly different from the mechanism of 
action of ipilimumab, but the basic principle is the same, that is to harness the immune 
system allowing for identification and elimination of tumor cells. PD-1 is a crucial im-
mune-checkpoint receptor that is mostly expressed by activated T cells, mediating im-
munosuppression, and is mostly activated in peripheral tissues. Here, the T cells can be 
exposed to immunosuppressive PD-1 ligands PD-L1 (B7-H1) and PD-L2 (B7-DC) ex-
pressed by tumor cells, stromal cells, or both. 66-69 Anti-PD-1 inhibitors such as nivolumab 
and pembrolizumab block the interaction between PD-1 and PD-L1 and this enhances 
T-cell responses. 70,71 
PD-1 inhibitors were initially evaluated in tumors that are known to be immunogenic, and, 
currently, also known for having a high tumor mutational load, namely melanoma and 
lung cancer. 72 Results showed that anti–PD-1 antibodies produced objective responses 
in approximately one in four to one in five patients with non–small-cell lung cancer, mel-
anoma, or renal-cell cancer. Further trials investigating PD-1 based immunotherapy in 
melanoma showed that this therapy was also able to induce higher response rates com-
pared to the SOC chemotherapy, in both treatment naïve patients, and patients who 
progressed under ipilimumab therapy. 73-85 These results were seen regardless BRAF 





Based on the results from these trials, nivolumab and pembrolizumab were approved by 
the FDA and the EMA for the treatment of inoperable metastatic melanoma. 86,87 
Over the years, the dosing regimen of nivolumab and pembrolizumab has been simpli-
fied, and instead of a weight-based dose, similar to chemotherapy, a flat dose of 240mg 
every 2 weeks or 480mg every 4 weeks is now used for nivolumab. Pembrolizumab can 
be administered every 3 weeks (200 mg) or every 6 weeks (400mg). The results 
achieved with flat dose and longer intervals were similar to the weight-based dose and 





Table 2: Summary of results from the trials investigating PD-1 based immunotherapy in advanced melanoma 1 
Study Immune checkpoint inhibitors 
 CHECKMATE KEYNOTE 
 
067 037 066 001 002 006 
Agent(s) Nivo + Ipi Nivo Nivo Nivo Pembro Pembro Pembro 
     (all pts) (tx naive) (2mg/kg) (10mg/kg) (Q2W) (Q3W) 
Patients, n (study arm) 314 316 272 210 655 151 180  181  279  277  
BRAF mutant, % 32 31 22 0 24 --- 24.4 22.1 35 35 
ECOG ≥ 1, % 26 25 40 28.6 --- --- 44.4 44.8 30 32 
M1c, % 58 58 75 61 8 --- 82.2 82.3 64 68 
LDH > ULN, % 48 47 52 37.6 38 --- 43.3 39.8 29 35 
Follow up, months >60 >60 24 38.4 55 55 28 28 45.9 
 
Median OS, months NR 36.9 15.7 37.5 23.8 38.6 13.4 14.7 32.7 
 
1-yr OS, % 73 74 58.9 --- --- --- 53.7 55.6 --- 
 
2-yr OS, % 64 59 38.7 --- --- --- 35.9 38.2 55.2 
 
3-yr OS, % 58 52 --- 31.2 --- --- --- --- 48.1 
 
4-yr OS, % 53 46 --- --- 38 48 --- --- 42.3 
 






Median PFS, months 11.5 6.9 3.1 5.1 8.3 16.9 2.9 3.0 8.4 
 
1-yr PFS, % 50 43 --- --- --- --- 22.1 27.9 --- 
 
2-yr PFS, % 41 37 --- --- --- --- 16 22 32.7 
 
3-yr PFS, % 39 32 --- 32.2 --- --- --- --- 28.8 
 
4-yr PFS, % 37 31 --- --- 25 35 --- --- 23 
 
5-yr PFS, % 36 29 --- --- 21 29 --- --- --- 
 
ORR, % 58 44.6 27 42.9 41 52 22 28 42 
 
CR/PR, % 22/36 19/26 27 40/50 16/25 25/27 --- --- 13/29 
 
Median DOR, months NR NR 31.9 NR --- NR 22.8 NR NR 
 
Related AEs, % 96 87 77 77.7 86 --- 56.7 59.2 79 
 
Discontinuation due to AE % 31 8 15 8.7 8 --- 13.5 16.2 10 
 
CTCAE grade 3/4 AEs, % 59 23 11 15 17 --- 3.3 6.1 17 17 






2.4.1.3. Nivolumab plus ipilimumab 
Combination of nivolumab and ipilimumab is the current SOC for stage IV melanoma. 
This combination was investigated in a prospective, randomized phase 3 study, the 
CheckMate 067 study, recently updated with survival data after 5 years of follow-up. 78,90 
This study compared nivolumab plus ipilimumab with nivolumab monotherapy and ipili-
mumab monotherapy in treatment-naïve patients. Although this trial was not powered to 
detect a difference between the combination therapy and the monotherapies, the con-
secutive survival updates have shown that the difference in terms of OS rates between 
nivolumab plus ipilimumab and the monotherapy arms have been consistently increas-
ing. The 2-y, 3-y, 4-y, and 5-y OS rates difference between nivolumab plus ipilimumab 
and nivolumab alone are 5%, 6%, 7% and 8%, respectively. 78,91,92 In the subgroup of 
patients with BRAFV600 mutation receiving combined immunotherapy or nivolumab 
monotherapy, the difference in the 5-y OS rates is even more notorious (60% versus 
46%).  
The authors of the Checkmate 067 also evaluated the subsequent therapies received by 
the patients included. The time until receiving another therapy is an important aspect, 
not only in terms of survival but also in terms of quality of life. The median time from trial 
inclusion to subsequent systemic therapy was more than 60.0 months (median not 
reached) in the nivolumab plus ipilimumab group, 25.2 months in the nivolumab group, 
and 8.0 months in the ipilimumab group. Besides the time to subsequent systemic ther-
apy, another aspect evaluated was the median treatment-free interval. Here, patients 
treated with combined immunotherapy also derived greater benefit compared to those 
receiving nivolumab or ipilimumab monotherapy; 18.1 months versus 1.8 months and 





receiving subsequent systemic at the time of the 5-y follow-up survival analysis: 74% in 
the combination arm, 58% in the nivolumab arm, and 45% in the ipilimumab arm. 78 
The superior results of the combination therapy were, however, associated with a higher 
toxicity. Common Terminology Criteria for Adverse Events (CTACE) grade 3-4 treat-
ment-related adverse events were seen in 59% of the patients receiving nivolumab plus 
ipilimumab, in 22% of the patients receiving nivolumab and in 28% of those treated with 
ipilimumab. 92 Taking that into consideration, the Checkmate 511 trial investigated 
whether a lower dose of ipilimumab (1mg/kg) combined with a higher dose of nivolumab 
(3mg/kg) could derive the same efficacy benefits as the standard dose, while resulting in 
lower toxicity rates. 93 With a lower dose of ipilimumab, the CTCAE grade 3-4 toxicity 
was reduced by half with a comparable efficacy. The follow-up in this study is however 
shorter than in the Checkmate 067 (18 months versus 60 months), and longer follow-up 
is required to confirm these results. 93  
 
2.4.2. Targeted therapy with BRAF and MEK inhibitors  
 
Approximately 40 to 60% of cutaneous melanomas harbor mutations in BRAF that lead 
to constitutive activation of downstream signaling through the MAPK pathway. 94 Approx-
imately 90% of these mutations result in the substitution of glutamic acid for valine at 
codon 600 (BRAFV600E), although other activating mutations are known (e.g., 
BRAFV600K and BRAFV600R). Vemurafenib, was the first selective BRAFV600 inhibi-
tor to be investigated in the treatment of advanced melanoma. 95 The BRIM-3 trial was a 
phase 3 randomized clinical trial that compared vemurafenib with the SOC dacarbazine 





mutation. The results showed that vemurafenib was superior to dacarbazine in terms of 
prolonging PFS and OS. 
Dabrafenib is another BRAF inhibitor investigated at the same time as vemurafenib with 
similar results in terms of efficacy. 96 The difference between the both BRAF inhibitors is 
mainly related with the toxicity profile. Dabrafenib induces almost no photosensitivity 
compared to vemurafenib (41%), fewer keratoacanthomas and squamous cell carcino-
mas (7% versus 20-30%). Arthralgia (56%), fatigue (46%) and rash (41%) were com-
monly reported with vemurafenib treatment. 95 On the other hand, pyrexia is the most 
common adverse event associated with dabrafenib treatment - almost 50% of the pa-
tients reported pyrexia that led to treatment interruption. 
Treatment with BRAF inhibitors monotherapy induces high response rates but resistance 
supersedes shortly after. 95,97,98 Combination with another MAPK inhibitor, in this case a 
MEK inhibitor, is one of the ways to overcome the resistance and short duration of re-
sponse of monotherapy with BRAF inhibitors. 99 
Three different BRAF/MEK combinations are currently available for patients with ad-
vanced melanoma. These combinations were investigated in randomized phase III trials, 
and compared with BRAF inhibitors monotherapy showing improved survival outcomes 
in BRAFV600 mutated melanoma. The combination of vemurafenib plus cobimetinib was 
investigated in the coBRIM trial, dabrafenib plus trametinib was investigated in the 
COMBI-d and COMBI-v study, and encorafenib plus binimetinib was investigated in the 
COLUMBUS study. 100-103 
Recently, a pooled analysis evaluating the survival of BRAFV600 mutated patients 
treated with BRAF/MEK inhibitors in the COMBI-d and COMBI-v trials showed that, with 





19% of the patients, and in this subgroup the 5-y OS rate was 71% (95% CI, 62 to 79). 
104 These results show that if targeted therapy is chosen to treat patients with BRAFV600 
mutated melanoma, combined targeted therapy and not monotherapy should be used. 
Since the efficacy and survival outcomes are very similar in with the three combinations 
of BRAF/MEK inhibitors, the combination chosen is mostly related with the safety profile 
that differs between them. Our recently published indirect analysis showed a non-signif-
icant risk reduction for progression and death in the subgroup with elevated baseline 
LDH receiving vemurafenib plus cobimetinib, compared with dabrafenib plus trametinib 
and encorafenib plus binimetinib. Therefore, in this subgroup of patients, combination of 
vemurafenib plus cobimetinib might be considered. 105 
Table 3 provides a summary of the survival outcomes in trials investigating targeted 
therapy in BRAFV600 mutated melanoma patients. 
 
Table 3: Summary of results from the trials investigating targeted therapy in advanced 
melanoma 
Study Combination targeted therapy 
 
COMBI-d COMBI-v CoBRIM COLUMBUS 
Agent(s) D + T D + T V + C E + B 
Patients, n (study arm) 211 352 247 577 (Part1) 258 (Part2) 
ECOG ≥ 1, % 27 29 24 29 27 
M1c, % 67 63 59 64 67 
LDH > ULN, % 36 34 46 29 31 
Follow up, months ≥ 36.0 23 21.2 36.8 
Median OS, months 25.1 26.1 22.5 33.6 
1-yr OS, % 74 73 74.5 76 





3-yr OS, % 44 45 38.5 47 
4-yr OS, % 37 
 
34.7 39 
5-yr OS, % 34 
 
--- --- 
Median PFS, months 11.0 12.1 12.3 14.9 12.9 
1-yr PFS, % --- --- --- 56 
2-yr PFS, % 30 30 --- 37 
3-yr PFS, % 22 24 --- 29 
4-yr PFS, % 21 
 
--- 25 
5-yr PFS, % 19 
 
--- --- 
ORR, % 69 67 70 64 66 
CR/PR, % 16/53 19/48 16/54 13/51 8/58 
Median DOR, months 12 13.8 13.0 18.6 12.7 
Related AEs, % 97 99 99 98 98 
Discontinuation due to AE % 14 16 13 15 12 
CTCAE grade 3/4 AEs, % 48 57 77 64 47 
D+T= Dabrafenib + Trametinib; V+C= Vemurafenib + Cobimetinib; E+B= Encorafenib + Binimetinib.  
 
 
2.5. Systemic therapies in melanoma brain metastasis 
Patients with MB pose a particular therapeutic challenge, and have a worse prognosis 
compared to stage other IV patients. This has been acknowledged in the new AJCC 
classification, that included patients with MBM in a particular subgroup – M1d. 44 This 
particular subgroup of patients and their outcomes to systemic therapy have been eval-
uated separately in this thesis (Manuscripts 5 and 6).  
The studies evaluating systemic therapy in stage IV melanoma patients have systemat-





exclusion criterion for the great majority of phase III clinical trials, regardless the tumor 
entity.  
Trials specifically investigating immunotherapy and targeted therapy in patients with 
MBM have shown that these therapies are also effective intracranially, and that the in-
tracranial response rate is similar to the extracranial response. 106-109 Currently, there is 
evidence that PD-1-based immunotherapy, and particularly combined immunotherapy 
with nivolumab and ipilimumab might be more effective than BRAF/MEK inhibitors. 110,111 
For patients with MBM, the combination of local and systemic therapies has long been 
investigated. Retrospective data show that the patients receiving a combination of local 
therapy and systemic therapy have better outcomes when compared to patients who do 
not receive local therapy. 112-119 The timing of the local therapy, i.e., up-front or later in 
the course of the disease, doesn’t seem to be statistically significant. However, local 
therapies given up-front seem to derive better outcomes. 120-123 There is still ongoing 
debate whether some patients might be better served with systemic therapy alone, con-
sidering the very positive outcomes seen in clinical trials. Not applying local therapy re-
duces local complications, potential cognitive impairment, and might be particularly ad-
equate for patients with a low number of asymptomatic MBM. This question along with 
the best sequence regarding local and systemic therapy will be addressed in ongo-
ing/planed clinical trials. 124,125 
 
2.6. Access to systemic therapies approved in the advanced 
setting in Portugal and Germany 
 
Despite the positive results of systemic therapy in advanced melanoma patients, these 





are approved by EMA become available and reimbursed in the clinical practice immedi-
ately after their approval. In other countries, namely in Portugal, the process is different 
(see Figure 1).  
The asymmetric re-imbursement process precludes access to effective therapy. Partic-
ularly in melanoma, this asymmetric access to systemic therapies was investigated in 
2017. The authors of this work reported that, at the time, more than 5000 patients with 
metastatic melanoma per year in Europe did not have access to recommended first-line 
innovative treatments. This obviously translates into pourer survival outcomes in patients 
from countries that do not have access to innovative therapies.  
In Europe, the European Society of Medical Oncology Magnitude of Clinical Benefit 
Scale working group (ESMO-MCBS WG), of which I am current member, has addressed 
this topic. The evolving classification has been available for the last five years, and using 
it one can easily identify and define whether the therapies available in a defined setting 
should or shouldn’t be reimbursed, based in criteria such as improved survival outcomes, 
toxicity, and quality of life. 126-128 The progress in systemic therapy of advanced mela-
noma, which is the topic of this thesis, is only important in the extent that it is available 









Aim 1) To determine long-term outcomes in patients with stage IV mela-
noma treated with targeted and immunotherapy between 2011-2019 
 
Work project 1 – this work used data available from the German Central Malignant Mel-
anoma Registry (CMMR) database in combination with data from other local databases. 
The manuscripts generated with this work project were manuscript 1, 2, 3 and 4.  
 
Aim 2) To evaluate the impact in survival outcomes of targeted and immu-
notherapy, and their combination with local therapies, in patients with mel-
anoma brain metastases 
Work project 2 – this work used data available from the CMMR database in combination 
with data from other local databases. The manuscripts generated with this work project 
were manuscript 5 and 6. 
 
  




4. Patients and methods 
 
The datasets used for the publications presented here were: 1) one registry-based da-
taset, the German CMMR, 2) data published from 3 randomized clinical trials, and 3) the 
German CMMR combined with local registry datasets, respectively:  
 
• The German CMMR (Manuscript 1, 2, 5)  
• The data publicly available from trials co-BRIM, COMBI-v and COLUMBUS part 
1 (Manuscript 3) 
• The German CMMR in combination with local registry datasets (Manuscripts 4 
and 6) 
This section provides a brief description of the methods used to evaluate data from each 
dataset. A detailed description of the methodology used in each work project is provided 
in the respective publication.  
 
4.1. The German CMMR (Manuscript 1, 2, 5) 
4.1.1. Study design and Data Source  
The German CMMR is a prospective database, active since April 1963. Sixty German 
centers have been contributing with data from patients diagnosed with primary mela-
noma. Currently, these centers report data only for defined variables, and are not fully 
active. The participation is not mandatory and there is no reimbursement. 
In manuscripts 1, 2, and 5, only patients treated and followed in the skin cancer center 
of Tuebingen were included. Patients includes had at least 3 months follow-up.  
 




4.1.2. Key Variables  
The German CMMR contains information on birthyear, gender, date of primary tumor 
diagnosis, type of melanoma, tumor localization, tumor thickness, clark level, presence 
of ulceration, presence of regression, date of sentinel lymph node biopsy (if applicable), 
presence of lymph node metastases, stage at first diagnosis, and date and localization 
of recurrence.  
The following variables were further collected based on patients’ clinical chart review: 
date and type of local and systemic therapy in advanced stages, toxicity, date and type 
of best overall response, date of progressive disease, last contact date, cause of death 
and death date. PFS was defined as the time between date of stage IV diagnosis, and 
date of progressive disease, or last contact or death, for patients who didn’t progress. 
OS was defined as the time between stage IV diagnosis and date of last contact or death.  
 
4.1.3. Statistical Analyses 
Descriptive statistics were used to characterize the patients’ population and treatment 
patterns. Estimates of survival rates were calculated among subgroups using Kaplan 
Meier estimates for PFS and OS. When appropriate, multivariate logistic regression mod-
els were used to examine associations between variables. All p-values presented were 
two-sided tests of statistical significance at 0.05. All statistical analyses were performed 
using SPSS v.25 (IBM Corp. Released 2017. IBM SPSS Statistics for Windows, Version 
25.0. Armonk, NY: IBM Corp).  
 




4.2. The co-BRIM, COMBI-v and COLUMBUS study database 
(Manuscript 3) 
4.2.1. Study design and Data Source  
Manuscript number 3 was based on the publicly available dataset from the studies co-
BRIM, COMBI-v and COLUMBUS. 130-132 
All data used has been previously published, therefore, there was no dedicated informed 
consent and ethical approval. 
 
4.2.2. Key Variables  
coBRIM, COMBI-v and COLUMBUS part 1 were randomized, double-blind phase 3 trials 
comparing oral vemurafenib, 960 mg twice daily, plus cobimetinib, 60 mg once daily, for 
21 days with placebo and vemurafenib (coBRIM), oral dabrafenib, 150 mg twice daily, 
plus trametinib, 2 mg once daily, with vemurafenib, 960 mg twice daily, (COMBI-v) or 
oral encorafenib, 450 mg once daily, plus binimetinib, 45 mg twice daily, with vemuraf-
enib, 960 mg twice daily, or encorafenib, 300 mg once daily, (COLUMBUS part 1). The 
primary endpoint of coBRIM and COLUMBUS trial was PFS. Primary endpoint of 
COMBI-v was OS. Key inclusion criteria were comparable across the studies. Patients 
with untreated brain metastases were not eligible.  
In this analysis the subgroups with normal and elevated LDH have been statistically an-
alyzed using a model for making indirect comparisons of the magnitude of treatment 
effects without losing the power of randomization (Bucher analysis). The aim of this anal-
ysis was the indirect comparison of PFS and OS as well as ORR in the subgroups with 
elevated LDH levels using the Bucher method. 
 




4.2.3. Statistical Analyses  
Due to data availability, the PFS analysis comparing coBRIM with COMBI-v was done 
using local assessment data, while the comparison with COLUMBUS part 1 used data 
from the independent central review. As defined by the particular study protocol, all en-
rolled patients were included in the analysis. The Bucher analysis was based on the 
assessments of benefit of the Federal Joint Committee (G-BA) for vemurafenib plus co-
bimetinib (module 5), dabrafenib plus trametinib (module 4) and encorafenib plus 
binimetinib (module 4) as well as data from the COLUMBUS-part 1. Median OS and PFS 
were calculated using the Kaplan–Meier method. 
 
4.3. The multicentric studies – German CMMR in combina-
tion with local databases (Manuscript 4,6) 
4.3.1. Study design and Data Source  
The centers included are detailed in the respective publications, and all adhered to the 
data collection procedures developed by the CMMR. The participating centers were all 
Certified German Cancer Centers, which means that regular inspections are performed 
by the Company OnkoZert, which is financed by the German Cancer Society. 
For each manuscript, an ethics committee approval was requested, and the numbers of 
the approval are included in the respective manuscripts. In each study, we used specific 
pseudo-anonymized forms to document patients’ data. All participating centers received 
the mentioned pseudo-anonymized forms including the prespecified information to be 
collected. Data were extracted from patients’ medical records, either by medical doctors 
or by clinical research documentation professionals, depending on the site. 
 




4.3.2. Key Variables  
For manuscript 4, besides the data already mentioned from the German CMMR, the 
following information was collected: demographic data, ECOG PS, available information 
on the genotype, number of organs with metastases, and previous therapies. As poten-
tial serum biomarkers, LDH, C-reactive protein, and the relative counts of lymphocytes, 
neutrophils, and eosinophils were also collected. 
For manuscript 6, besides the data already mentioned from the German CMMR, the 
following information was collected: BRAF mutation status, number of melanoma brain 
metastases, ECOG PS, LDH level and protein S100B level, treatment with corticoster-
oids at the time of starting combined immunotherapy, date and type of local and systemic 
therapy in advanced stages, toxicity, date and type of best overall response, date of 
progressive disease, last contact date, cause of death and death date.  
 
4.3.3. Statistical Analyses  
Descriptive statistics were used to characterize the patients’ population and treatment 
patterns. For manuscript 4, OS and PFS were calculated as the time from the initiation 
of the first cycle of combined checkpoint blockade until melanoma-specific or treatment-
related death and disease progression, respectively. Time-to-event analyses were cal-
culated where death or progression were considered as events. If neither occurred or if 
patients were lost to follow-up, the date of the last documented presentation was used 
as a censored observation. The survival and progression probabilities were calculated 
using the Kaplan-Meier method for censored failure time data assuming proportional 
hazards. When appropriate, multivariate logistic regression models were used to exam-
ine associations. Hazard ratios (HR) with 95% confidence intervals (CI) were calculated 
to quantify the impact on survival. The association of treatment response as a categorical 
variable with clinical characteristics or serum biomarkers was investigated with the Chi-




square test and logistic regression, as appropriate. Results were reported as two-sided 
p values with 95% CIs. All p-values presented are two-sided tests of statistical signifi-
cance at 0.05. All analyses were carried out with SPSS statistics version 23.0 (IBM) or 
GraphPad Prism version 5.01 (GraphPad Software).  
For manuscript 6, estimates of survival rates, OS and follow-up time were calculated 
considering the date of melanoma brain metastases diagnosis, and last patient contact 
or death. Kaplan-Meier estimates were used for the calculation of OS. Differences be-
tween groups were assessed using the log-rank test. When appropriate, multivariate lo-
gistic regression models were used to examine associations. Results were reported as 
two-sided p values with 95% CIs. All p-values presented are two-sided tests of statistical 
significance at 0.05. All statistical analyses were performed using SPSS v.25 (IBM Corp. 










For the elaboration of this thesis, 6 original manuscripts were included, and will be pre-
sented in dedicated separate sections. 
 
To evaluate the long-term outcomes in patients with stage IV melanoma treated with 
immunotherapy and targeted therapy between 2011-2019 (Work project 1), the following 
manuscripts were considered:  
 
• Improvement of overall survival in stage IV melanoma patients during 2011-
2014: analysis of real-world data in 441 patients of the German Central Ma-
lignant Melanoma Registry (CMMR) 
 
• Primary Resistance to PD-1-Based Immunotherapy - A Study in 319 Pa-
tients with Stage IV Melanoma 
 
• Indirect Comparison of Combined BRAF and MEK Inhibition in Melanoma 
Patients with Elevated Baseline Lactate Dehydrogenase 
 
• Combined immune checkpoint blockade for metastatic uveal melanoma: a 






For evaluating the impact in survival outcomes of immunotherapy and targeted therapy, 
and their combination with local therapies in patients with melanoma brain metastases 
(Work project 2), the following manuscripts were considered:  
 
• Immunotherapy plus surgery/radiosurgery is associated with favorable 
survival in patients with melanoma brain metastasis 
 
• Combined immunotherapy with nivolumab and ipilimumab with and with-
out local therapy in patients with melanoma brain metastasis: a DeCOG* 
study in 380 patients 
 
For all work projects as first author, Teresa Amaral, led the design of the study, per-
formed the data analyses, interacting with biostatisticians when needed, performing data 
analysis, interpreting results, and writing all the manuscripts that are presented in this 
thesis.  
For all the work projects as co-author, Teresa Amaral was involved in the design of the 















1. "Improvement of overall survival in stage IV melanoma patients during 
2011-2014: analysis of real-world data in 441 patients of the German Central 
Malignant Melanoma Registry (CMMR)." Forschner, A., F. Eichner, T. Amaral, 











J Cancer Res Clin Oncol (2017) 143:533–540
DOI 10.1007/s00432-016-2309-y
ORIGINAL ARTICLE – CLINICAL ONCOLOGY
Improvement of overall survival in stage IV melanoma patients 
during 2011–2014: analysis of real-world data in 441 patients 
of the German Central Malignant Melanoma Registry (CMMR)
Andrea Forschner1 · Felizitas Eichner1,2 · Teresa Amaral1,3 · Ulrike Keim1 · 
Claus Garbe1 · Thomas Kurt Eigentler1 
Received: 28 October 2016 / Accepted: 17 November 2016 / Published online: 22 November 2016 
© Springer-Verlag Berlin Heidelberg 2016
targeted therapy had a better OS (median 14 months) than 
patients with ipilimumab treatment (median 7 months). 
Among all patients with first-line systemic treatment, 
outcome of patients diagnosed in the years 2013/2014, 
compared to 2011 and 2012, showed an improved sur-
vival. Three-year OS for patients that entered stage IV in 
2013/2014 was 37% compared to those that entered stage 
IV in 2011 (18%) and 2012 (20%).
Conclusion The analysis of real-world data of treatment 
of metastatic melanoma showed an improvement of OS 
with both immunotherapy and targeted therapy. In case of 
cerebral metastasis, patients treated with targeted therapy 
showed a longer median OS than patients treated with 
ipilimumab.
Keywords Melanoma · Survival · Checkpoint inhibitors · 
Targeted therapy · Chemotherapy · Pembrolizumab · 
Nivolumab · Ipilimumab · Brain metastasis
Introduction
Systemic treatment of metastasized melanoma has been 
disappointing for decades. Chemotherapy with dacarbazine 
or carboplatin and paclitaxel resulted in median survival 
times of 7–9 months, and for a long time, no other treat-
ment regime was found to prolong survival in advanced 
metastatic melanoma patients (Dummer et al. 2012; 
Eigentler et al. 2003; Pflugfelder et al. 2011; Tsao et al. 
2004). At that time, one-year overall survival (OS) of stage 
IV melanoma patients was about 25–30% (Balch et al. 
2009).
It is impressive to see that in the last 5 years 1-year OS 
for stage IV patients reported in clinical trials has risen 
to over 70%. This dramatic improvement is due to the 
Abstract 
Background During 2011 and 2014, new treatment modali-
ties like tyrosine kinase inhibitors and checkpoint inhibi-
tors were introduced into the therapy of metastatic mela-
noma. This study addresses the question whether overall 
survival (OS) of metastatic melanoma patients has already 
been improved in 441 patients diagnosed with metastatic 
melanoma between 2011 and 2014 in the real-world setting 
at the University Hospital Tuebingen.
Methods All patients were documented with their different 
therapies by the CMMR and followed up until March 2016. 
Survival probabilities were calculated by Kaplan–Meier 
estimators, and log-rank tests were used to evaluate sig-
nificances. Hazard ratios were estimated by Cox regression 
analysis for survival probabilities and prognostic factors in 
stage IV melanoma.
Results Best OS was observed in patients (n = 93) treated 
by metastasectomy as primary treatment with the intention 
to completely excise all metastases (3-year OS 61%). OS 
for patients with first-line systemic treatment (n = 258) 
was unfavorable in general (3-year OS 23%). Of those, the 
most favorable outcome was observed in patients without 
brain metastasis and treated with immunotherapy (mostly 
ipilimumab), as first-line treatment (median OS 35 months, 
3-year OS 43%). In case of brain metastases, patients with 
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availability of multiple new drugs. So, it has become possi-
ble to inhibit the mitogen-activated protein kinase (MAPK) 
pathway in BRAF V600-mutant melanoma selectively by 
using BRAF/MEK inhibitors. Furthermore, checkpoint 
inhibitors enable an increase in host T cell response against 
tumor cells.
Monotherapy with BRAF inhibitors led to an increase 
in the median progression-free survival (PFS) of about 
5 months and 1-year OS reached 68% (Chapman et al. 
2011; Hauschild et al. 2012). Combinations of BRAF and 
MEK inhibitors prolonged median PFS to even ~10 months 
and improved 1-year OS to 74% (Larkin et al. 2014; Long 
et al. 2014). Concerning checkpoint inhibitors, treatment 
with ipilimumab resulted in a 1-year OS of 46% (Rob-
ert et al. 2011), whereas treatment with PD-1 inhibitors 
showed a one-year OS of ~70% (Robert et al. 2015a, b).
These new treatment options have significantly improved 
the prognosis of metastasized melanoma patients—but 
mainly in clinical trials with selected cohorts. For patient 
care, it is even more important to assess their efficacy in the 
real-world setting. To determine whether these new drugs 
can provide a survival benefit for patients in a real-world 
setting also, we performed an OS analysis of our patients 
suffering from advanced melanoma who entered stage IV 
between 2011 and 2014 and received treatment at the Uni-
versity Hospital Tuebingen.
Methods
Our analysis was performed on prospectively collected 
data of stage IV melanoma patients entered into the Cen-
tral Malignant Melanoma Registry (CMMR). Routinely, 
all melanoma patients of our hospital are registered in the 
CMMR. Informed consent was obtained from all patients 
included in this study. Captured data include general infor-
mation like date of birth, sex, origin and date of death, if 
applicable. In addition, the CMMR provides melanoma-
specific variables such as localization, size, histological 
type, Breslow’s tumor thickness and Clark level. For stage 
IV patients, 61 additional variables are documented includ-
ing localization of metastases, BRAF, KIT and NRAS 
mutation status, treatment lines, period of treatment, treat-
ment regimens, best response, dose modifications and type 
of outcome. Adverse events or serious adverse events are 
not captured. Data are entered into the database each time 
the patient visits the hospital for a treatment cycle, surgery 
or radiotherapy. Phone contact with the patient, the fam-
ily or external treating practitioners is included into the 
patient file if the patient had no contact with hospital for an 
extended amount of time.
Statistical analysis was performed using the statistical 
program for social sciences SPSS version 23 (IBM, New 
York, USA). Survival probabilities and median survival 
with 95% confidence intervals (CI) were estimated accord-
ing to the Kaplan–Meier method with the time depicted 
in months. A log-rank test was performed to reveal pos-
sible differences between the groups, and p-values < 0.05 
were considered statistically significant. Afterward, a Cox 
regression model was fitted to obtain hazard ratios (HR) 
and their 95% confidence intervals. Follow-up time was 
defined from the date entering stage IV to the date of last 
known contact or death. This study was approved by the 
local ethics committee of the University of Tuebingen (ref-
erence number 676/2016BO2).
Results
In September 2016, the CMMR comprised a total num-
ber of over 13,900 patients with invasive melanomas born 
between 1884 and 2007, who were treated at the University 
Hospital Tuebingen. The selected patient cohort for these 
analyzed consisted of 187 women and 254 men. Follow-
up ranged from 10 days to 61 months with a median fol-
low-up time of 14 months. The median age at time point 
of advanced disease was 59 years [19Y–96Y, interquartile 
range 48Y–72Y]. When entering stage IV, 105 patients 
(23.8%) had cerebral metastases, 256 patients (58%) lung 
metastases and 138 patients (30%) liver metastases.
OS between patients with metastases only to distant 
skin or lymph nodes (M1a, n = 53), metastases of the lung 
(M1b, n = 75) and metastases of other organs or increased 
LDH (M1c, n = 313) showed a significant survival differ-
ence (p < 0.0001, Fig. 1). One-year OS was best for M1a 
patients with 86.6%, followed by M1b patients with 74.3% 
and M1c patients with 51.6% (Table 1).
In the first-line situation, patients treated surgically 
(n = 93) had a significantly improved OS over patients 
treated systemically (n = 258) (p < 0.0001, Fig. 2). Fur-
thermore, patients whose metastases could be removed 
completely by surgery had the most favorable prognosis 
and a 1-year OS of 76.8% compared to 57.5% of systemi-
cally treated patients (Table 1).
Of the 258 patients who received first-line systemic 
treatment, 47% were BRAF wild type and 41% were 
BRAF mutated. In 12% of the cases, the mutation status 
was not determined. Of them, 37% suffered from uveal 
melanoma and the others were diagnosed with stage IV in 
2011 when BRAF inhibitors were not available outside of 
studies in Germany.
Figure 3 shows a comparison of OS for the differ-
ent systemic treatment options. Sixty-eight patients 
received targeted therapy, 52 patients immunother-
apy and 132 patients chemotherapy. Six patients were 
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a blinded clinical trial. Twelve of the 68 patients (17.6%) 
with targeted therapy were treated by a combination of 
BRAF and MEK inhibitor, seven (10.3%) received MEK 
inhibitor only and 49 (72%) received BRAF inhibitor 
monotherapy.
Forty-two of the 52 (80.8%) patients with immuno-
therapy received ipilimumab and five (9.6%) patients PD-1 
antibodies. The five remaining patients were treated with 
the bispecific antibody L19 IL2 in clinical trials, three of 
them in combination with dacarbazine.
We calculated a significant difference between the 
treatments options (p = 0.003). Best OS was detected in 
patients treated with immunotherapy. For these patients, 
median OS was 33 months, compared to 16 months for 
patients receiving targeted therapy and 11 months for 
patients in the chemotherapy group (Fig. 3; Table 1).
Fig. 1  Kaplan–Meier survival 
curves by stage M1a, M1b and 
M1c, p < 0.0001












Stage M1a (n = 53) Not reached 86.6 (77.4–95.8) 72.1 (59.6–84.6) 59 (43.3–74.7) 1
Stage M1b (n = 75) 26 (14.4–37.6) 74.3 (64.3–84.3) 53.6 (41.8–65.4) 41.7 (28.6–54.8) 1.75 (1.02–3.03)
Stage M1c (n = 313) 12 (9,8–14.2) 51.6 (46.1–57.1) 31.9 (26.6–37.2) 24 (18.7–29.3) 3.05 (1.91–4.87)
First-line surgery (n = 93) Not reached 76.8 (68.3–85.5) 66.8 (56.8–76.8) 61.1 (50.1–72.1) 0.36 (0.25–0.53)
First-line systemic therapy (n = 258) 15 (12.1–18) 57.5 (51.4–63.6) 35.8 (29.7–41.9) 23.4 (17.1–29.7) 1
First-line targeted therapy (n = 68) 16 (10.6–21.4) 64.7 (53.3–76.1) 36.3 (24.5–48.1) 27.6 (15.8–39.4) 0.73 (0.52–1.03)
First-line immunotherapy (n = 52) 33 (21.7–44.3) 67.1 (54.4–79.8) 60.3 (46.6–74.0) 37.4 (16.6–58.2) 0.5 (0.32–0.77)
First-line chemotherapy (n = 132) 11 (7.6–14.4) 49.6 (41–58.2) 26.9 (19.1–34.7) 15.9 (8.8–23) 1
Targeted therapy + brain metastases (n = 24) 14 (5.4–22.6) 58.3 (38.5–78.1) 28.6 (10.2–47) 15.9 (17.2–33.1) 1
Targeted therapy no brain metastases (n = 44) 17 (12.1–21.9) 68.2 (54.5–82) 40.8 (25.7–55.9) 34 (18.7–49.3) 0.75 (0.42–1.35)
Immunotherapy + brain metastases (n = 10) 7 (0–17.9) 50 (19–81) 40 (9.6–70.4) 1
Immunotherapy no brain metastases (n = 42) 35 (25.5–44.5) 71.2 (71.1–71.3) 65.4 (65.3–65.6) 43.1 (43.3–42.9) 0.38 (0.15–0.94)
Chemotherapy + brain metastases (n = 23) 9 (4.3–13.7) 26.1 (26–26.3) 1
Chemotherapy no brain metastases (n = 109) 14 (10.3–17.7) 54.7 (54.6–54.8) 32.9 (32.8–33) 19.4 (19.3–19.5) 0.45 (0.28–0.72)
2011 stage IV diagnosis (n = 68) 12 (8.3–15.7) 51.5 (51.4–51.6) 30.9 (30.8–31.0) 17.6 (17.5–17.7) 1
2012 stage IV diagnosis (n = 70) 13 (8.6–17.4) 58.2 (58.1–58.3) 32.2 (32.1–32.3) 19.7 (19.6–19.8) 0.82 (0.61–1.11)
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In the group of patients receiving targeted therapy, 24 
of 68 (35.3%) had brain metastases, but only ten of 52 
patients (19.2%) were in the immunotherapy group and 23 
of 132 patients (17.4%) were in the chemotherapy group.
For patients treated with targeted therapy, median OS 
was 14 months for patients with brain metastases compared 
to 17 months for patients without brain metastases (Fig. 4; 
Table 1). Patients who received immunotherapy as first-line 
treatment had a median OS of 7 months in case of brain 
metastases compared to 35 months for patients without 
brain metastases (Fig. 5; Table 1). For more details, please 
refer to Table 1. OS was significantly different between 
patients with and without brain metastases who were 
treated with first-line chemotherapy (p = 0.001; median 
OS 9 months for patients with cerebral metastases vs. 
14 months for patients without brain metastases; Table 1).
An illustration of the survival curves of patients treated 
systemically as first option depending on the year of enter-
ing stage IV melanoma is provided in Fig. 6. In 2011, 
70.1% of the patients were treated with chemotherapy, 
11.8% with immunotherapy and 16.2% with targeted ther-
apy. In 2012, 32.9% of the systemically treated patients 
Fig. 2  Kaplan–Meier survival 
curves by first-line surgical vs. 
systemic treatment, p < 0.0001
Fig. 3  Kaplan–Meier survival 
curves by first-line systemic 
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received targeted therapy first line, 11.4% immunotherapy 
and 55.7% chemotherapy, whereas in the years 2013/2014, 
32.8% of the patients were treated with targeted therapy, 
31.6% with immunotherapy and only 38.6% with chemo-
therapy. Median OS for patients entering stage IV in 2011 
was 12 months, in 2012 13 months and in 2013/2014 
17 months. The difference in survival probability between 
2012 and 2013/2014 was rather small after 1 year, but 
increased during longer follow-up. Three-year OS was 
19.7% for the 2012 group and 37.2% for the 2013/2014 
group (Table 1).
Discussion
In general, our analyses of real-world treated melanoma 
patients confirmed findings of clinical trials of novel drugs 
to improve OS. Not surprisingly, the improvement was less 
extensive compared to clinical trials, as these normally 
include selected patients, only. In contrast, in our study all 
real-life patients were included, who, e.g., suffered from 
brain metastases, had comorbidities or had a decreased per-
formance status. This approach is important as these are the 
patients in the daily clinical practice.
Fig. 4  Kaplan–Meier survival 
curves by first-line targeted 
therapy and cerebral status, 
p = 0.329
Fig. 5  Kaplan–Meier survival 
curves by first-line immuno-
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Compared to OS data of the time period without novel 
drugs in systemic melanoma therapy, survival for M1a, 
M1b and even M1c patients improved over the last years 
steadily: 1-year OS for M1a patients has increased from 
62%, reported by Balch et al. in 2009, to 85% in our cohort. 
Likewise, 1-year OS for M1b patients has improved from 
53 to 74% and for M1c patients from 33 to 52% (Balch 
et al. 2009). As the indication, when to start systemic treat-
ment and to perform surgery has not changed over the 
years, the improvement of OS in each M stage must be due 
to the availability of new, more effective drugs.
Regarding the year of entering advanced disease, we 
detected an improved OS for patients starting systemic 
treatment in the years 2013/2014 compared to those of the 
years 2012 and 2011. The reason for this improvement lies 
in the approval and availability of novel drugs. The BRAF 
inhibitor vemurafenib was approved in 2012 as was dab-
rafenib in 2013. Until 2013, chemotherapy pretreatment 
was requested before initiating ipilimumab. Ipilimumab 
was approved in Germany for first-line treatment not until 
2013. For these reasons, the proportion of patients treated 
first line by immunotherapy or targeted therapy increased 
markedly in 2011 and 2013/2014.
Patients that started systemic therapy in the years 
2013/2014 had a 1-year OS of 60% and 2-year OS of 42%. 
These results are even more favorable than those reported 
by Leeneman et al. (2015) from the Netherlands, compar-
ing OS in “real-world” systemically treated patients up 
to 2011 with those treated in the years 2012–2015. They 
reported a 1-year OS of 40% and a 2-year OS of 20% in 
the 2012–2015 group. The increased survival probability in 
our patients might be due to the close melanoma follow-up 
program in Germany that compromises radiologic staging 
in metastasized patients every 6 months permitting an early 
stage IV diagnosis and therefore an early time point to start 
systemic treatment. This so-called lead-time bias might 
explain the OS differences between our patients and the 
patients of Leeneman et al.
Comparing first-line systemic therapy to first-line surgi-
cal therapy, our data revealed that surgically treated patients 
still had an improved OS despite the availability of novel 
drugs. This benefit is at least partly due to a “selection 
bias”: Only patients with limited tumor burden are usually 
considered for complete metastasectomy, whereas wide-
spread metastases lead to the initiation of systemic treat-
ment. Our findings are consistent with the current literature. 
In 2012, Weide et al. reported a 5-year OS of 37% in case 
of complete metastasectomy in stage IV patients, compared 
to 10% for patients receiving other treatment modalities 
(Weide et al. 2012). In our cohort, 5-year OS of first-line 
surgically treated patients was even 58%. This improve-
ment of OS in surgically treated patients is probably due to 
better detection of metastases (a) by PET-CT scans with a 
better selection of patients and (b) by the newly established 
systemic treatment options which are now regularly applied 
second line in case of further disease progression.
Overall, our results confirm the necessity to consider a 
complete metastasectomy before initiating systemic treat-
ment as it is recommended in the malignant melanoma 
guidelines (Pflugfelder et al. 2013).
Concerning systemic treatment types, immunotherapy 
and targeted therapy seem to be more or less equally effec-
tive in the first year: One-year OS was 67% in the immu-
notherapy group and 65% in the targeted therapy group. 
Fig. 6  Kaplan–Meier survival 
curves by year entry stage IV 
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However, we detected an impressive difference in the 
2-year OS with 60% for patients receiving immunotherapy 
and 36% for patients receiving targeted therapy. Patients 
without cerebral metastases receiving immunotherapy as 
first-line treatment had a better median OS (35 months) 
than patients with targeted therapy (17 months). These 
data are consistent with the literature, also. Median OS in 
treatment naïve patients treated with ipilimumab was about 
30 months (Thompson et al. 2012), and patients treated 
with dabrafenib achieved a median OS of 19 months (Long 
et al. 2015).
On the one hand, this difference could be explained 
by the fact that most of the patients with targeted ther-
apy develop drug resistance over time, while patients 
responding to immunotherapy seem to have a long-lasting 
response. However, in selected patients acquired resistance 
to PD-1 antibodies after initial response has been described 
(Wong and Ribas 2016) (Niezgoda et al. 2015; Zaretsky 
et al. 2016). On the other hand, patients with extensive 
tumor masses and/or clinical symptoms were predomi-
nantly treated by BRAF/MEK inhibitors to achieve a fast 
response to get relief for the patient.
The development of resistance in patients treated by 
targeted therapy might be delayed by supplementing a 
MEK inhibitor with the BRAF inhibitor. The proportion of 
patients receiving such a combination treatment was only 
18%. This rather small number is due to the fact that in 
Germany MEK inhibitors were only available outside clini-
cal studies in the frame of an early access program from 
the end of 2014 on. The combination of BRAF and MEK 
inhibitors was approved in Germany in 2015.
Furthermore, the difference in OS might be due to 
imbalances in the presence of brain metastases throughout 
the treatment cohorts (35.3% in the group treated with tar-
geted therapy vs. 19.2% in the immunotherapy group vs. 
17.4% in the chemotherapy group). In case of cerebral 
metastasis, we detected a clear improvement of median 
OS for targeted treated patients (14 months) vs. patients 
treated by immunotherapy (7 months) or chemotherapy 
(9 months). Our data for patients with brain metastases 
treated by targeted therapy are even more favorable than 
published in the current literature. Long et al. reported 
a median OS of 8.3 months in treatment naïve cerebral 
metastasized patients that received a therapy with dab-
rafenib (Long et al. 2012). For vemurafenib, median OS of 
5.3 months in symptomatic cerebral metastasized patients 
was reported by Dummer et al. (Dummer et al. 2014). 
Regarding the intracranial activity of ipilimumab, our 
findings are consistent with a paper by Margolin and col-
leagues. In their cohort, asymptomatic cerebral metasta-
sized patients reached a median OS of 7 months under a 
treatment with ipilimumab (Margolin 2012).
This study has several limitations: It has to be consid-
ered that the number of patients with brain metastasis in 
each of our treatment groups was rather small. Therefore, 
our results have to be treated with caution and have to be 
confirmed in larger patient collectives. Furthermore, this 
study evaluated only first-line treatments. It would also 
be important to analyze the subsequent treatment lines, of 
course. For BRAF-mutant patients, however, our evaluation 
indicates a long-term survival benefit for patients treated by 
immunotherapy as first treatment option, despite all meth-
odological limitations. Due to the fact that these real-world 
data compromise all patients with different extensions of 
the disease requiring different treatment procedures we 
were not able to power our analyses to detect a difference 
between the treatment groups, adequately.
We also have to consider that less than 10% of the first-
line immunotherapy patients received PD-1 antibodies. In 
Germany, PD-1 antibodies were not approved until 2015 
for the first-line treatment of advanced melanoma followed 
by the approval of combined nivolumab and ipilimumab in 
2016. Likewise, first-line targeted therapy in 2016 consists 
in a combination of BRAF and MEK inhibition, whereas 
less than 20% of the first-line targeted treated patients 
received such a combination treatment in our study.
In summary, our analysis of real-world data of treatment 
schedules for metastatic melanoma during the years 2011–
2014 showed an improvement of OS by immunotherapy as 
well as targeted therapy. In patients with brain metastasis, 
targeted therapy seems to prolong OS over ipilimumab. 
Current studies evaluate whether the combination of check-
point and kinase inhibitors will furthermore prolong OS in 
metastatic melanoma patients.
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Abstract: Background: Primary resistance to immunotherapy can be observed in approximately
40–65% of the stage IV melanoma patients treated with immune checkpoint inhibitors. A minority of
the patients receive a second-line therapy, and the clinical benefit is small. Patients and methods:
Stage IV melanoma patients treated with first-line PD-1-based immunotherapy between January 2015
and December 2018 were investigated. Primary resistance was defined as progressive disease (PD) at
the time of the first tumor assessment after starting immunotherapy. Patients with complete response,
partial response, and stable disease were classified as having disease control (DC). Overall survival
(OS) and progression-free survival (PFS) were evaluated by Kaplan–Meier estimator. Univariate and
multivariate logistic regression analyses were performed to determine prognostic factors associated
with OS. Results: Three hundred and nineteen patients were included, and 40% had primary resistance
to immunotherapy. The median follow-up time was 22 months. Patients with primary resistance had
1-, 2-, and 3-year OS rates of 41%, 15%, and 10%, respectively, compared to 91%, 81%, and 65% for the
patients who achieved DC. The following independently significant prognostic factors for OS were
identified: protein S100B level and primary tumor localization. There was a statistically significant
di↵erence for OS (p < 0.0001) but not for PFS (p = 0.230) when analyzing risk groups formed with
a combination of these two variables (low-, intermediate-, and high-risk subgroups). Conclusions:
Melanoma patients with primary resistance to immunotherapy have a dismal prognosis. Response at
the first tumor assessment after starting immunotherapy is a stronger prognostic factor for the further
course of the disease than pretreatment risk factors.
Keywords: metastatic melanoma; primary resistance; checkpoint-inhibitors; combined
immunotherapy; pseudoprogression
1. Introduction
Immunotherapy with checkpoint inhibitors is currently the most e↵ective therapy for metastatic
melanoma, achieving high remission rates and long-term survival [1]. These therapies include
ipilimumab, a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, nivolumab and
pembrolizumab, both programmed cell death protein 1 (PD-1) antibodies, and the dual combination of
anti-PD-1 and anti-CTLA-4 antibodies nivolumab plus ipilimumab. Results from studies investigating
these therapies in melanoma patients are available [2–4]. Long-term survival data have also been
published, specifically the 5- and 10-year overall survival (OS) rates for ipilimumab monotherapy,
and 5-year OS rates for nivolumab, and the combination of nivolumab with ipilimumab [4–6]. The latest
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update showed that the 5-year OS survival rate for nivolumab and ipilimumab was 52%, for nivolumab
monotherapy was 44%, and for ipilimumab monotherapy was 26% [4].
Despite improvement in survival outcomes compared with the past (e.g., chemotherapy), primary
resistance to checkpoint inhibitor therapy exists, and a considerable number of patients still do not
derive benefit from these therapies [7,8]. Primary resistance is typically assumed in the clinical practice
if tumor progression is observed at the first tumor assessment after therapy starts, which in our center
takes place around week 12 (+/ 5 days). It is observed in a rather high percentage of patients, estimated
to be between 40% and 65%, depending on whether patients receive first-line immunotherapy or
immunotherapy after progression under other systemic therapies [3,9,10]. Higher percentages were
observed when patients were treated with ipilimumab monotherapy [2,11].
Resistance to immunotherapy can be classified as primary (or innate) and secondary or
acquired [12–15]. Some authors also refer to an intermediate phenotype that is adaptive resistance [16].
Clinically, resistance mechanisms to immunotherapy can be grouped into those that always preclude
response to immunotherapy and those that appear later, allowing tumor escape and progression after
an initial benefit. However, the molecular mechanisms of resistance to immunotherapy involving the
host, the tumor, and the tumor microenvironment can overlap and be present at di↵erent timepoints of
the course of the disease.
Regarding primary resistance to immunotherapy, which is the focus of our analysis,
the following resistance mechanisms have been described: (a) diminished sensitivity to the INF-
signaling pathway [8,16,17]; (b) insu cient T-cell activation or absence of T-cells in the tumor
microenvironment [18–20]; (c) increased infiltration of T-regulatory cells [21–23]; (d) upregulation of
immunosuppressive markers [24,25]; (e) insu cient antigen presentation and/or antigen recognition,
due to, for example, low tumor mutation burden, loss of MHC class I and  -2 microglobulin, or absence
of neo-antigen presentation [17,26–29].
In the present study, we focus on the clinical outcomes of stage IV melanoma patients with
primary resistance to first-line PD-1-based immunotherapy, specifically pembrolizumab, nivolumab,
and nivolumab plus ipilimumab. We evaluate the course of the disease in patients prospectively
registered in the Central Malignant Melanoma Registry (CMMR) of the German Dermatological
Society, and treated between January 2015 and December 2018 at the University Hospital Tübingen.
We addressed the following questions: (1) Which factors are associated with the development of
primary resistance? (2) How does survival of patients with primary resistance compare to those with
disease control (complete response (CR), partial response (PR), and stable disease (SD))? (3) Did the
patients with primary resistance to PD-1-based immunotherapy receive further therapies, and if so,
which therapies were o↵ered and what was the outcome?
2. Patients and Methods
2.1. Patients Cohort
Three hundred and nineteen patients with stage IV melanoma treated with first-line anti-PD-1
antibodies immunotherapy were included. These patients had available data on the type of response
at the time of the first tumor assessment after starting immunotherapy, and also data that allowed us
to identify the best overall response to immunotherapy. The Ethics Committee of the Medical Faculty
of the University of Tübingen approved this study (approval number 676/2016BO2).
All patients included signed the patients’ informed consent and were prospectively recorded
by the German Central Malignant Melanoma Registry (CMMR). Clinical data were obtained from
the clinical records from the University Hospital Tübingen, documented in an open source database,
Epi Info™, and later merged into a final SPSS® file. The following variables were recorded: gender,
date of birth, date of stage IV diagnosis, stage at initial diagnosis according to the American Joint
Committee on Cancer (AJCC) version 8 [30], localization and histopathological characteristics of the
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time of stage IV diagnosis, localization and number of metastatic organs, type of systemic therapy
for stage IV disease and respective start and end dates, response at the first tumor assessment after
systemic therapy start, best overall response to systemic therapy, and time of last follow-up or death
from any cause.
Primary resistance was defined as progressive disease (PD) at the time of first tumor assessment
after immunotherapy start. In our center, this is performed after 12 weeks (+/ 5 days). This evaluation
was performed using RECIST 1.1 [31]. Patients with CR, PR, and SD were considered to have
disease control (DC). Best overall response to first-line immunotherapy was defined as the best
response—intracranial and extracranial—that patients achieved during the time they were treated.
Taking that into consideration, patients for whom the best overall response was PD were, by definition,
patients with primary resistance. These patients did not continue to receive immunotherapy, since the
clinical evaluation also determined that they were not deriving benefit from the ongoing therapy.
Pseudoprogression was considered for patients who were classified as having PD by RECIST
1.1 [31] at the time of first assessment after immunotherapy start but, due to clinical benefit, continued
receiving immunotherapy and had a response later in the course of their disease. These patients were
not considered as primary resistant and were included in the group of disease control.
2.2. Statistical Analysis
Statistical analysis was performed using the statistical program for social sciences SPSS Version
25 (IBM, New York, NY, USA). STATA® v15 (StataCorp LLC, College Station, TX, USA) was used to
generate the final version of the Kaplan–Meier survival curves.
Descriptive statistical analyses, frequency tables, and chi-square tables were used to characterize
the patients’ population. Variables with missing information were excluded from the respective
analysis. Follow-up time was defined as the time between the date of stage IV diagnosis and the date
of the last follow-up or death from any cause. Survival analyses were performed according to the
Kaplan–Meier method. In addition, the 1-, 2-, and 3-year survival rates were calculated with a 95%
confidence interval. Factors that were significant in the univariate analysis were included into the
multivariate logistic regression analysis. The level of significance was 0.05 (two-sided) in all analyses.
The cut-o↵ date for data analysis was March 2019.
3. Results
3.1. Univariate and Multivariate Analysis
Table 1 shows characteristics of the study population: 192 patients (60%) had disease control (SD,
PR, CR) and 127 (40%) patients had primary resistance. The median age of the patients at the time of
stage IV melanoma diagnosis was 68 years; interquartile range (IQR) (56–77). Age was not associated
with primary resistance. Thirty-five patients (11%) had more than 3 organs with metastases at the time
of immunotherapy beginning and 292 patients (89%) had 1–3 organs with metastases. Sixty-three (19%)
patients had brain metastases and 118 (36%) patients had liver metastases. The number of organs
involved, the presence of brain metastases, and the presence of liver metastases were not associated
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Table 1. Patients characteristics, univariate and multivariate analysis for the whole cohort, according 
to best overall response to first-line PD-1-based immunotherapy. 
Characteristics 
ICI Cohort 












n = 127 (40) 
DC (CR, PR, SD) 
n = 192 (60) 
Age Distribution     
0.732  
Median (years [IQR]) 68 (56–77) 65 (55–78) 68 (56–77) 
<60y 101 (32) 37 (29) 64 (33) 
60y–75y 114 (36) 47 (37) 67 (35) 
>75y 104 (32) 43 (34) 61 (32) 
Sex    
0.049 0.822 Male 192 (60) 68 (54) 124 (65) 
Female 127 (40) 59 (46) 68 (35) 
Tumor localization *    
0.000 0.001 
Head and neck 54 (22) 12 (13) 42 (27) 
Trunk 73 (29) 18 (20) 55 (34) 
Extremity 109 (43) 54 (59) 55 (34) 
Other 15 (6) 7 (8) 8 (5) 
Histological subtype *    
0.007 0.452 
SSM 76 (32) 31(37) 45 (29) 
NM 72 (30) 18(21) 54 (35) 
LMM  13 (6) 0 13 (9) 
ALM 30 (12) 15 (18) 15 (10) 
Mucosal 15 (6) 7 (8) 8 (5) 
Other 32 (14) 14 (16) 18 (12) 
Stage at initial diagnosis *    
0.114  
I 48 (17) 19 (18) 29 (17) 
II 84 (31) 25 (23) 59 (35) 
III 95 (35) 38 (37) 57 (34) 
IV 47 (17) 24 (22) 23 (14) 
Number of organs with 
metastases    
0.098 0.470 
1-3  285 (89) 109 (86) 176 (92) 
>3  34 (11) 18 (14) 16 (8) 
Brain metastases    
0.618  No  258 (81) 101 (79) 157 (82) 
Yes 61 (19) 26 (21) 35 (18) 
Liver metastases    
0.139  No  204 (64) 75 (59) 129 (67) 
Yes 115 (36) 52 (41) 63 (33) 
BRAF mutation *    
0.844  BRAFmut 88 (45) 32 (44) 56 (46) 
BRAFwt 106 (56) 40 (56) 66 (54) 
LDH level *    
0.029 0.532 Normal 190 (68) 67 (60) 123 (73) 
Elevated 90 (32) 44 (40) 46 (27) 
S100B level *    
0.000 0.008 Normal 157 (56) 44 (40) 113 (65) 
Elevated 125 (44) 65 (60) 60 (35) 
* patients with no information available were excluded in the respective analysis; IQR = interquartile range; ! Chi-
square test performed between the two groups—primary resistance and disease control; ICI = immune-checkpoint 
inhibitors cohort—145 patients received first-line treatment with nivolumab plus ipilimumab and 174 received 
antiPD-1 antibodies monotherapy (nivolumab n = 46 and pembrolizumab n = 128).; y = years; SSM = superficial 
spreading melanoma; NM = nodular melanoma; LMM = lentigo malignant melanoma; ALM = acral lentiginous 
melanoma; BRAFmut = presence of BRAFV600E/K mutation; BRAFwt = BRAF wild-type; LDH = lactate 
dehydrogenase; S100B = tumor marker protein S100B. p-values that are statistically significant are noted in bold. 
In our cohort we had slightly more men (60%) than women (40%). In the univariate analysis, sex 
was a statistically significant factor associated with primary resistance, with male patients having 
better outcomes than female patients. In the multivariate logistic regression analysis, sex was not a 
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IV 47 (17) 24 (22) 23 (14) 
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1-3  285 (89) 109 (86) 176 (92) 
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Brain metastases    
0.618  No  258 (81) 101 (79) 157 (82) 
Yes 61 (19) 26 (21) 35 (18) 
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0.139  No  204 (64) 75 (59) 129 (67) 
Yes 115 (36) 52 (41) 63 (33) 
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0.844  BRAFmut 88 (45) 32 (44) 56 (46) 
BRAFwt 106 (56) 40 (56) 66 (54) 
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0.029 0.532 Normal 190 (68) 67 (60) 123 (73) 
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* patients with no information available were excluded in the respective analysis; IQR = interquartile range; ! Chi-
square test performed between the two groups—primary resistance and disease control; ICI = immune-checkpoint 
inhibitors cohort—145 patients received first-line treatment with nivolumab plus ipilimumab and 174 received 
antiPD-1 antibodies monotherapy (nivolumab n = 46 and pembrolizumab n = 128).; y = years; SSM = superficial 
spreading melanoma; NM = nodular melanoma; LMM = lentigo malignant melanoma; ALM = acral lentiginous 
melanoma; BRAFmut = presence of BRAFV600E/K mutation; BRAFwt = BRAF wild-type; LDH = lactate 
dehydrogenase; S100B = tumor marker protein S100B. p-values that are statistically significant are noted in bold. 
In our cohort we had slightly more men (60%) than women (40%). In the univariate analysis, sex 
was a statistically significant factor associated with primary resistance, with male patients having 
better outcomes than female patients. In the multivariate logistic regression analysis, sex was not a 
statistically significant factor. 
Chi-square test performed between the two groups—primary resistance and disease control;
ICI = immune-checkpoint inhibitors cohort—145 patients received first-line treatment with nivolumab plus
ipilimumab and 174 received antiPD-1 antibodies monotherapy (nivolumab n = 46 and pembrolizumab n = 128).;
y = years; SSM = superficial spreading melanoma; NM = nodular melanoma; LMM = lentigo malignant melanoma;
ALM = acral lentiginous melanoma; BRAFmut = presence of BRAFV600E/K mutation; BRAFwt = BRAF wild-type;
LDH = lactate dehydrogenase; S100B = tumor marker protein S100B. p-values that are statistically significant are
noted in bold.
In our cohort we had slightly more men (60%) than women (40%). In the univariate analysis,
sex was a statistically significant factor associated with primary resistance, with male patients having
better outcomes than female patients. In the multivariate logistic regression analysis, sex was not a
statistically significant factor.
Tumor localization was significantly associated with primary resistance. Tumors of the extremities,
including acral melanomas, showed significantly increased primary resistance. Tumor localization
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also associated with primary resistance. Primary resistance was found especially in acral lentiginous
melanoma, mucosal melanoma, and other melanomas. In the multivariate logistic regression analysis,
however, the histological subtype was not a significant factor.
Another significant factor in the univariate analysis was an elevated level of the tumor marker
protein S-100B, which was associated with a significantly increased primary resistance, both in the
univariate and in the multivariate logistic regression analysis. An elevated LDH level was also
significantly associated with increased primary resistance in the univariate analysis, but was not
significant in the multivariate logistic regression analysis. The following variables were not significant
either in univariate analysis or in multivariate analysis: stage at initial diagnosis, number of metastatic
organs, presence of brain metastases, presence of liver metastases, and BRAF mutation status.
Table S1 shows characteristics of the study population where the primary resistance group includes
patients with PD at the first evaluation after starting immunotherapy and patients with SD with a
duration of less than 6 months (n = 169), and the DC group includes patients with CR, PR, and SD with
a duration of more than 6 months (n = 190). The results are similar to the ones described above, except
that the number of organs with metastases is a statistically significant factor in the univariate analysis
and LDH level is no longer statistically significant.
3.2. Survival Analysis
The median overall survival (OS) and the 1-year, 2-year, and 3-year OS rates are summarized
according to the best response in Table 2. The 2-year OS rates were 96% for patients with CR, 84% for
patients with PR, and 64% for patients with SD. Patients with primary PD had a 2-year OS rate of 15%.
The corresponding progression-free survival (PFS) rates are summarized in Table 3. Here, 2-year PFS
was 81% for CR, 63% for PR, 22% for SD, and 3% for PD. The 2-year OS rate in the disease control
(SD + PR + CR) group was 81% versus 15% in patients with primary resistance. As for the 2-year PFS
rate it was 56% versus 3%, respectively.
Table 2. Median overall survival and overall survival rates for patients receiving first-line PD-1-based
immunotherapy according to best overall response and type of immunotherapy.
Best Response Median OS
(Months; 95% CI)
OS (%; 95% CI)
1-Year 2-Year 3-Year
CR
n = 50 (15.7%) not reached 100% 95.7 (87.3–100) 87.7 (70.8–100)
PR
n = 80 (25.1%) not reached 89.5 (82.1–96.9) 84.4 (74.4–94.4) 84.4 (74.4–94.4)
SD
n = 62 (19.4%) 28 (22.9–33.1) 86.3 (77.5–95.1) 63.8 (47.7–79.9) 24.6 (2.6–46.5)
PD
n = 127 (39.8%) 11 (9.0–13.0) 41.3 (31.9–50.7) 14.7 (7.4–22.0) 10.1 (3.4–16.8)
DC
n = 192 (60.2%) not reached 91.3 (87.0–95.6) 81.0 (73.7–88.3) 64.6 (53.2–76)
PD-1 monotherapy
n = 174 (66.2%) 26 (19.7–32.3) 71.1 (64.0–78.2) 53.3 (45.1–61.5) 41.3 (32.1–50.5)
PD-1 + CTLA4
n = 145 (54.6%) 31 (17.2–44.8) 72.8 (65–80.6) 54.5 (42.9–66.1) 42.5 (24.1–60.9)
OS = overall survival; CR = complete response; PR = partial response; SD = stable disease; PD = progressive
disease; DC = disease control (CR + PR + SD); PD-1 monotherapy = nivolumab or pembrolizumab; PD-1 + CTLA4






Cancers 2020, 12, 1027 6 of 13
Table 3. Median progression-free survival and progression-free survival rates for patients receiving
first-line PD-1-based immunotherapy according to best overall response and type of immunotherapy.
Best Response Median PFS
(Months; 95% CI)
PFS (%; 95% CI)
1-Year 2-Year 3-Year
CR
n = 50 (15.7%) Not reached 87.6 (78.4–96.8) 81.2 (68.9–93.5) 72.2 (52.2–92.2)
PR
n = 80 (25.1%) 37 (14.97–59.03) 74.4 (64.2–85.0) 62.7 (50.0–75.4) 62.7 (50.0–75.4)
SD
n = 62 (19.4%) 12 (8.97–15.03) 43.0 (29.3–56.7) 21.8 (6.3–37.3) -
PD
n = 127 (39.8%) 4 (3.56–4.44) 8.7 (3.8–13.6) 3.2 (0–6.5) 1.1 (0–3.1)
DC
n = 192(60.2%) 33 (20.4–45.6) 68.1 (61.0–75.2) 56.2 (51.8–64.8) 48.7 (37.7–59.7)
PD-1 monotherapy
n = 174 (66.2%) 8 (5.5–10.5) 40.3 (32.7–47.9) 30.5 (23.1–37.9) 24.1 (16.3–31.9)
PD-1 + CTLA4
n = 145 (54.6%) 9 (1.8–16.2) 48.5 (40.1–56.9) 39 (29.2–78.8) -
PFS = progression-free survival; CR = complete response; PR = partial response; SD = stable disease;
PD = progressive disease; DC = disease control (CR + PR + SD); PD-1 monotherapy = nivolumab or pembrolizumab;
PD-1 + CTLA4 = nivolumab plus ipilimumab.
A statistically significant di↵erence can be seen in OS when patients are classified as having
primary resistance or disease control at the time of first tumor assessment after starting immunotherapy
(Figure 1A; p < 0.0001). The same is true for PFS (Figure 1B; p < 0.0001). After three years, a plateau was
formed for the group with disease control at a level of 65%, while the PFS rate for primary resistance
decreased to 10%. After three years, a certain plateau formation around a 45% PFS rate was also visible
in patients with disease control, while in patients with primary resistance, the PFS rate dropped to 1%.
The OS curves according to Kaplan and Meier show that in cases of CR and PR, the survival
remained largely stable after two years. This was not the case in patients that achieved SD, where there
was a relatively steep drop in the survival curve after 18 months, leading to OS rates very close to those
in patients with PD (Figure 1C; p < 0.0001). In the PFS analysis, there were even clearer di↵erences
between CR and PR. After the first year, there was a clear drop in PFS rates for PR compared to CR.
After three years, patients with SD had approximately the same survival rates as patients with PD
(Figure 1D; p < 0.0001).
Table S2 shows the patients characteristics for the whole cohort, considering the type of first-line
immunotherapy received. One hundred and seventy-four patients received monotherapy with
anti-PD-1 (nivolumab or pembrolizumab), while 145 patients were treated with the combination of
nivolumab plus ipilimumab. The survival curves for OS overlapped completely, and in our cohort,
there was no apparent benefit for the combination treatment (Figure 1E; p = 0.993). The survival
curves for PFS separated approximately eight months after the start of treatment with a slightly
more favorable course for the combined regimen, but this di↵erence was not statistically significant
(Figure 1F; p = 0.216).
In order to evaluate whether primary resistance can be predicted based on pre-existing risk factors,
three subgroups were defined, considering the two factors that were significant in the multivariate
regression analysis (i.e., primary tumor localization and protein S-100B level) (Figure S1). The subgroups
were defined as follows: no risk factor (low-risk), one risk factor (intermediate-risk) and two risk
factors (high-risk). The survival analysis showed that OS overlapped for the low and intermediate
subgroups, while a significantly less favorable survival was observed for high-risk patients (Figure S1A;
p < 0.0001). There was no significant di↵erence in terms of PFS (Figure S1B; p = 0.230).
Finally, the analysis where the primary resistance group included patients with PD and SD for less






Cancers 2020, 12, 1027 7 of 13
(Figure S2A,B) showed that the di↵erence in terms of OS and PFS remained statistically significant
(p < 0.0001).
 
Figure 1. (A). Overall survival according to response to first-line PD-1-based immunotherapy
(p < 0.0001); (B). progression-free survival according to response to first-line PD-1-based immunotherapy
(p < 0.0001); (C). overall survival according to best overall response to first-line PD-1-based
immunotherapy (p < 0.0001); (D). progression-free survival according to best overall response to
first-line PD-1-based immunotherapy (p < 0.0001); (E). overall survival according to the type of first-line
PD-1-based immunotherapy (p = 0.993); (F). progression-free survival according to the type of first-line
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3.3. Second-Line Therapies and Outcomes
Tables S3 and S4 show the type of second-line therapy in patients with primary resistance, and also
the best overall response achieved, according to the BRAF mutation status. Approximately 50% (n = 63)
of the patients with primary resistance to immunotherapy received a second-line therapy. Sixty-four
patients did not receive further systemic therapies. Twenty-one patients had tumors harboring a
BRAFV600E/K mutation, 20 patients had BRAF wild-type tumors, and in 22 patients, there was no
information regarding BRAF mutation status. The majority of the patients with BRAFV600E/K mutation
(17/21) received targeted therapy with BRAF plus MEK inhibitors, three received immunotherapy,
and one patient chemotherapy. Patients with BRAF wild-type tumors received in equal number
immunotherapy (10/20) and chemotherapy (10/20).
Information on the best overall response for the second-line systemic therapy was available for
58 patients. In five patients, this information was not available. Patients with tumors harboring a
BRAFV600E/K mutation received predominantly targeted therapy which resulted in a high response
rate (CR or PR) of 63%. In patients with BRAF wild-type tumors treated either with second-line
immunotherapy or chemotherapy, the response rate was only 11% (Table S3).
3.4. Pseudoprogression
In our cohort (n = 319), we identified six patients with pseudoprogression. Of these six patients,
five showed initial PD but later achieved SD as best overall response to immunotherapy, and in one
patient after initial PD, the best overall response to immunotherapy was CR.
4. Discussion
Our study shows that patients with primary resistance and tumor progression at the time of first
tumor assessment after starting immunotherapy have a highly significantly unfavorable survival rate
as compared to those who achieve disease control. Response at the time of first tumor assessment after
starting immunotherapy is a better predictive factor for survival than other pretreatment risk factors
for the development of primary resistance. Achieving an objective remission (CR or PR) is decisive for
favorable OS. The median OS for patients with SD is significantly better than for patients with primary
resistance (28 months versus 11 months). After three years, however, the survival curves converge
strongly at an unfavorable level. This convergence is even more pronounced for PFS.
In the multivariate logistic regression analysis, only two significant risk factors for primary
resistance to immunotherapy were identified. These were primary tumor localization and an elevated
level of protein S-100B. In the univariate analysis, an elevated level of LDH was also a significant factor,
but this did not remain significant in the multivariate analysis. The decisive factor here may be that
the LDH value and the protein S-100B value usually increase in parallel, and that the S-100B value
increases earlier and in more patients.
In the univariate analysis, the histological subtype was also a significant factor. Here there is an
overlap with tumor localization, since ALM is more commonly seen in the extremities, and mucosal
melanomas were classified in the other localizations group. The higher discriminatory power was
observed for the tumor localization. There is also a relationship between tumor localization and sex,
as melanomas in the extremities occur more frequently in females, and females have a less favorable
response to immunotherapy than males [32–34]. Accordingly, sex was a significant risk factor in the
univariate analysis but not in the multivariate analysis.
The definition of risk groups considering the two risk factors that remained significant in the
multivariate analysis (i.e., primary tumor localization and protein S-100B) showed a relatively low
predictive value. We observed a statistically significant di↵erence in terms of OS between high- and
intermediate- and low-risk groups, whereas this di↵erence was not observed in PFS.
The three-year PFS and three-year OS rates reported here for PD-1 monotherapy and the
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trial [35]. This might be partially explained by the selection of the patients included in that study
compared to the unselected population in our cohort. As an example, patients with (active) brain
metastases are typically excluded from clinical trials. In fact, only 3.6% of the patients included in the
CheckMate 067 trial had brain metastases compared to 19% in our study. In our cohort, 36% of the
patients also had liver metastases, which is associated with worse response to immunotherapy [36,37].
The percentage of patients that had elevated LDH is similar in both reports (32% in our cohort vs.
36% in the CheckMate 067 trial). In the CheckMate 067 trial, the S100B levels, which are a known
prognostic factor [38,39], were not reported; in our study, 44% of the patients had elevated S100B.
Together, these aspects define a collective of patients that probably had a worse prognosis compared to
the patients included in the clinical trial.
In our cohort, there was no di↵erence in terms of OS between patients treated with PD-1
monotherapy and those receiving nivolumab plus ipilimumab. This might be related to the median
follow-up time of only 22 months, shorter than the last update from the CheckMate 067 trial, where
the di↵erence between combined immunotherapy and monotherapy was clearer with a five-year
follow-up [4]. In our cohort, a significantly higher proportion of patients with BRAFV600E/K mutation
received combined immunotherapy (p = 0.003). This subgroup seemed to respond better to combined
immunotherapy compared to PD-1 monotherapy [4,40], and this might explain why we started to see
a separation of the PFS curves. Possibly with a longer follow-up, a di↵erence in OS can be expected.
The absence of di↵erence in terms of OS in these two subgroups is probably also linked to the
fact that they were not homogenous, with a selection bias regarding the type of immunotherapy.
Older patients, who seem to respond better to immunotherapy [41], received predominantly PD-1
monotherapy (p = 0.007), patients with more than three metastatic organs received preferably combined
immunotherapy (p = 0.043), and a significantly higher proportion of patients with brain metastasis
were also treated with nivolumab plus ipilimumab (p = 0.018).
Only 50% of the patients with primary resistance to immunotherapy received a second systemic
therapy, similar to the percentage of patients reported in other series receiving a second-line therapy [42].
In our cohort, patients with BRAFV600E/K mutation received predominantly targeted therapy, and in
this subgroup, 63% of patients had a response (CR or PR). This was slightly higher than previously
published [43], but in our cohort, only 21 patients with BRAFV600E/K mutation received second-line
therapy, and therefore the outcomes need to be interpreted cautiously. Nevertheless, our group and
others have already demonstrated that patients with BRAFV600E/K first-line immunotherapy followed
by targeted therapy, similar to what patients in this cohort received, seem to have better outcomes than
the inverse sequence [44,45]. The high response rate in our cohort might be explained by this favorable
therapy sequencing.
On the other hand, for patients with BRAF wild-type tumors, only one patient responded to
second-line therapy. Again, the number of patients was low (n = 20), but these results show that a
second-line therapy in the BRAF wild-type cohort is not possible in a high number of patients and,
when possible, still has a small impact on survival.
Strengths of this investigation are the fact that the data included was from a German certified skin
cancer center with high standards for data quality. Three hundred and nineteen patients were analyzed,
which is a large cohort of patients with stage IV melanoma managed with PD-1-based immunotherapy
in a routine clinical setting. This high number of patients allowed us to perform subgroup analyses,
with results of reasonable sensitivity. Further, this study provides follow-up data covering a period of
up to 22 months.
The study limitations are related to its retrospective and monocentric design. Patients included
were those receiving first-line immunotherapy for stage IV melanoma and for whom a response to
therapy was documented. Since no other selection criteria were applied, the heterogeneity of the study
population might have contributed to the di↵erences observed in survival. Another limitation is the
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This approach is currently changing and, in the future, it would certainly be of value to include other
factors in the definition of primary resistance.
5. Conclusions
Patients with progressive disease at the first tumor assessment after starting first-line PD-1-based
immunotherapy have a very unfavorable prognosis. Predicting primary resistance based on pre-existing
risk characteristics is possible only to a limited extent. Response at time of first tumor assessment
after starting immunotherapy is a stronger predictive factor. In future analysis, other factors, namely
histological and molecular characterization of the progressive lesions, should be included in the
definition of primary resistance.
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Figure S1: (A) Overall survival according to risk groups (low, intermediate, and high) (p < 0.0001). The factors
used were primary tumor localization and protein S-100B level. The subgroups were defined as follows: no risk
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protein S-100B level. The subgroups were defined as follows: no risk factor (low), one risk factor (intermediate),
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7DUJHWHG WKHUDS\ KDV VLJQL¿FDQWO\ LPSURYHG WKH SURJQR-
VLVRISDWLHQWVZLWK%5$)PXWDWHGPHWDVWDWLFPHODQRPD
6LQFH WKHUHDUHGLIIHUHQW WDUJHWHG WKHUDS\ UHJLPHVDY-











cantly improved treatment outcomes for patients with 
%5$)PXWDWHGPHWDVWDWLFPHODQRPD 7KH  ¿UVWOLQH
targeted therapy trials have provided similar results, 
DQG WKXV WKH LGHQWL¿FDWLRQ RI SUHGLFWLYH ELRPDUNHUV
may generate a more precise basis for clinical deci-
VLRQPDNLQJ(OHYDWHGEDVHOLQHODFWDWHGHK\GURJHQDVH
(LDH) has already been determined as a strong prog-
nostic factor. Therefore, this indirect analysis compa-
red subgroups with elevated baseline LDH across the 
pivotal targeted therapy trials co-BRIM, COMBI-v and 
COLUMBUS part 1. The Bucher method was used to 
compare progression-free survival, objective response 
rate and overall survival indirectly. The results show 
DQRQVLJQL¿FDQWULVNUHGXFWLRQIRUSURJUHVVLRQLQWKH
subgroup with elevated baseline LDH receiving vemu-
rafenib plus cobimetinib compared with dabrafenib 
plus trametinib and encorafenib plus binimetinib. Al-
though an indirect comparison, these data might pro-
vide some guidance for treatment recommendations in 




Corr %DVWLDQ 6FKLOOLQJ 'HSDUWPHQW RI 'HUPDWRORJ\ 9HQHUHRORJ\ DQG
$OOHUJRORJ\ 8QLYHUVLW\ +RVSLWDO :U]EXUJ -RVHI6FKQHLGHU6WU  '(
:U]EXUJ*HUPDQ\(PDLOVFKLOOLQJBE#XNZGH
Small molecule BRAF and MEK inhibitors have clear-ly improved the prognosis for patients with BRAF 
mutant metastatic melanoma (1–3). In the coBRIM 
(NCT01271803) and COMBI-v trials (NCT01597908), 
combined BRAF and MEK inhibition with vemurafenib 
plus cobimetinib (coBRIM) or dabrafenib plus trame-
tinib (COMBI-v) improved progression-free survival 
(PFS), overall response rate (ORR) and overall survi-
val (OS) compared with vemurafenib monotherapy in 
BRAF-V600-mutated metastatic melanoma. A third 
trial (COLUMBUS part 1, NCT01909453) compared 
combined encorafenib plus binimetinib with vemurafenib 
monotherapy, and also demonstrated an advantage for 
PFS and ORR in the combination arm (3). While these 
WULDOVKDYHSURYLGHGVLPLODUUHVXOWVLQWHUPVRIHI¿FDF\
in treatment-naive patients with BRAF-V600-mutated 
PHWDVWDWLFPHODQRPD WKH LGHQWL¿FDWLRQ RI SUHGLFWLYH
biomarkers may generate a more precise basis for clinical 
decision-making and patient management.
Well-accepted prognostic factors in patients with me-
tastatic melanoma include disease stage, baseline Eastern 
Cooperative Oncology Group performance status (ECOG 
PS) and baseline lactate dehydrogenase levels (LDH) (4, 
5). In particular, an elevated baseline level of LDH has 
been determined as a strong negative prognostic factor 
in patients with advanced melanoma (6–8), now incor-
porated into the AJCC staging system as an independent 
factor (9). LDH is a ubiquitous enzyme that plays a key 
role in cell metabolism and growth. By catalysing the 
reduction of pyruvate to lactate, the so-called Warburg 
effect, LDH creates an acidic milieu that is favourable 
for tumour angiogenesis and suppression of anti-tumour 
immune responses (10). In prospective clinical trials 
HYDOXDWLQJGXDO0$3.LDQHOHYDWHG/'+GH¿QHGDV
> local upper limit of normal (ULN)) predicted inferior 
outcome compared with patients without elevated LDH. 
The extent of this association was different in coBRIM, 
COMBI-v and COLUMBUS part 1. However, the clini-
FDOVLJQL¿FDQFHRIWKHVHGLIIHUHQFHVKDVQRWEHHQDQDO\-
sed comprehensively. To this end, this study conducted 
an indirect analysis (1) to compare PFS, ORR and OS 
in the subgroups with elevated baseline LDH from the 
clinical trials coBRIM, COMBI-v and COLUMBUS 
part 1 and consequently (2) to interrogate if a particular 
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regime in this particular subgroup might provide greater 
EHQH¿WWRSDWLHQWV
MATERIALS AND METHODS
Detailed methods of the particular trials have already been re-
SRUWHG ±%ULHÀ\ FR%5,0&20%,Y DQG&2/80%86
part 1 were randomized, double-blind phase 3 trials comparing 
oral vemurafenib, 960 mg twice daily, plus cobimetinib, 60 mg 
once daily, for 21 days with placebo and vemurafenib (coBRIM), 
oral dabrafenib, 150 mg twice daily, plus trametinib, 2 mg once 
daily, with vemurafenib, 960 mg twice daily, (COMBI-v) or oral 
encorafenib, 450 mg once daily, plus binimetinib, 45 mg twice 
daily, with vemurafenib, 960 mg twice daily, or encorafenib, 
300 mg once daily, (COLUMBUS part 1). Baseline patient cha-
racteristics are summarized in Table I. The primary endpoint of 
coBRIM and COLUMBUS trial was PFS. Primary endpoint of 
COMBI-v was OS. Key inclusion criteria were comparable across 
the studies including patients with unresectable stage III or stage 
IV BRAF-V600-mutated melanoma, adequate organ functions 
and ECOG PS 0 or 1. Patients with untreated brain metastases 
were not eligible.
In this analysis the subgroups with normal and elevated LDH 
have been statistically analysed using a model for making indirect 
comparisons of the magnitude of treatment effects without losing 
the power of randomization (Bucher analysis) (11). 
Statistical analysis
The aim of this analysis was the indirect comparison of PFS and OS 
as well as ORR in the subgroups with elevated LDH levels using 
the Bucher method. For our analysis, data cut-off dates of 9 May 
2014 (PFS), 16 January 2015 (ORR) and 28 August 2015 (OS) for 
coBRIM; 17 April 2014 (PFS, ORR) and 13 March 2015 (OS) for 
COMBI-v and 19 May 2016 (PFS) and 7 November 2017 (OS) for 
COLUMBUS part 1 were used. Due to data availability, the PFS 
analysis comparing coBRIM with COMBI-v was done using local 
assessment data, while the comparison with COLUMBUS part 1 
XVHGGDWDIURPWKHLQGHSHQGHQWFHQWUDOUHYLHZ$VGH¿QHGE\WKH
particular study protocol, all enrolled patients were included in 
the analysis. The Bucher analysis was based on the assessments 
RIEHQH¿WRIWKH)HGHUDO-RLQW&RPPLWWHH*%$IRUYHPXUDIHQLE
plus cobimetinib (module 5), dabrafenib plus trametinib (module 
4) and encorafenib plus binimetinib (module 4) as well as data 
from Dummer et al. (3). Median OS and PFS were calculated 
using the Kaplan–Meier method.
RESULTS
Patients’ characteristics
Baseline patients’ characteristics of the 3 studies are 
summarized in Table I. The percentage of patients 
with elevated baseline levels of LDH was higher in the 
coBRIM cohort being treated with vemurafenib plus 
cobimetinib (n = 112, 46%) than in the combination arms 
of the COMBI-v (n = 118, 34%) and the COLUMBUS 
(n   WULDOV Ȥ2, p < 0.001). Other prognostic 
factors, such as ECOG PS and number of patients with 
M1c disease according to the AJCC 2009 staging sys-
tem, were comparable across the 3 trials (Table I) (2, 12, 
13). Of note, there was a low number of patients with 
¿UVWOLQHPRGHUQLPPXQRWKHUDS\LQWKH&2/80%86
part 1 trial (encorafenib + binimetinib group: 7 (4%) 
ipilimumab, 1 (1%) anti-PD-1 or anti-PD-L1; vemura-
fenib group: 7 (4%) ipilimumab, 0 (0%) anti-PD-1 or 
anti-PD-L1). 
Progression-free survival
Median PFS in the combination arms was 12.3 months 
for vemurafenib and cobimetinib (coBRIM, data cut-off 
16 January, 2015, median follow-up 14.2 months), 11.4 
months for dabrafenib and trametinib (COMBI-v, data 
cut-off 17 April, 2014, median follow-up 10 months) 
and 14.9 months for encorafenib and binimetinib (CO-
LUMBUS part 1, data cut-off 19 May, 2016, median 
follow-up 14.4 months) (1–3). In all 3 studies median 
3)6ZDVVLJQL¿FDQWO\ ORQJHU LQ WKHFRPELQDWLRQDUPV
than in those treated with vemurafenib monotherapy. 
Table I shows the corresponding hazard ratios (HR) for 
progression or death comparing vemurafenib and dual 
MAPKi regimes. 
Table I. Patient characteristics
FR%5,0 &20%,Y &ROXPEXV3DUW
Therapy 9& 93 '7 9 (% ( 9
Patients (n)       191
3ULPDU\HQGSRLQWV 3)6 26 3)6(%YV9
6HFRQGDU\HQGSRLQWV 26255'R53)6 3)6255'R56 3)6(%YV(%25'R56HWF
0HGLDQDJH\HDUV       
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Across the 3 trials, the subgroups with normal baseline 
OHYHO RI/'+FOHDUO\ EHQH¿WHG IURP WKH FRPELQDWLRQ
therapy (Fig. 1), whereas only the coBRIM trial could 
show an equal advantage for the subgroup with eleva-
WHGEDVHOLQHOHYHOVRI/'++5FRQ¿GHQFH
interval (95% CI), 0.42–0.78), data cut-off 16 January 
2015) (Fig. 1) (1). Kaplan–Meier estimates of PFS for 
the subgroups with elevated LDH derived from coBRIM 
and COMBI-v are shown in Fig. 2A. 
Using the Bucher method, an indirect comparison of 
PFS, OS and ORR data from coBRIM, COMBI-v and 
COLUMBUS part 1 was performed. In this indirect 
FRPSDULVRQDQRQVLJQL¿FDQWULVNUHGXFWLRQIRUSURJUHV-
sion or death for patients with elevated baseline LDH 
receiving vemurafenib plus cobimetinib (data cut-off 9 
May 2014) was found. When compared with dabrafenib 
plus trametinib (data cut-off 17 April 2014), a 24% risk 
reduction (HR 0.76 (95% CI, 0.48–1.23)) and compa-
red with encorafenib plus binimetinib (data cut-off 19 
May 2016), an 11% risk reduction (HR 0.89 (95% CI, 
0.50–1.58)) was observed (Table II). 
Overall response rate
The objective response rate was 70% (172/247 patients) 
in the vemurafenib plus cobimetinib group vs. 50% 
(124/248 patients) in the vemurafenib plus placebo group 
(coBRIM, data cut-off 16 January 2015); 64% (226/351 
patients) in the dabrafenib plus trametinib group vs. 51% 
(180/350 patients) in the vemurafenib monotherapy group 
(COMBI-v, data cut-off 17 April 2014) and 63% (121/192 
patients) in the encorafenib plus binimetinib group vs. 
40% (77/191 patients) in the vemurafenib monotherapy 
groups (COLUMBUS part 1, data cut-off 19 May 2016) 
(1–3). The indirect comparison showed an advantage for 
vemurafenib plus cobimetinib (data cut-off 16 January 
Fig. 2. Kaplan–Meier estimates for (A) median progression-free survival (mPFS) and (B) median overall survival (mOS) in the subgroups 
with elevated lactate dehydrogenase (LDH) for coBRIM (data cut-off 16 January 2015 for PFS and 28 August 2015 for OS) and COMBI-v 
(data cut-off 17 April 2014 for PFS and 13 March 2015 for OS).&FRELPHWLQLE9YHPXUDIHQLE'GDEUDIHQLE7WUDPHWLQLE+5KD]DUGUDWLR
UHIHUHQFHDQG5REHUW&(6022UDOSUHVHQWDWLRQ
Fig. 1. Progression-free survival (PFS) subgroup 
analyses for lactate dehydrogenase (LDH) for 
coBRIM (data cut-off 16 January 2015), COMBI-v 
(data cut-off 17 April 2014) and COLUMBUS Part 
1 (data cut-off 19 May 2016) & FRELPHWLQLE
9 YHPXUDIHQLE ' GDEUDIHQLE 7 WUDPHWLQLE (
HQFRUDIHQLE%ELQLPHWLQLE&,FRQ¿GHQFHLQWHUYDO
8/1XSSHUOLPLWRIQRUPDOUHIHUHQFHV±DQG
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2015) compared with dabrafenib plus trametinib (data 
cut-off 17 April 2014) in the subgroup with elevated 
baseline levels of LDH (HR 1.35 (95% CI, 0.88–2.07). 
ORR data for COLUMBUS were not available.
Overall survival
Median OS in the combination arms was 22.3 months 
for vemurafenib and cobimetinib (coBRIM, data cut-off 
28 August 2015) and was not reached for dabrafenib and 
trametinib (COMBI-v, data cut-off 17 April 2014) (2) and 
encorafenib and binimetinib (COLUMBUS, data cut-off 
19 May 2016) (3). In updated analyses, the OS was sig-
QL¿FDQWO\ORQJHULQWKHFRPELQDWLRQDUPVFRPSDUHGZLWK
BRAF inhibitor monotherapy across all 3 trials (Fig. 3) 
(14, 15). Fig. 2B shows OS survival curves for coBRIM 
and COMBI-v for the subgroups with elevated LDH. For 
COLUMBUS, such OS data from patients with elevated 
LDH were not available.
In the subgroup of patients with elevated baseline le-
vels of LDH, the indirect comparison showed a similar 
risk of death for patients receiving vemurafenib plus 
cobimetinib (data cut-off 28 August 2015) or dabrafe-
nib plus trametinib (data cut-off 13 March 2015) (HR 
0.95 (95% CI, 0.61–1.49)) (Table II). A slight and non-
VLJQL¿FDQWULVNUHGXFWLRQIRUGHDWKE\ZDVIRXQG
when coBRIM was compared with COLUMBUS part 
1 (data cut-off 7 November 2017) (HR 0.81 (95% CI, 
0.48–1.37)) (Table II). 
DISCUSSION
This study undertook an indirect analysis in BRAF-
V600 mutated patients treated with combined BRAF and 
MEK inhibition with elevated baseline levels of LDH. 
In pooled analyses reported recently, baseline levels of 
LDH, ECOG PS, number of involved organ systems and 
baseline sum of longest diameter of target lesions (SLDs) 
ZHUHLGHQWL¿HGDVNH\SUHGLFWLYHIDFWRUVIRU3)6DQG26
in BRAF-V600-mutated patients treated with combined 
BRAF and MEK inhibition (6–8). In particular, baseline 
LDH level was the strongest predictive factor across all 
3 trials. Therefore, our analysis focused on the compa-
rison of patients with elevated baseline LDH level to 
further investigate PFS, ORR and OS comprehensively 
DFURVVWKH¿UVWOLQHWDUJHWHGWKHUDS\77WULDOVLQWKLV
particular subgroup. 
Two major clinical decisions need to be addressed 
in patients with advanced BRAF-mutant melanoma. 
Firstly, patients can either receive an anti-PD-1 based 
immunotherapy or dual MAPKi. Since no prospective 
head-to-head data are available, this decision is based 
mainly on patient characteristics and preference as well 
as the physicians’ preference. Looking at data from a 
survey conducted in melanoma experts, symptomatic 
disease, a high tumour burden and elevated baseline 
LDH are features associated with using dual MAPKi as 
¿UVWOLQHWUHDWPHQW5HFHQWO\ZHZHUHDEOHWRVKRZ
this association in a retrospective study (17). When com-
paring consecutive patients receiving either dual MAPKi 
(n = 195) or PD-1 monotherapy (n = 106), the TT cohort 
ZDVVLJQL¿FDQWO\HQULFKHGZLWKSDWLHQWVVKRZLQJQRQ
pulmonary visceral metastases and an elevated LDH. 
6HFRQGO\WKHVSHFL¿FUHJLPHQHHGVWREHFKRVHQ,IGXDO
MAPKi is recommended, 3 different combinations are 
DSSURYHGE\)'$DQG(0$,QWHUPVRIRYHUDOOHI¿FDF\
no regime seems to be superior to the others. However, 
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Fig. 3. Overall survival (OS) subgroup analyses for 
lactate dehydrogenase (LDH) for coBRIM (data 
cut-off 28 August 2015), COMBI-v (data cut-off 
17 April 2014) and COLUMBUS Part 1 (data cut-off 
17 November 2017).&FRELPHWLQLE9YHPXUDIHQLE
' GDEUDIHQLE 7 WUDPHWLQLE ( HQFRUDIHQLE %
ELQLPHWLQLE&,FRQ¿GHQFHLQWHUYDO8/1XSSHUOLPLW
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DJLYHQFRPELQDWLRQPLJKWSURYLGHJUHDWHUEHQH¿WLQD
particular subgroup of patients. 
Although indirect comparisons of pivotal trials warrant 
great caution, the usage of vemurafenib as comparator 
coBRIM, COMBI-v and COLUMBUS part 1 allows to 
perform a Bucher analysis (18). Looking at the vemura-
fenib monotherapy arms, results indicate similar response 
to treatment and prognosis due to resemblance across 
multiple endpoints (e.g. PFS and OS) in the respective 
vemurafenib groups (1, 3, 17). Prognostic factors, such as 
ECOG PS and degree of organ involvement, were compa-
rable across the trials (Table I) (2, 12, 13). However, the 
coBRIM trial included the highest percentage of patients 
with elevated baseline levels of LDH in the combination 
arm (46%) compared with only 34% in the COMBI-v and 
29% in the COLUMBUS trial (1–3). In real-world data-
VHWVXSWRRISDWLHQWVUHFHLYLQJGXDO0$3.L¿UVWOLQH
showed an elevated LDH resembling the coBRIM cohort 
(19, 20). Although an elevated baseline LDH accounts for 
a worse outcome, the HR for progression or death in the 
total trial populations was comparable across the 3 trials 
(Table I). This indicated an advantage of vemurafenib plus 
cobimetinib in the subgroup with elevated baseline LDH. 
7KHFR%5,0GDWDFRQ¿UPHGWKLVK\SRWKHVLVUHJDUGLQJ
a PFS advantage of combined BRAF and MEK inhibi-
tion with vemurafenib plus cobimetinib compared with 
a vemurafenib monotherapy independent of the baseline 
LDH level (Fig. 1). Consequently, BRAF-V600 mutated 
SDWLHQWVZLWKDQHOHYDWHGEDVHOLQH/'+OHYHOPLJKWEHQH¿W
from a combined TT with vemurafenib and cobimetinib 
to a similar extend as patients with normal LDH do when 
compared with vemurafenib monotherapy. This could 
not be demonstrated for dabrafenib plus trametinib or 
encorafenib plus binimetinib (Fig. 1). The Bucher analysis 
FRQ¿UPHGWKHVH¿QGLQJVVKRZLQJDQRQVLJQL¿FDQWDG-
vantage for vemurafenib plus cobimetinib in the subgroup 
with elevated baseline LDH compared with dabrafenib 
plus trametinib and encorafenib plus binimetinib regar-
ding PFS (Table II). Although this retrospective indirect 
Bucher analysis does not allow an exclusion of all selec-
tion bias, our results indicate that the LDH level should 
EHFRQVLGHUHGZKHQFKRRVLQJDVSHFL¿F%5$)DQG0(.
inhibitor to achieve disease control. 
,QFRQWUDVWWRWKH3)6GDWDRXUDQDO\VLVGLGQRWDI¿UP
D EHQH¿FLDO HIIHFW RI YHPXUDIHQLE SOXV FRELPHWLQLE
compared with dabrafenib and trametinib, and showed 
only a slight advantage compared with encorafenib and 
binimetinib regarding OS. Likewise, the coBRIM data do 
not provide an OS advantage for combined TT compared 
with vemurafenib monotherapy. Therefore, the choice 
of a particular BRAF and MEK inhibitor combination 
seems to have no impact on OS. However, when inter-
SUHWLQJHI¿FDF\UHVXOWVVXFKDV26SULRUDQGVXEVHTXHQW
treatment regimens, such as immunotherapies, as well 
as prognostic factors apart from LDH have to be taken 
into consideration, creating a potential bias.
%HVLGHV HI¿FDF\ VDIHW\ DQG WROHUDELOLW\ DUH RI KLJK
clinical relevance and have an impact on treatment re-
commendations. Distinct patterns of treatment-related 
adverse events can be found in melanoma patients recei-
ving dabrafenib + trametinib, vemurafenib + cobimetinib 
or encorafenib + binimetinib. Pyrexia is most frequently 
observed in patients receiving dabrafenib + trametinib, 
while vemurafenib + cobimetinib causes the highest num-
ber of cutaneous adverse events (AEs), and encorafenib 
+ binimetinib leads to more nausea and constipation than 
the other combinations (1–3). In an indirect comparison 
similar to ours, a lower incidence of treatment-related AEs 
was found for dabrafenib + trametinib compared with 
vemurafenib + cobimetinib (18). However, when looking 
at any AE, serious AEs or AEs leading to treatment dis-
continuation, no differences were observed. Regarding 
OS and PFS (dabrafenib + trametinib vs. vemurafenib 
+ cobimetinib), Daud et al. calculated a HR of 0.94 and 
1.05, respectively, when applying the Bucher method. In 
contrast to our indirect comparison, earlier data cuts were 
used and most importantly, the total patient populations 
of the combination arms were analysed. 
We cannot provide any data explaining the differences 
observed. Lactate accumulating in the tumour microen-
YLURQPHQWPLJKWFDXVHDFLGL¿FDWLRQGHFUHDVLQJWKHS+
(19). Since it is known that bioavailability of dabrafe-
nib is dependent on pH, while that of vemurafenib is 
not (20), our hypothesis is that antineoplastic activity 
of dabrafenib, but not vemurafenib, is pH dependent. 
Experimental and pharmacokinetic data are needed to 
test this hypothesis. 
Elevated LDH is a very important biomarker in ad-
vanced melanoma, and has been incorporated into the 
AJCC Melanoma Staging system since 2009 (5). Three 
UHFHQWSRROHGDQDO\VHVFRQ¿UPHGDQHOHYDWHG/'+DV
predictive factor for shorter PFS and OS in melanoma 
patients receiving combined TT (6–8). In the real-world 
setting, melanoma patients receiving palliative MAPKi 
¿UVWOLQHKDYHSRRUSURJQRVWLFIHDWXUHVLQFOXGLQJEXWQRW
limited to, elevated LDH (21, 22). There might be other 
subgroups in which a particular treatment regime might 
tend to be superior to the others. However, taking other 
biomarkers, such as involvement of particular organs or 
the sum of lesions diameters, into account was not pos-
sible. Patient cohorts are slightly heterogeneous across 
the 3 trials and more importantly, the way the trials are 
reported limits the availability of data for comparisons. 
In conclusion, there is no statistically significant 
GLIIHUHQFHLQHI¿FDF\EHWZHHQWKH77FRXSOHVXVLQJ
the Bucher method. However, our data indicate a trend 
towards a lower risk for progression or death in mela-
noma patients with elevated LDH when receiving ve-
murafenib + cobimetinib in comparison with dabrafenib 
WUDPHWLQLEDQGHQFRUDIHQLEELQLPHWLQLEDV¿UVWOLQH
therapy. In light of the current preference to use dual 
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tients with poor prognostic features including elevated 
LDH, our indirect analysis might provide a rationale to 
XVHDVSHFL¿FWUHDWPHQWUHJLPH+RZHYHUWKLV¿QGLQJ
needs to be validated prospectively. Although a Bucher 
analysis partially retains the randomization of the indi-
vidual trials, data provided by an indirect comparison 
must be interpreted with caution.
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Abstract
Background: Uveal melanoma (UM) is highly refractory to treatment with dismal prognosis in advanced stages.
The value of the combined checkpoint blockade with CTLA-4 and PD-1 inhibition in metastatic UM is currently
unclear.
Methods: Patients with metastatic or unresectable UM treated with ipilimumab in combination with a PD-1
inhibitor were collected from 16 German skin cancer centers. Patient records of 64 cases were analyzed for
response, progression-free survival (PFS), overall survival (OS), and safety. Clinical parameters and serum biomarkers
associated with OS and treatment response were determined with Cox regression modelling and logistic
regression.
Results: The best overall response rate to combined checkpoint blockade was 15.6% with 3.1 and 12.5% complete
and partial response, respectively. The median duration of response was 25.5 months (range 9.0–65.0). Stable
disease was achieved in 21.9%, resulting in a disease control rate of 37.5% with a median duration of the clinical
benefit of 28.0 months (range 7.0–65.0). The median PFS was 3.0 months (95% CI 2.4–3.6). The median OS was
estimated to 16.1 months (95% CI 12.9–19.3). Regarding safety, 39.1% of treated patients experienced a severe,
treatment-related adverse event according to the CTCAE criteria (grade 3: 37.5%; grade 4: 1.6%). The most common
toxicities were colitis (20.3%), hepatitis (20.3%), thyreoiditis (15.6%), and hypophysitis (7.8%). A poor ECOG
performance status was an independent risk factor for decreased OS (p = 0.007).
Conclusions: The tolerability of the combined checkpoint blockade in UM may possibly be better than in trials on
cutaneous melanoma. This study implies that combined checkpoint blockade represents the hitherto most effective
treatment option available for metastatic UM available outside of clinical trials.
Keywords: Ipilimumab, Nivolumab, Combined immune checkpoint blockade, Uveal melanoma, Biomarker
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Uveal melanoma (UM) is a malignant tumor of the eye
that originates from the pigment cells of the choroid
layer or the ciliary body which is clinically and biologic-
ally distinct from cutaneous melanoma. Although the in-
cidence is much lower than that of cutaneous
melanoma, UM belongs to the most common malignant
intraocular tumors in adults [1]. In approximately 50%
of all cases, patients develop distant metastasis during
the course of the disease, which affects predominantly
the liver. Clinical risk factors for metastases are posterior
localization in the eye, tumor size of more than 10mm,
and presence of vascular loops. Molecular biomarkers
associated with a higher risk of metastasis are mono-
somy 3 or genomic alterations of BAP-1 [2]. Once dis-
tant metastases have occurred, the prognosis is dismal
with an average survival time of approximately 1 year
across all therapeutic regimens [3].
Patients with metastatic UM have so far benefited little
or not at all from the treatment innovations achieved in
cutaneous melanoma in recent years. Neither targeted
therapy with MEK inhibitors nor checkpoint blockade
with ipilimumab or PD-1 inhibitors as monotherapy was
able to significantly improve the prognosis of patients
with UM [4, 5]. The response rates were consistently in
the single-digit percentage range in a panel of previous
studies [6–9]. In cutaneous melanoma, combined check-
point blockade with ipilimumab and nivolumab revealed
response rates and survival outcomes superior to PD-1
inhibitor monotherapy, albeit at the cost of high
immune-related toxicity [10]. However, the significance
of combined checkpoint blockade in UM is unclear and
has only been investigated in case reports and small case
series [6, 11, 12]. In this study, we evaluate the clinical
course of 64 patients with metastatic UM who received
combined checkpoint blockade. We report clinical out-
comes with respect to response, survival, and adverse
events (AE). Furthermore, clinical and laboratory param-
eters were investigated which may have prognostic value
in UM patients treated with checkpoint blockade.
Patients and methods
Patient population and study approval
This study was designed as a retrospective multi-center
explorative analysis. Patients were included if they had a
diagnosis of stage IV UM and received combined check-
point blockade of ipilimumab with a PD-1 inhibitor in
any treatment line. A follow-up period of at least 3
months was required. The clinical data of 64 patients
from 16 German skin cancer centers who met the inclu-
sion criteria were investigated. The cases were collected
from June 23, 2018 to October 4, 2019. Clinical data and
the treatment outcomes of interest were extracted from
the original patient records and merged into a central
database prior to analysis. This study was approved by
the institutional review board of the medical faculty of
the Munich University Hospital (approval number 413–
16 UE) and was conducted in accordance with the prin-
ciples of the Helsinki Declaration in its current version.
Data collection and treatment outcomes
The clinical data recorded at baseline prior to immuno-
therapy comprised demographics with Eastern Coopera-
tive Oncology Group (ECOG) performance status,
available information on the genotype, sites of metasta-
sis, number of organ systems affected by metastases, and
previous antineoplastic therapies. As potential serum
biomarkers, lactate dehydrogenase (LDH), C-reactive
protein (CRP), and the relative counts of lymphocytes
(RLC), neutrophils (RNC), and eosinophils (REC) were
specifically collected from patient charts and analyzed
for their prognostic value [13, 14].
Combined checkpoint blockade was carried out using
different treatment schedules (Table 1). Ipilimumab was
given at either 3 mg/kg or 1 mg/kg body weight for up
to 4 treatment cycles. Nivolumab was applied at 1 mg/kg
together with ipilimumab, followed by 3 mg/kg every 2
weeks (Q2W) as maintenance therapy. Treatment with
pembrolizumab was applied every 3 weeks (Q3W) at 2
mg/kg. Patients were treated until disease progression or
until the development of unacceptable toxicity. AE were
retrospectively graded by the site investigators based on
the patient records and clinical outcomes according to
the Common Terminology Criteria for Adverse Events
(CTCAE) v5.0 published by the National Institutes of
Health in 2017. Immune-related adverse events were
managed according to pertinent guidelines and algo-
rithms that were previously published [15, 16]. Besides,
fatal adverse events and events leading to permanent dis-
continuation of treatment were specifically recorded and
evaluated. The best radiologic response to treatment was
assessed by the site investigators and indicated as
complete response, partial response, stable disease, or
progressive disease based on the RECIST criteria version
1.1 [17]. Complete response and partial response were
summarized as best overall response rate (ORR).
Complete response, partial response, and stable disease
were summarized as disease control rate (DCR).
Statistical analyses
Overall survival (OS) and progression-free survival (PFS)
were calculated as the time from the initiation of the first
cycle of combined checkpoint blockade until melanoma-
specific or treatment-related death and disease progres-
sion, respectively. Time-to-event analyses were calculated
where death or progression were considered as events. If
neither occurred or if patients were lost to follow-up, the
date of the last documented presentation was used as a






Table 1 Baseline characteristics of the patient population
Patient population





< 60 years 28 (43.8)






















! 2 2 (3.1)
Previous ipilimumab monotherapy 2 (3.1)









Lymph nodes 12 (18.8)
CNS 4 (6.3)
Treatment regimen
Ipilimumab 3mg/kg + nivolumab 1 mg/kg Q3W, followed by nivolumab 3 mg/kg Q2W 59 (92.2%)
Ipilimumab 1mg/kg + pembrolizumab 2mg/kg Q3W, followed by pembrolizumab 2 mg/kg Q3W 5 (7.8%)
aMultiple metastatic sites per patient were possible (values do not sum up to 100%); abbreviations: CNS Central nervous system, Q2W Every two weeks, Q3W Every
three weeks






censored observation. The survival and progression prob-
abilities were indicated with the Kaplan-Meier method for
censored failure time data assuming proportional hazards.
The survival curves were compared with the log-rank test
[6]. The duration of the clinical response and clinical
benefit was defined as time from treatment initiation to
progressive disease if a response or stable disease was
achieved, respectively. The time to response was defined
as time from treatment start until a response was evident
radiologically.
Cox proportional hazards regression modelling was ap-
plied to investigate the relationship of clinical risk factors
and serum biomarkers with OS. Cox regression was per-
formed as a univariate and multivariate analysis in a step-
wise approach [6]. Imputation of missing data was not
allowed and patients with missing values of a given par-
ameter were excluded from the analysis. Hazard ratios
(HR) with 95% confidence intervals (CI) were calculated
to quantify the impact on survival. P-values were calcu-
lated based on Wald statistics [6]. The association of treat-
ment response as a categorical variable with clinical
characteristics or serum biomarkers was investigated with
the Chi-square test and logistic regression, as appropriate.
In all cases, two-tailed p-values were calculated and con-
sidered significant with values p < 0.05. All analyses were
carried out with SPSS statistics version 23.0 (IBM) or
GraphPad Prism version 5.01 (GraphPad Software).
Results
A total of 64 (100%) patients with metastatic UM were
included. Fifty patients (78.1%) were naïve to systemic
treatment and received combined checkpoint blockade as
first-line systemic therapy. Regarding genotype, the pres-
ence of monosomy 3 as risk factor was specifically investi-
gated in 7 patients and identified in 2 of them. BRAF,
NRAS and KIT were analyzed and reportedly wildtype as
expected in 30, 22, and 20 patients, respectively. Muta-
tions and inactivations of MBD4 which were previously
linked to a hypermutator profile with high sensitivity to
PD-1 inhibition were not investigated in any case [18, 19].
Previous ipilimumab and PD-1 inhibitor monotherapy
were applied in 2 (3.1%) and 12 (18.8%) cases, respect-
ively. Both patients treated with ipilimumab before
showed PD. Specifically, 4 patients (6.3%) had received
nivolumab and 8 (12.5%) pembrolizumab before. In 4
cases, SD was achieved while 8 patients showed PD
upon PD-1 inhibitor monotherapy. The median duration
of the clinical benefit was 6.5 months in the 4 patients
with SD. Liver-directed therapies were reported in 31
patients (48.4%). Most patients had an ECOG status of 0
(n = 49, 76.6%). Serum LDH was elevated in 33 cases
(51.6%) at baseline. Other baseline characteristics are
listed in detail in Table 1. Ipilimumab plus nivolumab
was given in 59 patients (92.2%), while 5 patients (7.8%)
received ipilimumab plus pembrolizumab. The median
number of treatment cycles was 3 (range 1–4) for the
combination of ipilimumab with a PD-1 inhibitor in the
induction phase, and 0 (range 0–27) for PD-1 inhibitor
maintenance therapy in the overall population. A total
of 19 patients (29.7%) received a PD-1 inhibitor main-
tenance therapy. Among these, the median number of
PD-1 inhibitor cycles was 3 (range 1–27).
The best ORR to combined checkpoint blockade was
15.6% (n = 10) relating to the entire population (4 patients
were not evaluable for a radiologic response). Two pa-
tients achieved a complete response (3.1%) and 8 (12.5%)
a partial response. The median duration of response was
25.5months (range 9.0–65.0). Stable disease was achieved
in further 14 cases (21.9%), resulting in a disease control
rate of 37.5% with a median duration of the clinical benefit
of 28.0months (range 7.0–65.0) (Table 2). The median
PFS was 3.0months (95% CI 2.4–3.6). The median OS
was estimated to 16.1months (95% CI 12.9–19.3) with a
median follow-up period of 9.2 months (95% CI 7.8–10.6)
(Fig. 1).
The median time to response in patients with CR or
PR after treatment initiation was 12 weeks (range 5–31).
For the patients with SD, the median duration until the
benefit was observed also amounted to 12 weeks (range
9–30). Interestingly, all 4 patients with SD after previous
single PD-1 inhibitor blockade had PD to combined
checkpoint blockade. Among the remaining 8 patients
with PD after previous single PD-1 inhibitor blockade,
one achieved a PR to combined checkpoint blockade.
Thus, these data suggest that the effects of single and
combined checkpoint blockade were observed independ-
ently from each other.
A total of 78 AE were reported in 39 patients. Thus,
the majority of patients developed any treatment-related
AE (60.9%). Of all events, 37 AE were graded as severe
(grade 3 + 4). They were observed in 25 patients (39.1%;
grade 3: 37.5%; grade 4: 1.6%). The treatment was dis-
continued in 25 cases (39.1%) due to unacceptable tox-
icity. However, no treatment-related deaths occurred
during treatment or the observation period. The most
common events were colitis (20.3%), hepatitis (20.3%),
Table 2 Best response rates to combined checkpoint blockade
Cases (%) Cumulative
percentage (%)
Complete response 2 (3.1) 3.1
Partial response 8 (12.5) 15.6 (ORR)
Stable disease 14 (21.9) 37.5 (DCR)
Progressive disease 36 (56.3) 93.8
Unknown 4 (6.3) 100
Total 64 (100) 100
Abbreviations: ORR Objective response rate, DCR Disease control rate






thyreoiditis (15.6%), hypophysitis (7.8%), fever (4.7%),
and myalgia with myositis (4.7%). In all 5 cases with
hypophysitis, the individual hormone axes including
ACTH, cortisol, FSH, LH, TSH, and testosterone were
investigated but not specifically graded. In 3 cases, the
pituitary gland was enlarged in MRI examinations. All
patients received systemic replacement of hydrocorti-
sone. All AE are listed in Additional file 1.
In univariate Cox regression, ECOG status (p =
0.000096), the presence of bone metastasis (p = 0.011),
and the best response to checkpoint blockade (p = 0.002)
were significantly associated with OS (Additional file 2).
The risk factors ECOG status, serum LDH, serum levels
of CRP, and presence of bone metastasis were further in-
tegrated into a multivariate Cox regression model. Of
these factors, a significant association with OS was con-
firmed for ECOG status (p = 0.007) only (Table 3, Fig. 2a).
We recently identified a prognostic score of the serum
biomarkers LDH, CRP, and relative eosinophil count
(REC) in a cohort of 94 UM patients receiving PD-1 in-
hibitors [6]. The score assigns one risk point for each
unfavorable factor, i.e., elevated LDH, elevated CRP, and
a REC < 1.5%, defining four distinct prognostic groups
(low, intermediate, high, and very high risk). Each pa-
tient receiving combined checkpoint blockade was
assigned to a risk group and the score was validated with
Kaplan-Meier estimates. Due to a small sample size, pa-
tients with low and intermediate risk were pooled. The
risk groups showed significantly different survival prob-
abilities (p = 0.000005). The median survival times were
superior for the low plus intermediate group (17.7
months, 95% CI 14.7–20.8) compared to the high (15.4
months, 95% CI 12.7–18.2) and very high risk group
(7.1 months, 95% CI 0.0–16.2) (Fig. 2b). However, the
score neither correlated with the response rate (p =
0.609) nor with the DCR (p = 0.446), suggesting that it
was generally prognostic but not specifically predictive
for the response to combined checkpoint blockade.
Subgroup analysis were performed for patients with
metastasis to the central nervous system (CNS) at treat-
ment initiation and for the treatment responders. Four
patients showed an involvement of the CNS. Two of
them had neurological symptoms. Two patients achieved
SD, 2 showed PD. The median PFS for the CNS sub-
group was 3.0 months (95% CI 0.0–6.1) while the me-
dian OS was not reached. In contrast, none of the
treatment responders (CR or PR) had CNS involvement
when the treatment was initiated (Table 4). The median
time from detection of the primary tumor to metastatic
disease was 43 months among the responders. Data on
the assessment of the risk of metastasis formation of the
primary tumors were sparse, as e.g. the presence of
monosomy 3 or the MBD4 status was not investigated
in any of the responders.
Fig. 1 Kaplan-Meier estimates of the patient population for a progression-free survival (PFS) and b overall survival (OS). The median PFS and OS
was estimated to 3.0 months (95% CI 2.4–3.6) and 16.1 months (95% CI 12.9–19.3), respectively. One patient was not included in the Kaplan-Meier
analysis for PFS and OS due to missing data
Table 3 Multivariate Cox regression analysis of clinical
parameters and serum biomarkers
Parameter Category HR (95% CI) P-value
ECOG status n.a. (ordinal) 3.19 (1.36–7.47) 0.007*
LDH normal 1 0.428
elevated (>ULN) 1.83 (0.41–8.08)
CRP normal 1 0.534
elevated (>ULN) 1.73 (0.31–9.74)
Bone metastasis no 1 0.331
yes 2.02 (0.49–8.27)
Four parameters were included in the multivariate Cox regression analysis. Of
these factors, ECOG status was significantly associated with overall survival in
this model. Abbreviations: CI Confidence interval, n.a. not applicable, ULN
Institutional upper limit of normal, LDH Lactate dehydrogenase, CRP C-reactive
protein; *p<0.05.







Here, we present a comparatively large cohort of pa-
tients with metastatic UM who were treated with com-
bined checkpoint blockade. We detected a 15.6% ORR,
with a 3.1% complete and 12.5% partial response rate.
This response rate is in line with our previous report
showing 16% ORR, although only 12 patients were eva-
luable for their radiologic response and the follow-up
time was short [6]. Another case series was recently pub-
lished from a single-center experience where 2 out of 8
patients treated with nivolumab and ipilimumab had a
partial response [11]. Other preliminary data on the effi-
cacy of the combined checkpoint blockade have been
proposed as conference abstracts, but appear preliminary
to date. Najjar et al. reported results from a multi-
center, retrospective analysis in 66 patients from 11 U.S.
centers, revealing an ORR of 13% and a DCR of 31%
[20]. In addition to these estimates in a real-world set-
ting, prospective trials are currently underway. A prelim-
inary analysis of the Spanish phase II trial GEM1402
(NCT02626962) showed an ORR of 12% and disease
stabilization in 52% of cases [21]. Another phase II trial
is currently ongoing in the U.S. in 30 patients with UM
(NCT01585194). A recently presented interim analysis
revealed an ORR of 17% and disease control in 50% [22].
Thus, we conclude that the ORR of 15.6% identified in
this population is a solid estimate for the efficacy of
combined checkpoint blockade in UM and a good indi-
cator of what we can expect from the final analyses of
the prospective trials. This regimen appears to be signifi-
cantly superior compared to the sobering efficacy values
observed with ipilimumab and PD-1 inhibitor monother-
apy [6–9, 23–26]. Considering the data available so far,
we conclude that the increase of ORR of the combined
blockade versus PD-1 inhibition alone amounts to ap-
proximately 10%. Further evidence for a better efficacy
of the combined regimen is supported by the observa-
tion of complete responders, albeit to a small extent.
This is notable as UM is considered a “cold” tumor due
to a low mutational burden and a unique immunosup-
pressive tumor microenvironment [27–29]. Further re-
search is urgently needed to identify the radiologic,
immunologic, and molecular determinants for treatment
response in this small subset of patients. Regarding
safety, the rate of severe AE was lower compared to the
events reported in the pivotal trial in cutaneous melan-
oma (CheckMate-067) [30]. In particular, the occurrence
of potentially life-threatening grade 4 AE was surpris-
ingly low, suggesting that the regimen may be better tol-
erated in UM. However, it is also conceivable that the
retrospective design and the small number of cases of
this study causes an underreporting of AE.
Among clinical parameters and serum biomarkers,
only the ECOG performance status was a consistent
prognostic factor in multivariate analysis. Other parame-
ters such as serum LDH, CRP, and the REC showed a
significant association neither with OS nor with the
treatment response when they were considered as single
factors. However, when integrated into a prognostic
score, they were useful for risk stratification and dis-
criminated groups with distinct survival probabilities.
Thus, the risk score identified previously in a distinct
Fig. 2 a Kaplan-Meier estimates for overall survival (OS) according to ECOG performance status. The median OS was 17.7 months (95% CI 13.1–
22.3) for ECOG 0 versus 2.5 months (95% CI 0.0–9.6) for ECOG !1. Three patients were not included due to missing data. b Kaplan-Meier
estimates for OS according to the prognostic score based on the serum parameters LDH, CRP, and REC. The groups with low and intermediate
risk were pooled due to a small number of cases. The median OS was 17.7 months (95% CI 14.7–20.8) in the low plus intermediate group versus
15.4 months (95% CI 12.7–18.2) in the high risk group versus 7.1 months (95% CI 0.0–16.2) in the very high risk group. The p-values indicated were
calculated with the log-rank test. One patient was not included due to missing data









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































cohort was successfully validated in this population [6].
As there was a significant association neither with the
ORR nor the DCR, we conclude that the score is gener-
ally prognostic but not specifically predictive for the re-
sponse to checkpoint blockade.
The major limitations of this study are its retrospective
design and the lack of a control group. When compared
to historical controls, the median OS of 16.1 months is
superior to survival estimates from other studies. Re-
cently, the median OS benchmark for metastatic UM
was identified as 10.2 months in a meta-analysis on indi-
vidual data from 912 patients pooled from 29 trials [31].
Another analysis on individual-level data from 2494 pa-
tients proposed a median OS of 1.07 years across all
treatment modalities. In this context, the OS observed in
our cohort treated with combined checkpoint blockade
appears more favorable, although external cohorts
should be interpreted with caution and the comparison
may be subject to significant confounding. A further
limitation comes from the paucity of molecular and gen-
etic analysis on the primary and metastatic tumors
which are urgently needed to better characterize and
understand the pattern of treatment response in UM.
Conclusions
Altogether, our study implies that combined checkpoint
blockade represents the hitherto most effective treat-
ment option available for metastatic UM available in
routine care outside of clinical trials. Based on our ana-
lysis and preliminary data from others, we hypothesize
that the ORR achieved with combined checkpoint block-
ade will be 15–17%. Future trials are warranted to iden-
tify specific biomarkers for treatment response.
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Aim: Melanoma brain metastases (MBM) are associated with a dismal prognosis. Few clinical trials evalu-
ated the impact of immunotherapy (IT) and targeted therapy (TT) alone or in combination with surgery
and radiotherapy in this population. Patients & methods: Retrospective analysis of data from 163 patients
diagnosed with MBM between January 2014 and December 2016. Prognostic factors of overall survival
were analyzed using Kaplan–Meier survival curves, classi!cation and regression tree and multivariate Cox
regression analysis. Results: The median follow-up was 25 months; median overall survival (mOS) for all
patients was 7 months. For patients receiving IT, the mOS was 13 months and 7 months for patients re-
ceiving TT or chemotherapy (CT). The mOS for patients treated with surgery/radiosurgery in combination
with IT, TT and CT was 25, 14 and 11 months, respectively. Conclusion: New systemic therapies, especially
IT, improve mOS in patients with MBM, particularly when combined with surgery/radiosurgery upfront.
First draft submitted: 27 September 2017; Accepted for publication: 26 November 2018; Published
online: 4 January 2019
Keywords: chemotherapy • dominant systemic therapy • immunotherapy • melanoma brain metastases • overall
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Melanoma brain metastases (MBM) are associated with the most unfavorable prognosis of all metastatic melanoma
patients. In the eighth AJCC classification, an independent substage was defined in stage IV of melanoma for
patients with MBM, as these patients usually have the shortest survival time [1]. Prior to the introduction of
new systemic therapies, median overall survival (mOS) for patients with MBM and normal lactate dehydrogenase
(LDH) was 6 months, and for patients with elevated LDH was 3 months [2].
Few clinical studies evaluated the influence of new systemic therapies in patients with MBM [3,4] and, in the
large Phase III trials the presence of MBM was an exclusion criteria [5–8].
Our retrospective study assesses the influence of new therapies using a collective of subsequent patients diagnosed
with MBM, and treated with a multimodal approach.
We analyzed prognostic factors and survival considering the type of systemic therapy received and the combination
of systemic therapy with surgery and/or radiotherapy. We also describe the multiple subsequent treatments using
swimmer plots outlining the dominant therapy for each patient.
The primary end point of this analysis is overall survival; intracranial disease control and intracranial response
are outside the scope of this manuscript, and will be analyzed and reported separately.
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Patients & methods
Patients’ collective
We included in our analysis 163 consecutive patients diagnosed with MBM between January 2014 and December
2016. The cut-off data analysis was January 2018. The patients’ collective was identified using data available in
the German Central Malignant Melanoma Registry (CMMR) from the University Department of Dermatology in
Tuebingen, Germany. Information from CMMR was compiled in a Statistical Package for Social Sciences (SPSS)
table including – gender; date of birth; date of first diagnosis, date of entry stage IV disease and date of MBM
diagnosis; stage at first diagnosis; localization of distant metastases; and histopathological characteristics from the
primary tumor. The ethics committee of the Medical Faculty of the University of Tuebingen approved this study
(Reference 136/2017 BO2).
Documentation of prognostic & predictive factors
Besides the data from the CMMR previously described, further information was retrieved from the electronic patient
files. These additional data included BRAF status, previous therapies (if any) for stage IV disease, LDH, Eastern
Cooperative Oncology Group performance status (ECOG PS), presence or absence of neurological symptoms,
number of MBM, type of systemic therapy received after MBM diagnosis, type of local therapy (surgery and/or
radiotherapy), best response to each treatment and time of last follow-up (FU) or death from any cause. Melanoma-
specific graded prognostic assessment (GPA) that combines Karnofsky performance status and number of MBM [9]
was calculated for each patient. The cut-off criterion of three MBM is used not only in the GPA score but also in
other analyses similar to ours. We are aware that this cutoff is currently being discussed and others that include a
higher number of MBM might be used in the future. However, since this analysis included patients diagnosed with
MBM between 2014 and 2016, and this was the cutoff used for ablative therapy at that time, we understand that
it should be applied in our analysis as well.
The data previously mentioned was included in the SPSS table using corresponding variables.
Analysis of dominant therapy
Currently, multiple systemic therapies are available for patients with MBM and it is difficult to determine the
prognostic influence of the individual therapies. Conventional analyses followed the concept of investigating first-
line therapies and second-line therapies separately. With the current expanded and complex use of immunotherapy
(IT), targeted therapy (TT) and chemotherapy (CT) for stage IV melanoma, such evaluation does not seem to be
reasonable, as the decisive therapeutic influence can be attributed to the first-line therapy as well as to the therapies
received in the second or third line. Considering this background, we propose to identify and evaluate the therapy
that was ‘dominant’ for the course of the disease in each patient. The dominant systemic therapy was defined
as the therapy that has been administered for the longest period of time or has achieved the best disease control
or response. For each patient, two authors (T Amaral, C Garbe) defined independently which therapy should be
regarded as the dominant therapy.
In order to be able to evaluate this reliably, we developed multiple systemic therapies swimmer plots and divided
the patients in three groups – patients with more than 12 months OS that were still alive, patients with more
than 12 months OS that were already deceased and patients with less than 12 months OS. Each therapy episode
and the best objective response (intracerebral + extracerebral) were displayed on a time axis. This enabled us to
define the dominant therapy for each patient and the combination of dominant systemic therapy with surgery
and/or radiotherapy. By applying the concept of dominant therapies, we obtained four different ‘systemic therapy
groups’: IT (CTLA-4 ± PD-1 or PD-1 inhibitors), TT (BRAF ± MEK inhibitors), CT (carboplatin/paclitaxel,
dacarbazine or temozolomide) and no systemic therapy. All systemic therapies mentioned throughout the article
refer to this concept. The colored circle before each patient’s swimmer plot identifies the dominant therapy for this
particular patient, and the number refers to the OS in days.
Combination of dominant therapy & surgery/radiosurgery
Since the nature of intracranial intervention plays a role in the outcome of patients with MBM, survival analysis
for the combination of dominant therapy and surgery and/or radiotherapy was also performed. For all patients
who underwent surgery/radiosurgery (S/RS), an MRI examination is performed for the postoperative control and
response evaluation. For this analysis, the following possible combinations were used: S/RS + IT, S/RS + TT,






Immunotherapy + surgery/radiosurgery associated with favorable survival in MBM Research Article
S/RS + CT, S/RS with no systemic treatment, whole brain irradiation (WBRT) with or without systemic treatment
and no radiotherapy (with or without systemic treatment).
Statistics
FU time was defined as the date of last FU or death minus the date of MBM diagnosis. Survival probabilities were
calculated using the date of diagnosis of MBM. In the OS analyses, all causes of death were considered. Survival
curves and median survival with 95% confidence intervals (95% CIs) were obtained according to the Kaplan–Meier
(KM) estimators and compared using the log-rank test. The following factors were included in the classification
and regression tree analysis and in the multivariate Cox regression analysis: gender, BRAF status, number of MBM,
ECOG PS, LDH, presence or absence of extracerebral disease, previous systemic therapy, dominant therapy and
combination of dominant therapy and surgery and/or radiotherapy (6 groups as described above). Survival analyses
were performed with SPSS v.24 (SPSS Inc., IL, USA). STATA R! program v15 was used to generate the final version
of KM survival curves and R version 3.4.3 by the R Foundation of Statistical Computing (Vienna, Austria) was
used to generate the swimmer plots, classification and regression tree and multivariate forest plot analysis [10].
Results
Patients’ characteristics
Table 1 summarizes the patients’ characteristics. The median age at the time of MBM diagnosis was 63 years
(54.0–74.0). The majority of patients (92%) had cerebral and extracerebral disease and half of the patients had
already received at least one systemic therapy for stage IV melanoma before being diagnosed with MBM. When
analyzing the prognostic factors, 56% had !3 MBM, 52% harbored a BRAF mutation, 43% had elevated LDH
and 70.6% had ECOG 0. Finally, 28.2% were GPA class 3.5–4.0. The median FU was 25 months (95% CI:
21.4–28.6) and at the time of data cut-off analysis, 19% of the patients were still alive.
Systemic therapies swimmer plots
As mentioned before, we divided the patients in three subgroups according to OS – more than 12 months OS and
still alive at time of cut-off analysis; more than 12 months OS and already deceased and less than 12 months OS.
We used the 12 months’ limit due to the fact that previous reports and analyses for melanoma brain metastases
show median overall survivals less than 12 months and to produce an easily understandable graphic representation
and swimmer plots of the three groups.
In the first subgroup (Figure 1A; n = 31), IT was the dominant therapy in the majority of the patients (23
patients), followed by TT (five patients). Three patients did not receive systemic therapy. 13 patients (42%)
obtained a complete intracranial and extracranial response (CR), based on the RECIST criteria [11].
In the second subgroup (Figure 1B; n = 23), IT was the dominant therapy in 12 patients; TT in eight patients,
CT in two patients and one patient received no systemic therapy. In this subgroup, no CRs were observed.
Finally, in the third subgroup (Figure 1C; n = 109), a third of the patients did not receive systemic therapy (33
patients). TT was the dominant therapy in 31 patients, IT in 29 patients and CT in 16 patients.
Overall survival
Figure 2A–D shows the KM curves for the prognostic factors identified (number of MBM, LDH, previous systemic
therapy and GPA class). In the subgroup of patients with !3 MBM the mOS was 10 months, significantly superior
to the 4 months mOS observed in the group with >3 MBM (95% CI: 7.1–12.9 and 2.7–5.3). There was no
significant difference in the mOS between patients with normal and elevated LDH at the time of MBM diagnosis:
7 and 6 months, respectively (95% CI: 3.3–10.7 and 3.8–8.2). In the subgroup of patients that have not received
previous systemic therapy, the mOS was significantly higher compared with those already treated for stage IV
disease – 10 versus 6 months (95% CI: 7.0–12.9 and 5.0–6.9). Finally, for patients in GPA class 3.5–4.0, the mOS
was 11 months, in GPA class 2.5–3.0, it was 10 months, in GPA class 1.5–2.0, it was 6 months and in GPA class
0.0–1.0 the mOS was 4 months (95% CI: 5.9–16.1; 7.1–12.9; 4.6–7.4 and 2.9–5.1, respectively).
Figure 2E represents the KM OS curves considering the dominant therapy classification. Patients treated with
IT had an mOS of 13 months, significantly higher compared with the other subgroups – 7 months mOS for TT;
7 months mOS for CT and 3 months mOS for the subgroup not receiving systemic therapy. The 1 year (1 y)
OS was 53.1% for patients receiving IT and 29.5% for those treated with TT. The 2 y OS was 37.5 and 8.4%,
respectively.
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Table 1. Patients characteristics.
All patients Overall survival p-value
>12 m alive >12 m deceased !12 m
N 163 31 23 109
Age
!55 y 44 19.4% 34.8% 27.5% 0.670
!55 y ! 70 y 58 45.2% 30.4% 33.9%
!70 y 61 35.5% 34.8% 38.5%
Gender
Males 93 45% 57% 61% 0.311
Females 70 55% 43% 39%
Extracerebral disease
Yes 150 90% 87% 94% 0.526
No 13 10% 13% 6%
Previous therapy
Yes 81 32% 35% 58% 0.013
No 82 68% 65% 42%
LDH
Normal 66 55% 44% 36% 0.183†
Elevated 69 39% 26% 47%
Not available 28 6% 30% 17%
Number of BM
"3 92 77% 70% 48% 0.005
"3 71 23% 30% 52%
BRAF status
Mutated 84 45% 70% 49% 0.233†
Wild-type 74 45% 30% 49%
Not available 5 10% 0 2%
ECOG PS
0 115 84% 74% 66% 0.147
! 1 48 16% 26% 34%
GPA
0.0–1.0 33 7% 17% 25% 0.054
1.5–2.0 59 29% 26% 40%
2.5–3.0 25 19% 17% 14%
3.5–4.0 46 45% 39% 21%
Clinical features and disease characteristics from all patients are presented, as well as their distribution in three subgroups used to perform the graphic representation in Figure 1 (patients
with OS "12 months, still alive at the time of analysis; patients with OS !12 months and already dead at the time of analysis; patients with OS "12 months). To determine the relationship
between these characteristics in the three different subgroups, we used crosstabs and results are presented in the last column.
Bold p-values represent those that are signi!cant.
†Analysis performed only for patients with available data.
BM: Brain metastasis; ECOG PS: Eastern Cooperative Oncology Group performance status; GPA: Melanoma-speci!c graded prognostic assessment; LDH: Lactate dehydrogenase; m:
Month; Y: Year.
Figure 2F shows OS analysis for the combination between the dominant therapy and local therapies. For patients
treated with S/RS + IT, the mOS was 25 months compared with 7 months for patients receiving the combination
S/RS + TT. For each of the previous subgroups, the 1 y OS was 69.4 and 62.5% and the 2 y OS was 50.6 and
19.4%, respectively. The mOS for patients treated with WBRT ± systemic therapy was 5 months, and the 1 y
OS and 2 y OS were 12.7 and 6.8%, respectively. Table 2 provides more information on OS analysis of systemic
therapy and combination with local therapy.
Figure 3 provides OS data stratified by the presence of symptoms and treatment with corticosteroids at the time
of MBM diagnosis. The mOS for asymptomatic and symptomatic patients was 7 and 4 months (95% CI: 4.6–9.4
and 0.9–4.1; p = 0.359) and for patients not treated and treated with corticotherapy was 8 and 4 months (96%
CI: 5.4–10.6 and 1.7–6.3; p = 0.053).
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Figure 1. Multiple therapies swimmer´s plots. (A) Patients with OS >12 months, still alive. (B) Patients with OS >12 months deceased. (C)
Patients with OS !12 months. The number displayed before each patient’s individual swimmers plot represents the OS in days.
OS: Overall survival.
Finally, the mOS for all patients was 7 months (95% CI: 5.4–8.6) and the 1 year and 2 years OS was 32.5 and
18.7%, respectively. Table 2 provides more information on the mOS for all therapy groups and on the 1 and 2
years OS.
Classi!cation & regression tree
The classification and regression tree is shown in Figure 4. Node 1 represents the most significant prognostic factor
for this population, which is S/RS. Two groups were then generated: Node 2 (patients treated with S/RS) and
Node 5 (patients not treated with S/RS, that includes patients treated with WBRT and patients who did not receive
radiotherapy). In both groups, the effect of the combination with dominant therapy is subsequently evaluated.
The best mOS (17.4 months) was observed in the group of patients treated with S/RS and IT or TT (Node 3).
For patients treated with S/RS + CT or no systemic therapy (Node 4) the mOS was 9.9 months. In the group of
patients not treated with S/RS but receiving systemic therapy (Node 6), the mOS was 6.6 months for those treated
with IT (Node 7) and 6.2 months for those treated with TT or CT (Node 8). The shortest mOS (2 months) was
observed in the subgroup of patients that did not receive S/RS or systemic therapy (Node 9).
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Figure 2. Overall survival. Strati!ed by (A) number of brain metastases (1–3 vs >3), p smaller than 0.0001; (B) LDH (elevated vs normal),
p = 0.053; (C) prior systemic therapy (yes vs no), p = 0.005; (D) melanoma-speci!c GPA, p = 0.002; (E) dominant systemic therapy (IT vs TT vs
CT vs No sys. Tx), p smaller than 0.0001; (F) combination dominant systemic therapy and local therapy (S/S + IT vs S/S + TT vs S/S + CT vs
S/S and no sys. Tx vs WBR ± sys. Tx vs no RT), p smaller than 0.0001.
CT: Chemotherapy; GPA: Graded prognostic assessment; LDH: Lactate dehydrogenase; IT: Immunotherapy; No sys. Tx: No systemic therapy;
RT: Radiotherapy; S/S: Surgery/radiosurgery; TT: Targeted therapy; WBR: Whole brain irradiation.
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OS (%; 95% CI)
1 year OS 2 years OS
Systemic therapy (p < 0.0001)
Immunotherapy 13 (8.1–17.8) 53.1 (40.9–62.2) 37.5 (25.3–49.6)
Targeted therapy 7 (3.8–10.2) 29.5 (16–43) 8.4 (0–18)
Chemotherapy 7 (5.6–8.4) 11.1 (0–25.6) –
No systemic therapy 3 (1.5–4.8) 10.8 (0.8–20.8) –
Radiotherapy + systemic therapy (p < 0.0001)
S/SRS + immunotherapy 25 (14.6–35.4) 69.4 (54.3–84.4) 50.6 (33.5–67.5)
S/SRS + targeted therapy 14 (12.1–15.9) 62.5 (38.8–86.2) 19.4 (0–41.3)
S/SRS + chemotherapy 11 (8.4–13.6) 28.6 (0–62.1) –
S/SRS without systemic therapy 4 (0–2.1) 21.4 (0–43) –
Whole brain irradiation
± systemic therapy
5 (3.9–6.1) 12.7 (3.9–21.5) 6.8 (0–13.7)
No radiotherapy 3 (1.7–4.2) 11.4 (0.8–22) –
CI: Con!dence interval; OS: Overall survival; S/SRS: Surgery/radiosurgery.
Multivariate analysis
In the multivariate analysis (Figure 5), the type of therapy (combination of systemic therapy with surgery and/or
radiotherapy) remained a significant prognostic factor (hazard ratio [HR] for S/RS + IT = 0.25) along with ECOG
PS (HR: 1.67). The number of MBM was borderline significant (HR: 1.52). The other factors evaluated – gender,
BRAF status, presence of extracerebral disease, LDH at the time of diagnosis and previous systemic therapy for
stage IV disease were not significant in the multivariate analysis.
Discussion
The main finding of our study is the considerable impact of IT on OS of patients with MBM, particularly in
combination with S/RS.
The mOS of patients receiving predominantly IT was significantly longer (mOS = 13 months) than for those
treated with other systemic therapies, namely TT and CT. Surprisingly, the mOS for patients predominantly treated
with TT and CT was the same (mOS = 7 months) in our population. The combination of systemic immunotherapy
and S/RS showed an impressive mOS of 25 months. The 1 year and 2 years OS rates were 69.4 and 50.6%, higher
than previously reported [12–16]. However, it should be taken into consideration that these studies, contrary to ours,
analyzed the outcomes of monotherapies with CTLA-4 and PD1 inhibitors only.
The inclusion of S/RS and WBRT in the analysis already implies a selection bias. S/RS is mainly used in patients
with !3 MBM while WBRT is used exclusively in patients with >3 MBM. By using this approach in the clinical
practice, we are selecting patients with the best prognostic factors to receive predominantly S/RS upfront, which
might partially explain the best outcomes with this approach. However, the subgroup of patients treated with S/RS
and systemic therapies (Figure 2F, groups 1–4) also includes patients with >3 MBM. In this case, S/RS was not
performed upfront but later on at the time of progression of individual brain metastases. In a retrospective analysis,
this selection bias cannot be completely avoided, and prospective studies are required to answer the questions that
remain unanswered here.
As for the patients treated with S/RS + TT, the mOS was 14 months and the 1 year OS rate was 62.5% (95%
CI: 38.8–86.2), which is better than compared with previously reported data [4,17].
55 patients treated with WBRT were included (Figure 2F). In this subgroup, the mOS was only 5 months. In the
two subgroups of patients that either did not receive systemic therapy or radiotherapy, the mOS was 3 months. In
view of the fact that IT and TT are available in clinical practice, and also achieve good results in MBM, treatment
with WBRT should be judged critically.
For patients who did not receive S/RS but were treated with IT (Figure 4; Node 7), the mOS was 6.6 months,
which does not exceed the mOS for patients receiving S/RS and CT or no systemic therapy (Node 4). However,
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Figure 3. Overall survival. Strati!ed by (A) presence of symptoms (no symptoms vs symptomatic), p = 0.359; and (B)
therapy with corticosteroids (no corticotherapy vs corticotherapy) at the time of MBM diagnosis, p = 0.053.
MBM: Melanoma brain metastasis.
in the first group a higher percentage of the patients (>20%) were long-term survivors. We understand that this
favors IT as first-line systemic therapy when S/RS is not possible.
Our analysis shows that the previous therapies for stage IV disease have a prognostic significance in this
population, as well as the number of MBM and performance status, already described by other authors [2,4,18,19].
In our population, LDH, presence of symptoms and corticotherapy at the time of MBM diagnosis were not
significant.
A considerable large subgroup (23% of the patients) did not receive any systemic treatment for MBM. The
majority of these patients were either heavily pretreated for metastatic disease before developing MBM or were
clinically unfit, resulting in an OS <12 months.
Retrospective analysis including real-world patients’ data remain important since trials addressing specific ques-
tions associated with the treatment of patients with MBM are scarce. Results available from the ABC [3] and
CheckMate 204 [20] trials showed that the combination of CTLA-4/PD-1 inhibitors is safe and active in patients
with asymptomatic MBM, with similar intra- and extra-cranial responses, and with better outcomes when given
upfront. In the COMBI-MB [4] trial, the first interim analysis showed that, for BRAF mutated patients with
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Figure 4. Classi!cation and regression tree analysis. Y-axis represents the OS probability and X-axis represents time in months. In Node 5
are included the patients who received WBRT and those who did not receive any radiotherapy.
CT: Chemotherapy; IT: Immunotherapy; mOS: Median overall survival; n: Number of patient; no ST: No systemic therapy; OS: Overall
survival; S/RS: Surgery/radiosurgery; TT: Targeted therapy; WBRT: Whole brain irradiation.
asymptomatic MBM, ECOG PS 0/1 and no previous intracranial local therapy, the mOS was 10.8 months, with
a 1 year OS of 46%, supporting the use of the combination dabrafenib/trametinib in this subgroup.
The following limitations need to be considered when examining the results. This is a retrospective analysis from
a single center. However, we present data from a rather large number of patients obtained from a very detailed
dataset. We included patients diagnosed in 2014, for whom the currently first-line IT and TT were not yet available.
The therapeutic approach changed considerably since then. A selection bias has to be considered. The patients with
better prognostic factors (!3 MBM, not progressing under previous therapy and with higher GPA score) mostly
received S/RS and IT, which could explain the better outcomes observed. Hence, the results obtained by comparing
groups 1–4 (which include patients treated with S/RS and therefore with better prognostic factors upfront) with
groups 5 and 6 need to be interpreted with caution (Figure 2F).
Our study also presents strengths. In this study, we present OS data from patients with MBM, for which very
few data are available. Most of the information available is focused on intracranial response and intracranial disease
control. The analysis based on multiple therapies swimmer plots, enabled us to identify the dominant therapy
for the individual patient outcome. The results of our study show that this analytic approach can successfully
identify effective combinations of systemic treatments with surgery and/or radiotherapy. Although a selection
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# Events: 132; Global p-value (log-rank): 7.196e-10
A/C: 1132.35; Concordance Index: 0.74
Figure 5. COX multivariate analysis.
ECOG: Eastern Cooperative Oncology Group performance status; LDH: Lactate dehydrogenase; RT + Sys. Tx: Radiotherapy plus systemic
therapy; S/S: Surgery/radiosurgery; S/S + CT: Surgery/radiosurgery plus chemotherapy; S/S + IT: Surgery/radiosurgery plus
immunotherapy; S/S + TT: Surgery/radiosurgery plus targeted therapy; No RT: No radiotherapy; Nr. of MBM: Number of melanoma brain
metastases; Previous Sys. Tx: Previous systemic therapy; WBRT ± ST: Whole brain irradiation with or without systemic therapy.
bias was present regarding the prognostic factors previously mentioned, the multivariate analysis showed that the
combination of S/RS + IT seems to be the best approach, with a clear survival advantage. The median FU after
MBM diagnosed was 25 months, which is highly uncommon, supporting our long-term outcomes. Our results are
based on data from the CMMR, which is a very detailed database, continuously updated, with well-documented
therapy and FU information.
Conclusion
This retrospective study included 163 patients with MBM treated with a multidisciplinary approach in a tertiary
center. This analysis confirmed the prognostic significance of the number of cerebral metastases, the ECOG
performance status and GPA score that combines these two aspects. The LDH value was only marginally significant.
The new systemic therapies, especially IT, improve the OS of patients with MBM, especially when combined
with ablative therapies (S/RS). Finally, our results suggest that in MBM, local therapy should be considered as
the first approach whenever possible. IT or TT should be the systemic therapies of choice. If upfront S/RS is not
possible, first-line IT should be considered, which is also in line with the results from the ABC and CheckMate
204 clinical trials.
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Future perspective
The therapeutic approach for patients with MBM changed significantly in the last years. Previously, OS for these
patients did not exceed 4–6 months, depending on the publications considered. However, IT and TT changed the
spectrum of therapeutic options for these patients, which resulted in improved disease control and survival.
Based on the results from clinical trials, combined IT (CTLA-4 + PD-1 inhibitors) seems to be the systemic
therapy with the best outcomes in patients with MBM. The combination of dabrafenib and trametinib also showed
an improvement in OS in patients with MBM and BRAF mutation. To be noted, intracranial and extracranial
response do not seem to differ both for IT and TT.
Nonetheless, some questions remain open. The best combination of systemic and local therapy is yet to be
determined. Should they be given concurrently or sequential? Data show that concurrent therapy does not seem to
increase intracranial toxicity, contrary to what might be expected.
Ongoing clinical trials will show the role of the triple combination therapy (PD-1/PD-L1 in-
hibitors + BRAF/MEK inhibitors) in stage IV melanoma. The triple combination in MBM should also be
investigated, particularly if no limiting toxicity is observed in the current ongoing trials.
Currently, the cutoff of the MBM for receiving ablative therapy is also the subject of an intense discussion.
However, the exact number is not consensual and depends on several factors including the experience of the
treating multidisciplinary team. New concepts that are not limited by the number of MBM are being investigated.
For patients with more than three MBM, should we treat locally the lesions that will most probably cause
symptoms or are progressing, and initiate/continue systemic therapy or should we skip the local therapy and focus
predominantly in systemic approaches?
Finally, we need to mention the group of patients with symptomatic MBM that are normally excluded from
clinical trials. Moreover, immunotherapy might be delayed in these patients since the therapy for symptomatic
MBM includes corticosteroids. This aspect is particularly important for patients with BRAF wild-type melanoma
who have no other valid systemic therapeutic options and other strategies that help mitigate this problem need to
be addressed.
Summary points
• Treatment of patients with melanoma brain metastases (MBM) has changed signi!cantly in the last years, but
remains challenging.
• Immunotherapy (particularly the combination of CTLA-4 and PD-1 inhibitors), and targeted therapy (BRAF + MEK
inhibitors) have shown to improve disease control and survival in patients with asymptomatic MBM.
• A total of 163 consecutive patients diagnosed with MBM between 2014 and 2016 were included in this analysis.
• The dominant therapy for each patient was de!ned based on the therapy duration and outcome of each systemic
therapy.
• Prognostic signi!cance factors were number of cerebral metastases, Eastern Cooperative Oncology Group
performance status, melanoma-speci!c graded prognostic assessment score and previous systemic therapies
received for stage IV disease. In our population, lactate dehydrogenase, presence of symptoms and
corticotherapy at the time of MBM diagnosis were not signi!cant.
• The median overall survival (mOS) of patients receiving IT was signi!cantly longer (mOS = 13 months) than for
those receiving targeted therapy (TT) and chemotherapy (mOS = 7 months for both TT and CT).
• The combination of IT and surgery/radiosurgery (S/RS) showed an mOS of 25 months. The 1 year and 2 years OS
rates were 69.4 and 50.6%.
• In our analysis, IT and TT improve mOS in patients with MBM, particularly when combined with S/RS.
• If upfront S/RS is not possible, !rst-line IT should be considered.
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ABSTRACT
Background Nivolumab combined with ipilimumab 
have shown activity in melanoma brain metastasis 
(MBM). However, in most of the clinical trials investigating 
immunotherapy in this subgroup, patients with 
symptomatic MBM and/or prior local brain radiotherapy 
were excluded. We studied the ef"cacy of nivolumab plus 
ipilimumab alone or in combination with local therapies 
regardless of treatment line in patients with asymptomatic 
and symptomatic MBM.
Methods Patients with MBM treated with nivolumab plus 
ipilimumab in 23 German Skin Cancer Centers between 
April 2015 and October 2018 were investigated. Overall 
survival (OS) was evaluated by Kaplan- Meier estimator 
and univariate and multivariate Cox proportional hazard 
analyses were performed to determine prognostic factors 
associated with OS.
Results Three hundred and eighty patients were included 
in this study and 31% had symptomatic MBM (60/193 
with data available) at the time of start nivolumab plus 
ipilimumab. The median follow- up was 18 months and 
the 2 years and 3 years OS rates were 41% and 30%, 
respectively. We identi"ed the following independently 
signi"cant prognostic factors for OS: elevated serum 
lactate dehydrogenase and protein S100B levels, 
number of MBM and Eastern Cooperative Oncology 
Group performance status. In these patients treated with 
checkpoint inhibition "rst- line or later, in the subgroup of 
patients with BRAFV600- mutated melanoma we found no 
differences in terms of OS when receiving "rst- line either 
BRAF and MEK inhibitors or nivolumab plus ipilimumab 
(p=0.085). In BRAF wild- type patients treated with 
nivolumab plus ipilimumab in "rst- line or later there was 
also no difference in OS (p=0.996). Local therapy with 
stereotactic radiosurgery or surgery led to an improvement 
in OS compared with not receiving local therapy (p=0.009), 
regardless of the timepoint of the local therapy. Receiving 
combined immunotherapy for MBM in "rst- line or at a later 
time point made no difference in terms of OS in this study 
population (p=0.119).
Conclusion Immunotherapy with nivolumab plus 
ipilimumab, particularly in combination with stereotactic 
radiosurgery or surgery improves OS in asymptomatic and 
symptomatic MBM.
INTRODUCTION
Melanoma brain metastasis (MBM) is a 
known characteristic for poor prognosis. The 
median overall survival (mOS) in the era of 
chemotherapy was 4 months and decreased 
to 2 months in patients with elevated lactate 
dehydrogenase (LDH).1 2 The response of 
MBM to chemotherapy was approximately 
5%. This applies to both, drugs that cross the 
blood- brain barrier, such as temozolomide 
and fotemustine, and to drugs that do not 
cross the blood- brain barrier, such as dacar-
bazine.3 4 The American Joint Committee 
on Cancer has acknowledged the negative 
impact of brain metastasis on the prog-
nosis of patients with melanoma in its latest 
eighth edition staging system by defining this 
subgroup as M1d.5
With the introduction of targeted treat-
ment (BRAF/MEK inhibitors) and immune 
checkpoint inhibitors, the prognosis of meta-
static melanoma has drastically improved.6–8 
In contrast to ample data on the efficacy of 
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novel therapies in stage IV melanoma without MBM, 
there are only a few small studies on the efficacy of these 
drugs in patients with cerebral disease. This lack of infor-
mation is mainly due to the fact that large phase II/III 
multicenter studies systematically excluded patients with 
MBM, particularly if symptomatic or previously treated 
with local therapy, such as stereotactic radiosurgery and 
surgery (STR/surgery). The first studies investigating 
targeted therapy and immune checkpoint inhibitors in 
patients with MBM showed that these therapies were also 
very effective intracranially.9–12 Currently available data 
suggest that PD-1- based immunotherapy and particularly 
combined immunotherapy with nivolumab and ipilim-
umab (NIVO+IPI) might be more effective than BRAF/
MEK inhibitors.8 13 In two retrospective studies with 
patients with MBM, the authors reported that patients 
receiving immunotherapy had a mOS between 13 and 
14.8 months (95% CI: 8.1 to 17.8 and 9.9 to 19.7, respec-
tively), while in those receiving targeted therapy the mOS 
was only 7 and 10 months (95% CI: 3.8 to 10.2 and 7.8 
to 11.7, respectively).14 15 This difference was also present 
when these systemic therapies were given in combination 
with stereotactic radiosurgery, favoring the combination 
with immunotherapy, which resulted in a mOS between 
21–25 months (95% CI: 12.9 to 29.1 and 14.6 to 35.4, 
respectively) and 12.9–14 months with targeted therapy 
(95% CI: 12.9 to 29.1 and 9.1 to 16.7, respectively).
Our study provides real- world outcome data from 23 
German skin cancer centers, retrospectively assessing the 
activity of NIVO+IPI alone or in combination with local 
therapies regardless of treatment line in patients with 
asymptomatic and symptomatic MBM.
We addressed the following questions: (a) Which prog-
nostic factors for OS can be identified in patients with 
MBM treated with combined immunotherapy? (b) Does 
local therapy (STR/surgery) improves survival in patients 
with MBM treated with NIVO+IPI? (c) Are STR/surgery 
more effective when given before or after combined 
immunotherapy? (d) Is there a difference in terms of 
survival when combined immunotherapy is given as a 
first- line treatment for MBM or later in the course of the 
disease? (e) In patients with BRAF V600- mutated mela-
noma, which first- line systemic therapy for MBM trans-
lates into better OS: first- line immunotherapy or first- line 
targeted therapy? (f) Is there a difference in terms of OS 
when patients with symptomatic and asymptomatic MBM 
receive NIVO+IPI? Since a total of 380 patients were 
included, we were able to perform subgroup analyses with 
reasonable statistical power.
METHODS
Patients’ characteristics and treatments
We used pseudo- anonymized forms to document retro-
spective data from patients with MBM treated with 
NIVO+IPI between April 2015 and October 2018. All 
participating centers received the mentioned pseudo- 
anonymized forms including the prespecified information 
to be collected. Data were extracted from patients’ 
medical records in 23 German skin cancer centers either 
by medical doctors or by clinical research documenta-
tion professionals, depending on the site. Patients were 
included regardless of previous local or systemic thera-
pies, provided that they received combined immuno-
therapy for treating MBM.
Multiple MBM were irradiated by whole brain irradia-
tion with opposite lateral field in mask technique. Stereo-
tactic radiosurgery was used to irradiate small brain 
metastasis. Neuroimaging consisted of a stereotactic 
three- dimensional T1- weighted postcontrast Magnetic 
Ressonance Imaging (MRI) acquisition und an planning 
CT scan. Selection of dosimetry parameters (maximum 
dose, marginal isodose and number of isocenters) was 
made according to size, shape, localization and relation-
ship for brain metastasis to critical structures. Target 
localization was referenced to a coordination system and 
target position was tracked during treatment. The data 
cut- off date was October 31, 2018.
Statistical Analysis
We performed univariate and multivariate Cox regres-
sion analysis to evaluate the impact of baseline patient 
and disease characteristics on OS. Cox multivariate anal-
ysis included the following factors: sex, BRAF mutation 
status, number of MBM, Eastern Cooperative Oncology 
Group performance status (ECOG- PS) as categorical vari-
ables and age, LDH level and protein S100B level as both 
categorical and numerical variables. The use of cortico-
steroids at the start of combined immunotherapy was also 
documented. As these data are rather complex regarding 
dosage and duration of each individual treatment, they 
will be analyzed in a separate investigation.
OS and follow- up (FU) time were calculated consid-
ering the date of MBM diagnosis and last patient contact 
or death. Kaplan- Meier estimates were used for the calcu-
lation of OS. Differences between groups were assessed 
using the log- rank test. Patients were grouped consid-
ering the timing of combined immunotherapy (first- line 
or not first- line) for treatment of MBM and according 
to BRAF mutation status (BRAFV600 mutant or BRAF 
wild type). Pretreatment protein S100B and LDH values 
were assigned categorical variables (normal, elevated and 
2- fold or 10- fold elevated), according to the institutional 
upper limit of normal. Patients with missing values were 
excluded from the respective analysis. Further subgroups 
considering the number of MBM, presence of neurolog-
ical symptoms and ECOG- PS were defined. To investigate 
the effect of local therapies on OS, data from patients 
receiving STR/surgery were compared with data from 
patients not receiving local therapies. Timing of local 
therapy and its effect on OS were analyzed by defining two 
groups: STR/surgery before start of NIVO+IPI treatment 
or STR/surgery at a later time point. Patients treated 
with whole brain radiotherapy (WBRT) were evaluated 
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Table 1 Patients characteristics of the whole collective (n=380) considering combined immunotherapy at !rst line or not at 
!rst line
Baseline characteristics
Total CombiIT first line CombiIT not first line P value*
N (%)
Sex
  Male 240 (63.2) 165 (66) 75 (57.7) 0.111
  Female 140 (36.8) 85 (44) 55 (42.3)
Age (years) at the time of CombiIT
  <54 153 (40.3) 90 (36) 63 (48.5) 0.024
  54–64 105 (27.6) 69 (27.6) 36 (27.7)
  >64 122 (32.1) 91 (36.4) 31 (23.8)
BRAF status
  BRAF wild type 138 (36.3) 112 (44.8) 26 (20) <0.0001
  BRAF mutant 242 (63.7) 138 (55.2) 104 (80)
LDH level†
  Normal 189 (51.4) 131 (54.1) 58 (46.0) 0.223
  Elevated 133 (36.1) 85 (35.1) 48 (38.1)
  2">ULN 46 (12.5) 26 (10.8) 20 (15.9)
S100B level†
  Normal 109 (32.8) 69 (31.2) 40 (36.4) 0.597
  Elevated 156 (47) 106 (47.7) 50 (45.4)
  10">ULN 67 (20.2) 47 (21.1) 20 (18.2)
Number of MBM at the time of CombiIT†
  1–3 167 (46.8) 127 (53.6) 40 (33.3) <0.0001
  >3 190 (53.2) 110 (46.4) 80 (66.7)
ECOG- PS†
  0 249 (66.4) 168 (67.7) 81 (63.8) 0.741
  1 87 (23.2) 55 (22.2) 32 (25.2)
  >1 39 (10.4) 25 (10.1) 14 (11)
Presence of symptoms†
  Yes 60 (31) 44 (32.1) 16 (28.6) 0.629
  No 133 (69) 93 (67.9) 40 (71.4)
Local therapy
  STR/surgery‡ 220 (57.9) 135 (54) 85 (65.4) 0.011
  No local therapy 90 (23.7) 71 (28.4) 19 (14.6)
  WBRT 70 (18.4) 44 (17.6) 26 (20)
Bold values indicate statistically signi!cant results.
*Pearson’s !2 test.
†Denotes variables for which the missing/unknown values were excluded from the analysis.
‡Ten patients (4.5%) received only surgery. Four patients receiving STR/surgery before combined immunotherapy and two patients receiving 
STR/surgery after combined immunotherapy were treated with the two techniques within an interval of 2 weeks.
CombiIT, nivolumab plus ipilimumab; ECOG- PS, Eastern Cooperative Oncology Group performance status; MBM, melanoma brain 
metastases; n, number of patients in each subgroup; STR, stereotactic radiosurgery; ULN, upper level normal; WBRT, whole brain 
radiotherapy.
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  Male 240 (63.2) 1 1 0.855
  Female 140 (36.8) 0.94 (0.69 to 1.27) 0.682 1.35 (0.70 to 1.50)
Age (years) at the time of CombiIT   
  <54 153 (40.3) 1 0.616 1 0.689
  54–64 105 (27.6) 1.13 (0.78 to 1.62) 1.17 (0.75 to 1.81) 0.491
  >64 122 (32.1) 1.19 (0.83 to 1.70) 1.20 (0.76 to 1.90) 0.428
BRAF status   
  BRAF wild type 138 (36.3) 1 0.962 1
  BRAF mutant 242 (63.7) 0.99 (0.72 to 1.37) 1.13 (0.76 to 1.67) 0.548
LDH level*   
  Normal 189 (51.4) 1 <0.0001 1 0.069
  Elevated 133 (36.1) 1.24 (0.88 to 1.74) 1.05 (0.69 to 1.59) 0.831
  2!>ULN 46 (12.5) 2.53 (1.67 to 3.83) 1.80 (1.05 to 3.09) 0.031
S100B level*   
  Normal 109 (32.8) 1 0.099 1 0.325
  Elevated 156 (47) 1.35 (0.92 to 2.00) 1.39 (0.90 to 2.11) 0.135
  10!>ULN 67 (20.2) 1.61 (1.02 to 2.54) 1.30 (0.76 to 2.24) 0.341
Number of MBM at the time of CombiIT*   
  1–3 167 (46.8) 1 0.001 1 0.008
  >3 190 (53.2) 1.74 (1.26 to 2.40) 1.67 (1.14 to 2.44)
ECOG- PS*   
  0 249 (66.4) 1 0.001 1 0.006
  1 87 (23.2) 1.3 (0.91 to 1.87) 1.31 (0.87 to 1.99) 0.188
  >1 39 (10.4) 2.58 (1.66 to 4.00) 2.42 (1.39 to 4.20) 0.002
Presence of symptomatic MBM*   
  No 133 (69) 1   
  Yes 60 (31) 1.46 (0.96 to 2.23) 0.078 N/A
Bold values indicate statistically signi"cant results (p<0.05).
*Denotes variables for which the missing/unknown values were excluded from the analysis.
CombiIT, nivolumab plus ipilimumab; ECOG- PS, Eastern Cooperative Oncology Group performance status; MBM, melanoma brain 
metastases; N 
, number of patients in each subgroup; N/A, not performed for this factor, since information was available to only 50% of the patients; ULN, 
upper level normal.
separately. Results are reported as two- sided p values with 
95% CIs. Statistical significance was set at p<0.05.
RESULTS
Patients characteristics
A total of 380 patients with MBM and NIVO+IPI treatment 
were included in the analysis (table 1, online supplemen-
tary figure S1). Thirty- seven per cent of the patients were 
females and median age at the time of MBM diagnosis 
was 58 years (IQR 49–68). The majority of melanomas 
(63.7%) carried a BRAFV600 mutation.
In the univariate Cox regression analysis (table 2), 
we found the following significant prognostic factors 
for OS: LDH level, favoring patients with normal LDH 
(p<0.0001), number of MBM (p=0.001) favoring patients 
with 1–3 MBM and ECOG- PS (p=0.001) favoring patients 
with ECOG- PS=0. No significant OS difference was 
observed for baseline S100B level (p=0.099), BRAFV600 
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mutation status (p=0.962), age groups (p=0.616), sex 
(p=0.682) and presence of symptomatic MBM (p=0.078). 
Multivariate Cox regression analysis using categorical 
variables (table 2) showed that the number of MBM 
(p=0.008) and ECOG- PS (p=0.006) were independent 
prognostic factors for OS. In the multivariate Cox regres-
sion analysis using numerical variables for age, serum 
LDH and protein S100B (online supplementary table 
S4), the following prognostic factors were found to be 
an independently associated with OS: LDH (p=0.001), 
protein S100B (p=0.001), number of MBM (p=0.017) and 
ECOG- PS (p=0.041).
Overall survival analysis considering systemic and local 
therapy
The mOS for the whole cohort was 19 months (95% CI: 
15.9 to 22.0) and the median FU time was 18 months 
(IQR 9–28 months). The 1- year, 2- year and 3- year OS 
rates were 69%, 41.1% and 30.1%, respectively (table 3; 
figure 1A; 95% CI: 63.5 to 74.5; 34.9 to 47.9 and 22.2 to 
37.9, respectively).
Figure 1B–E show the Kaplan- Meier OS curves consid-
ering BRAF mutation status, serum LDH level, number 
of MBM, protein S100B level, and online supplementary 
figure S2A–D show the Kaplan- Meier OS curves according 
to age groups, sex, ECOG- PS and presence of symptom-
atic MBM. The results shown are in line with what has 
been previously described in the univariate Cox regres-
sion analysis (table 2), that is, there is a statistically signif-
icant difference between the groups analyzed regarding 
serum LDH level (p<0.0001), number of MBM (p=0.001) 
and ECOG- PS (p<0.0001).
Stratifying for the best intracranial response (figure 1F), 
best OS was observed in patients with complete response 
(CR) and the difference between the subgroups with CR, 
partial response (PR), stable disease (SD) and progressive 
disease (PD) was statistically significant (p<0.0001). The 
mOS for patients with an intracranial CR or SD was not 
reached and for patients with PR and PD was 42 and 10 
months, respectively (table 3; 95% CI: 22.6 to 61.4; 16.7 to 
23.3, respectively). Patients achieving an intracranial CR 
had an improved 1- year OS rate of 92.7% compared with 
those with PD with a 1- year OS rate of only 39% (95% 
CI: 82.9 to 100; 31.4 to 46.6, respectively). Patients with 
SD showed favorable OS that was better than those with 
PR at 2 years and similar to PR at 3 years. The subgroups 
of patients with PR and SD did not differ significantly 
regarding serum LDH level, protein S100B, number of 
MBM, ECOG- PS or presence of extracerebral metastases.
Local therapy (STR/surgery) also improved OS 
(table 3, figure 2A): patients who received local therapy 
(at any time point of the course of the disease) reached a 
mOS of 24 months compared with patients without local 
therapy with only 16 months (p=0.009; 95% CI: 19.6 to 
28.4 and 7.6 to 24.4, respectively). There was no signif-
icant difference in terms of patients’ characteristics in 
these two groups, except for S100B level and presence 
of symptomatic MBM (online supplementary table S1). 
However, we need to acknowledge that information 
regarding the presence of symptomatic MBM was missing 
in approximately 50% of the patients.
When analyzing the time point of local therapy (ie, 
before or after NIVO+IPI), we found no significant differ-
ence in terms of patients’ characteristics (online supple-
mentary table S2) and the mOS was similar in the two 
subgroups (figure 2B; p=0.110). However, there seems to 
be a trend for a benefit of STR/surgery upfront (mOS=26 
months vs 16 months; 95% CI: 21.1 to 30.9; 10.8 to 21.2, 
respectively). Patients who received WBRT had a mOS of 
8 months (table 3, figure 2C; 95% CI: 4.9 to 11.0) and 
were analyzed separately.
No OS difference was observed for patients receiving 
first- line NIVO+IPI compared with those that received 
combined immunotherapy later (figure 2D; p=0.119). 
When looking at the patients’ characteristics from these 
two groups, there was a significant difference between 
them regarding age, BRAFV600 mutation status, number 
of MBM and treatment with local therapy (STR/surgery) 
at the time of starting NIVO+IPI (table 1). These differ-
ences might contribute for similar OS outcomes regard-
less of therapy line.
In the subgroup of patients with BRAFV600 muta-
tion (242 patients), 83 received first- line treatment with 
BRAF/MEK inhibitors, 138 received first- line NIVO+IPI 
and all received combined immunotherapy for MBM in 
the course of the disease. There was no OS difference 
when comparing first- line targeted therapy with first- line 
combined immunotherapy (figure 2E; p=0.085). The 
line of treatment for combined immunotherapy (first- 
line or not first- line) had no effect on survival outcome 
in patients with BRAF wild- type melanoma (figure 2F; 
p=0.996).
Regarding presence of symptomatic MBM, information 
was available for only 193 patients (online supplementary 
figure S2D), but there is a trend benefiting patients with 
asymptomatic MBM (p=0.065). However, if we consider 
only the patients that received first- line NIVO+IPI for 
MBM (n=137), the difference in OS between symptom-
atic and asymptomatic MBM is not significant (p=0.084; 
data not shown).
Safety
In the present cohort, a total of 236 (62%) patients were 
reported to have at least one immune- related adverse 
events (irAEs). In 142 (37%) patients, no irAEs were 
documented and there was no available information in 2 
(1%) patients.
We found no difference (Pearson’s !2 test) in terms of 
onset of irAEs in patients with 1–3 MBM compared with 
patients with >3 MBM (p=0.069). Regarding the onset 
of irAEs in patients who received STR/surgery versus 
those who did not receive STR/surgery, there was also no 
significant difference between the two groups (p=0.657). 
Finally, when analyzing the relation between receiving 
STR/surgery or not, and the interruption of therapy 
 on M

















6 Amaral!T, et!al. J Immunother Cancer 2020;8:e000333. doi:10.1136/jitc-2019-000333
Open access 
Table 3 Median OS and 1- year, 2- year and 3- year OS rates







All patients 19 (15.9 to 22.0) 69 (63.5 to 74.5) 41.1 (34.9 to 47.9) 30.1 (22.2 to 37.9)
Number of MBM
  1–3 29 (16.9 to 41.4) 71.2 (63.6 to 78.8) 57.0 (46.8 to 67.2) 42.3 (28.6 to 56.0)
  >3 14 (10.2 to 17.9) 52.1 (44.3 to 59.9) 32.2 (23.9 to 40.4) 22.7 (13.5 to 31.9)
BRAF status
  BRAF wild type 19 (14.9 to 23.0) 61.3 (51.9 to 70.7) 40.1 (28.3 to 51.9) N/A
  BRAF mutant 18 (14.1 to 21.9) 60.7 (53.8 to 67.6) 42.0 (34.2 to 49.8) 27.3 (18.1 to 36.5)
LDH level
  Normal 21 (15.1 to 26.9) 69.3 (61.6 to 76.7) 45.9 (36.3 to 55.5) 32.6 (20.4 to 44.6)
  Elevated 19 (12.8 to 25.1) 58.4 (48.8 to 68.0) 40.1 (29.1 to 51.1) 32.9 (19.9 to 45.8)
  2!>ULN 7 (6.1 to 7.9) 32.1 (17.6 to 46.6) 22.9 (8.0 to 37.8) 8.6 (5.5 to 22.7)
S100B level
  Normal 22 (18.2 to 25.8) 78.4 (68.6 to 88.2) 44.7 (30.8 to 58.6) 36.1 (20.6 to 51.6)
  Elevated 17 (9.6 to 24.4) 57.0 (48.2 to 65.8) 42.8 (32.8 to 52.8) 32.3 (20.5 to 44.6)
  10!>ULN 17 (8.2 to 25.8) 53.5 (40.4 to 66.6) 30.9 (15.8 to 45.9) 20.6 (1.2 to 40.0)
Best intracerebral response
  CR Not reached 92.7 (82.9 to 100) 85.6 (69.3 to 100) N/A
  PR 42 (22.6 to 61.4) 86.9 (76.9 to 96.9) 62.9 (46.0 to 79.8) 55.1 (34.5 to 75.7)
  SD Not reached 93.6 (86.5 to 100) 83.6 (71.1 to 96.1) 50.2 (19.0 to 81.4)
  PD 10 (16.7 to 23.3) 39.0 (31.4 to 46.6) 20.0 (13.1 to 26.9) 12.8 (6.0 to 19.3)
CombiIT
  First line 17 (10.7 to 23.9) 56.4 (48.9 to 63.8) 44.7 (35.9 to 53.5) 27.9 (11.2 to 44.6)
  Not "rst line 21 (17.8 to 24.2) 67.9 (59.9 to 75.9) 41.9 (32.7 to 51.1) 31.6 (21.8 to 41.4)
BRAF mutant patients     
  First- line targeted therapy 22 (17.2 to 26.77) 65.6 (55.2 to 76) 44.3 (34.5 to 57.7) 32.0 (20 to 44)
  First- line CombiIT 16 (7 to 25) 53.6 (43.2 to 64) 42.9 (30.7 to 55.1) N/A
BRAF wild- type patients     
  First- line CombiIT 21 (10.2 to 31.8) 59.6 (52.6 to 73.4) 47 (33.8 to 60.1) 47 (33.8 to 60.1)
  First- line not CombiIT 19 (16.3 to 21.7) 68.3 (50.1 to 74.2) 31.9 (11.5 to 52.3) 31.9 (11.5 to 52.3)
STR/surgery (at any time 
point)
  Yes 24 (19.6 to 28.4) 70.6 (63.7 to 77.5) 49.5 (40.9 to 58.1) 36.5 (26.3 to 46.7)
  No 16 (7.6 to 24.4) 53.2 (41.0 to 65.4) 40.9 (26.6 to 55.2) N/A
WBRT 8 (4.9 to 11.0) 40.7 (28.4 to 53.0) 20.8 (9.4 to 32.2) 10.4 (1.4 to 22.2)
STR/surgery
  Upfront 26 (21.1 to 30.9) 72.5 (65.1 to 79.9) 50.9 (41.3 to 60.5) 39.5 (28.3 to 50.7)
  Later 16 (10.8 to 21.2) 63.7 (47.6 to 79.8) 44.3 (24.9 to 63.7) 22.2 (1.5 to 45.9)
ECOG- PS
  0 22 (16.4 to 27.6) 65.7 (59.0 to 72.4) 47.1 (39.1 to 55.1) 36.4 (26.4 to 46.4)
  1 18 (7.3 to 28.7) 52.3 (40.1 to 64.5) 38.0 (34.1 to 519) 22.2 (6.1 to 38.3)
  >1 8 (7.3 to 17.1) 49.3 (31.8 to 66.7) 23.5 (5.5 to 41.5) 5.9 (5.1 to 16.9)
Presence of symptomatic 
MBM
    
  No 19 (10.7 to 27.2) 62.5 (53.4 to 71.8) 45.4 (34.6 to 56.2) 35.1 (21.8 to 48.4)
Continued
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  Yes 12 (7.0 to 17.0) 46 (32.1 to 59.9) 28.1 (13.8 to 42.4) 15.0 (0 to 30.7)
CombiIT, nivolumab plus ipilimumab; CR, complete response; ECOG- PS, Eastern Cooperative Oncology Group performance status; 
MBM, melanoma brain metastases; mOS, median overall survival; PD, progressive disease; PR, partial response; SD, stable disease; STR, 
stereotactic radiosurgery; ULN, upper level normal; WBRT, whole brain radiotherapy.
Table 3 Continued
Figure 1 Kaplan- Meier curves for overall survival (A) and 
considering the different factors: (B) BRAF status; (C) LDH 
level; (D) number of melanoma brain metastases (MBM) at 
the time of therapy with nivolumab+ipilimumab; (E) protein 
S100B level; (F) best intracranial response. CR, complete 
response; PD, progressive disease; PR, partial response; SD, 
stable disease.
Figure 2 Kaplan- Meier curves for overall survival (OS) 
according to the following factors: (A) local therapy (STR/
surgery, stereotactic radiosurgery or surgery); (B) time of 
local therapy (before or after combined immunotherapy with 
nivolumab+ipilimumab); (C) for patients receiving whole 
brain radiotherapy (WBRT); (D) combined immunotherapy 
for melanoma brain metastasis (MBM) in !rst line or later; 
(E) !rst- line therapy in patients harboring a BRAF mutation 
and (F) combined immunotherapy !rst line or later in 
BRAF wild- type patients. Patients treated with WBRT were 
excluded from the analysis in !gure"2A. Ten patients (4.5%) 
from the STR/surgery group (n=220) received only surgery. 
In the Kaplan- Meier analysis in !gure"2B, four patients 
receiving STR/surgery before combined immunotherapy 
and two patients receiving STR/surgery after combined 
immunotherapy were treated with the two techniques in an 
interval of 2 weeks.
due to irAEs, we again found no significant difference 
between the two groups (p=0.913).
DISCUSSION
The present study shows that combined immunotherapy 
with NIVO+IPI can result in improved survival of patients 
with MBM, comparable to results in other stage IV 
patients. This is particularly true if intracranial CR, PR or 
SD has been achieved. The type of intracranial response 
is a strong predictor for OS. In our cohort, the 2- year OS 
rates of patients with SD, PR and CR ranged from 63% 
to 86%, whereas patients with PD had a 2- year OS rate of 
only 20% (table 3). Similar favorable results have been 
reported in the ABC trial, a randomized phase II study 
of nivolumab or NIVO+IPI in patients with MBM.16 The 
3- year intracranial PFS was above 90% for patients with 
asymptomatic, treatment- naïve MBM achieving an intra-
cranial CR, and above 50% for patients with PR. We have 
no explanation why in our cohort patients with SD did 
better than patients with PR.
In our study, the 1- year and 2- year OS rate were 69% 
and 41%, respectively, in line with previous reports.9 10 In 
the already mentioned ABC trial, patients who received 
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combined immunotherapy had a 1- year and 2- year OS 
rate of 63%16 and in the Checkmate-204 trial the reported 
1- year OS rate was even higher (81.5%).10 The survival 
rates in these trials are higher than those reported in 
our cohort. Compared with the ABC trial and the Check-
mate-204 trial, which included patients with asymptom-
atic MBM and treatment- naïve BRAF wild- type patients, 
31% (60/193) of the patients in our trial had symp-
tomatic MBM and 20% of the BRAF wild- type patients 
were pretreated. In the Checkmate-204 trial, 17% of 
the patients had received previous systemic therapy for 
MBM and 52% had only one MBM compared with 34% 
pretreated patients and 53% patients with more than 
three MBM in our cohort.
Two studies evaluating pembrolizumab in patients with 
MBM also reported similar outcomes.17 18 The first study 
evaluated treatment with pembrolizumab monotherapy 
in 23 patients with one or more asymptomatic and 
untreated MBM. With a longer follow- up of 38 months, 
the mOS time was 17 months (95% CI: 10 months to not 
reached) and the 2- year OS was 48%. These are in line 
with our results for patients who did not receive STR/
surgery for whom the mOS was 16 months (95% CI: 7.6 
to 24.4) and the 2- year OS rate was 41%. However, in 
this trial, only asymptomatic patients were included and 
87% had <3 MBM, a population with potentially better 
outcome that the one included in our report. In the 
second study, Anderson et al reported the results of the 
combination from pembrolizumab and radiation therapy 
in 21 patients with MBM. Despite the low number of 
patients included, the percentage of lesions that had a 
CR (>30%), was higher than previously reported with 
systemic therapy or STR alone.
The combination of immunotherapy and local therapy 
with stereotactic irradiation or surgery improved patients’ 
survival compared with patients who only received 
NIVO+IPI. This benefit might be related to a synergic 
effect between radiotherapy and immunotherapy that 
has been demonstrated both in preclinical and clinical 
studies.19–23 The combination of radiation and immune 
checkpoint inhibitors seems to be effective both in the 
irradiated and non- irradiated lesions, and this effect 
might be associated with the activation of cytotoxic T- cells 
and reduction of myeloid- derived suppressor cells.18 24 25
The benefit of combining local and systemic therapy 
in MBM has been previously shown by our group and 
others, with mOS that range from 14 to 25 months and 
1- year OS rates between 58% and 78% in the groups that 
received local and systemic therapy, clearly superior to 
the outcomes of patients receiving only systemic therapy 
(mOS between 6 and 13 months and 1- year OS rates 
ranging from 34% to 53%).14 15 26–33
In our study, the time point at which the patients 
received local therapy did not seem to play a significant 
role in OS: local therapy performed upfront or after initi-
ation of NIVO+IPI resulted in similar OS rates, with a 
trend benefiting local therapy upfront (mOS 26 months 
vs 16 months). Different retrospective studies have also 
addressed this question, and, similar to our cohort, 
upfront local therapy seems to have better outcomes 
(mOS of 11–23 months in the group receiving local 
therapy upfront and 3–9 months in patients receiving 
local therapy after systemic therapy).34 35
There is still an ongoing debate whether some patients 
might be better served with systemic therapy alone, as 
we see very positive outcomes.9–11 36 Not applying local 
therapy reduces local complications, potential cogni-
tive impairment and might be particularly adequate for 
patients with a low number of asymptomatic MBM. This 
question along with the best sequence regarding local 
therapy is being addressed in ongoing clinical trials, and 
in the future, we might be better equipped to decide 
which patients to treat with the different modalities.37 38
In this study, there was a high proportion of patients with 
BRAFV600- mutated melanoma (63%), but similar to other 
publications where this subgroup represents between 52% 
and 65% of the patients.14 15 26 28 Previously, it has been postu-
lated that even in patients with BRAFV600- mutated MBM, 
first- line systemic treatment should consist of combined 
immunotherapy. Our analysis showed that there was no 
difference in OS of patients receiving first- line NIVO+IPI 
or first- line targeted therapy followed by combined immu-
notherapy (p=0.085). The two subgroups did not differ 
significantly (online supplementary table S4), except for 
the number of MBM, where a higher proportion of patients 
with >3 MBM received first- line targeted therapy (p=0.002). 
Our results in this subgroup need to be interpreted with 
caution since we have not included patients with BRAFV600 
mutation who only received targeted therapy.
In the multivariate Cox regression analysis, we identified 
LDH, S- 100B, ECOG- PS and number of MBM as indepen-
dent prognostic factors. These prognostic factors have 
already been described in previous analyses,8 14 39–41 but to 
the best of our knowledge, S100B has only been described 
as independent prognostic factor for checkpoint inhib-
itor immunotherapy in one monocentric study.42 It is 
interesting, however, that both tumor markers, LDH and 
S100B, remained independent prognostic factors in the 
multivariate analysis, suggesting that these non- invasive 
and easy to determine blood parameters can and should 
be used early in the course of the disease to inform about 
patients’ prognosis.
Regarding the presence of symptomatic MBM, there 
was no OS differences between patients with and without 
symptoms (p=0.065), but a trend can be seem showing 
that patients with symptomatic MBM have worse prog-
nosis that those who are asymptomatic (1- year OS rate 
46% and 63%, respectively). In other prospective studies 
investigating similar cohorts, the OS rate ranged from 
66% at 6 months43 to 31% at 12 months.16 Unfortunately, 
information regarding the presence of symptomatic 
MBM is missing in approximately 50% of the patients in 
our study, and therefore, definitive conclusions cannot be 
drawn from our data.
Strengths of this investigation are that data from 23 
German- certified skin cancer centers with high standards 
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for data quality were included. Three- hundred and 
eighty patients were analyzed which is thus far the largest 
published cohort of patients with MBM managed in a 
routine clinical setting. This high number of patients 
allowed us to perform subgroup analyses, with results of 
reasonable sensitivity. Furthermore, this study provides 
long- term follow- up data of patients with MBM covering a 
period of up to 18 months.
The study limitations are related to its retrospective 
design. Patients were included regardless of previous 
systemic and local therapies prior to the combined immu-
notherapy and thus some heterogeneity of the study 
population might have contributed to differences in 
survival outcomes observed in our cohort. The decision 
to offer local therapy or not was probably influenced by 
the number and size of MBM. Additionally, the maximum 
number of MBM considered to be treated individually by 
STR/surgery might vary between different centers. We 
have not evaluated intracranial toxicities. However, this 
aspect might have been considered when planning local 
therapy and targeted therapy in patients with BRAFV600- 
mutated melanoma, influencing the systemic therapy 
offered as well as the therapy sequence in this subgroup.
In conclusion, our study shows that treatment with 
NIVO+IPI, particularly in combination with STR/surgery 
improves survival of patients with MBM. Results presented 
herein also suggest that local therapy with STR/surgery 
either before or after starting combined immunotherapy 
might be advantageous to prolonging OS.
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7.1. Systemic treatment of stage IV cutaneous melanoma 
Treatment of advanced melanoma has changed amazingly in the last decade, and the 
results presented in this thesis confirm that. Ten years ago, only chemotherapy with 
dacarbazine, was approved for treating stage IV melanoma. 49 Non-approved chemo-
therapies, namely temozolomide, and different combinations of cytotoxic therapies were 
also used, with marginal benefit. Objective responses to dacarbazine were reported in 
approximately 25% of the patients in phase II trials. However, later investigations showed 
that the real percentage was about 5%-12%, and the percentage of patients that derived 
a long-term benefit was extremely disappointing between 1%-2%. 133-135 Intense investi-
gation was already on the way for other therapeutic options as mentioned by Garbe et 
al 49, namely CTLA-4 inhibitors and BRAF/MEK inhibitors, but the data available was not 
enough to grasp the future impact of these therapies. 
The first manuscript included in this thesis shows that, in our population of patients 
treated between 2011 and 2014, there was still an important percentage of patients 
treated with chemotherapy (51.5%; n=132), particularly dacarbazine and carboplatin plus 
paclitaxel. 136 Immunotherapy with checkpoint inhibitors was mostly represented by ipili-
mumab monotherapy. In our analysis, 42 patients treated with ipilimumab were included, 
representing 80.8% of all the patients treated with immunotherapy and 20% of all patients 
treated with first-line systemic therapy. Finally, 49 patients were treated with BRAF in-
hibitors, namely vemurafenib or dabrafenib, which represented 72% of the patients 
treated with targeted therapy, and 23% of all patients treated with first-line systemic ther-
apy.  
We showed that the OS for stage IV melanoma patients has steadily improved over the 
years: the 1-year (1-y) OS rate for M1a patients increased from 62% to 85%, for M1b 





with data from Balch et al from 2009. 137 As the indication, for starting systemic therapy, 
and performing surgery in stage IV melanoma didn’t change in the period analyzed, the 
improvement of OS in each M sub-stage was due to the availability of more effective 
systemic therapies. 
When looking into the type of therapy received, we also saw a significant improvement 
compared with the historical data referred by Garbe et al. 49 The median OS (mOS) was 
33 months, 16 months, and 11 months for immunotherapy, targeted therapy, and chem-
otherapy (95% CI: 21.7-44.3; 10.6-21.4 and 7.6-14.4, respectively) and the difference 
between the three groups was statistically significant (p= 0.003). Our OS results for pa-
tients treated with immunotherapy and targeted therapy were in line with the previously 
reported in clinical trials for treatment naïve patients receiving ipilimumab, and patients 
treated with dabrafenib monotherapy, i.e., the mOS was 30 months and 19 months, re-
spectively (95% CI: 16.6-not reached and 15.2–23.7). 138,139 The 3-y OS rate for the pa-
tients treated with immunotherapy, in our cohort mostly ipilimumab, was 37.4% (95%CI: 
16.6-58.2). These OS rates were slightly better than the ones from a pooled analysis 
reporting the 10-y OS rates of patients treated with ipilimumab monotherapy in different 
clinical trials.64 However, in this pooled analysis the patients included were both treat-
ment naïve patients and patients that have already received other systemic therapies, 
which might explain the better outcomes n our cohort, which included only treatment 
naïve patients. Schadendorf et al. showed that an OS plateau forms around the three 
years, with a 3-y OS rate of 21% (95% CI: 17%-24%). These results confirmed that ap-
proximately one third to one fourth of the patients receiving ipilimumab alone can derive 
long survival benefit, and led for the first time to a discussion whether stage IV melanoma 






7.2. Primary resistance to PD-1 based immunotherapy  
The immune-checkpoint inhibitors pembrolizumab, nivolumab, ipilimumab, and the com-
bination of nivolumab plus ipilimumab are approved in Europe for the treatment of stage 
IV melanoma. 65,86,87 The EMA’s approval was based on the results from phase II and 
phase III trials, showing sustained benefits in both PFS and OS. 78 60 79-82,84,138 The 5-y 
OS rate for nivolumab plus ipilimumab, nivolumab monotherapy and pembrolizumab is 
52%, 44% and 34-41%, and the 5-y PFS rate is 36%, 26% and 21-29%, respectively.  
Despite these very positive outcomes, primary resistance to immunotherapy, defined as 
the absence of benefit from immunotherapy, still is observed in a rather high percentage 
of patients. It is estimated to be between 40% and 65%, depending on whether patients 
receive first-line immunotherapy or immunotherapy after progression under other sys-
temic therapies. 76 90,140 Higher percentages were observed when patients were treated 
with ipilimumab monotherapy. 141 142 For patients with primary resistance to immune 
checkpoint therapy, there are not many therapeutic options available, particularly if they 
have BRAF wild-type tumors.  
In manuscript number 2, we analyzed the survival outcomes of stage IV melanoma pa-
tients treated with first-line PD-1 based immunotherapy between 2015 and 2018.143 By 
then, pembrolizumab, nivolumab, the combination of nivolumab plus ipilimumab, and two 
combinations of BRAF/MEK inhibitors were already available in the clinical practice. We 
addressed the following questions: (1) Which factors are associated with the develop-
ment of primary resistance? (2) How does survival of patients with primary resistance 
compare to those with disease control (CR, PR, and SD)? (3) Did the patients with pri-
mary resistance to PD-1-based immunotherapy receive further therapies, and if so, 
which therapies were offered and what was the outcome? We defined primary resistance 
as the presence of PD using the RECIST 1.1 criteria 144 at the time of the first radiological 





In our cohort, we found that 40% of the patients (127/319) were primary resistant accord-
ing to our definition. Our results confirm the percentages previously reported by Robert 
et al., and Larkin et al. 76,90,140 We further showed that patients with primary resistance 
have a highly significantly unfavorable PFS and OS as compared to those who achieve 
CR, PR or SD (p < 0.0001). The mOS in patients with primary resistance was only 11 
months (95% CI: 9.0–13.0), which is similar to what was observed in patients receiving 
first-line chemotherapy in our series from 2011-2014. 136 These unfavorable outcomes 
stress the need for further investigation on the mechanisms associated to primary re-
sistance to immunotherapy.  
The percentage of patients achieving a CR or PR in our study, approximately 40%, was 
very similar to the one reported in the Checkmate 067 trial, 78 and achieving an objective 
response (CR or PR) was decisive for favorable OS. This seems to be true not only for 
the metastatic setting, as in our cohort, but also in the neo-adjuvant setting, as we saw 
in the OpACIN-neo trial. 145 Here, patients with an objective response, in this case a 
pathologic objective response, had a numerically higher long-term benefit compared to 
those with no pathologic objective response. The estimated 24-months relapse free sur-
vival was 97% and 36% for patients with and without a pathological objective response, 
respectively (95% CI: 93-100% and 17-74%). 
We saw no differences in terms of OS for patients receiving PD-1 monotherapy or com-
bination of nivolumab plus ipilimumab, but the two groups were not homogenous, and 
therefore no definitive conclusions can be drawn. Furthermore, the follow-up of 22 
months is shorter than the one from the Checkmate 067 trial, and in this study the clini-
cally significant OS differences were seen only after 48 months of follow-up. 78 
Finally, and similar to other series, only half of the patients with primary resistance re-
ceived a second-line therapy. 146 The median PFS and the mOS were 3 months and 10 





low, only 11%, in patients with BRAF wild-type tumors. In patients with BRAFV600 mu-
tated melanoma, the response rate was 66%, and slightly superior to others previously 
published. 147 This high response rate is explained by the fact that the majority of the 
patients received second-line targeted therapy with BRAF/MEK inhibitors. Also, in the 
metastatic setting, immunotherapy followed by targeted therapy seems to derive greater 
benefits than the inverse sequence. 148,149  
 
7.3. Combined BRAF/MEK inhibitors in Stage IV BRAFV600 
mutated cutaneous melanoma 
Currently, there are three different combinations of BRAF/MEK inhibitors available for 
treatment of stage IV BRAFV600 mutated melanoma patients: dabrafenib plus tramet-
inib, vemurafenib plus cobimetinib and encorafenib plus binimetinib. 150-155 Monotherapy 
with BRAF inhibitors was abandoned due to the superior outcomes of the combination, 
and the only MEK inhibitor approved to be used as monotherapy is cobimetinib. 
100,103,131,139  
The three BRAF/MEK combinations differ in terms of safety profile, and this is the aspect 
that is most frequently considered when choosing one of the three. 156,157 Contrary to the 
toxicity profile, the efficacy results are very similar in the metastatic setting. The response 
rates reported in clinical trials were 64%–67% for dabrafenib plus trametinib, 68% for 
vemurafenib plus cobimetinib, and 75% for encorafenib plus binimetinib. 131,139 158 103 The 
landmark survival analyses showed 2-y OS rates of 53%, 48% and 58%, respectively. 
159 100 132  
Two major aspects need to be considered when defining the therapeutic plan in patients 
with advanced BRAF mutated melanoma. Firstly, patients can either receive PD-1 based 
immunotherapy or BRAF/MEK inhibitors. Since no prospective head-to-head data are 





as the physicians’ preference. Treating physicians tend to use first-line BRAF/MEK in-
hibitors in BRAFV600 mutated patients with worse prognosis, for whom a rapid response 
is necessary. 160 This subgroup of patients has been extensively characterized, and in-
cludes patients with symptomatic disease, high tumor volume, and elevated baseline 
LDH, which was the strongest predictive factor. 104,161 Secondly, the specific regime 
needs to be chosen. If BRAF/MEK inhibition is recommended, one the approved combi-
nations can be chosen. However, since no head-to-head comparison is or will be avail-
able in the future, only indirect comparisons are possible. In manuscript number 3, 105 we 
performed such an indirect comparison, and evaluated whether patients with elevated 
baseline LDH could derive greater benefit from a particular BRAF/MEK combination.  
ECOG PS and degree of organ involvement, were similar across the three trials evalu-
ated. 131 100 103 However, the coBRIM trial included the highest percentage of patients 
with elevated baseline LDH in the combination arm, 46%, compared with only 34% and 
29% in the COMBI-v and the COLUMBUS trials, respectively. In publications reporting 
data from real-world setting, up to 48% of patients receiving first-line BRAF/MEK inhibi-
tors showed an elevated baseline LDH resembling the coBRIM cohort.162,163 Our results 
show a non-significant risk reduction for progression and death in the subgroup with el-
evated baseline LDH receiving first-line therapy vemurafenib plus cobimetinib, compared 
with dabrafenib plus trametinib, and encorafenib plus binimetinib. However, we saw no 
OS benefit of vemurafenib plus cobimetinib compared with dabrafenib and trametinib, 
and only a slight advantage when comparing with encorafenib and binimetinib. Although 
deriving from an indirect comparison, these data may provide guidance for treatment 






7.4. Systemic treatment of stage IV uveal melanoma 
Uveal melanoma has always been associated with a poor prognosis. 164 Despite the high 
rates of local tumor control, most patients will eventually die of metastasis. The particular 
pattern of metastatic spreading is associated with the presence of liver metastasis in the 
vast majority of patients, and this is the leading cause of death. 165 Because of that, local 
therapies namely surgery, SIRT, chemosaturation and TACE have been used to ap-
proach treatment of stage IV disease. 32,35,36 166,167 The expertise needed to execute these 
technics, along with a learning curve that is associated with performing liver-directed 
therapies, should speak for the need of referring uveal melanoma patients to a special-
ized center. Clinical trials specifically evaluating systemic therapy in stage IV uveal mel-
anoma patients are scarce. Older protocols evaluating chemotherapy alone or in combi-
nation with interferon showed no survival benefit. 166,168-170 Despite the presence of driver 
mutations involving GNAQ or GNA11 genes, and the downstream convergence on com-
mon signaling pathways such as MAPK and PI3K/AKT, targeted therapies have not been 
able to show clinically meaningful benefit in uveal melanoma. 171-176  
Monotherapy with immune checkpoint inhibitors, namely ipilimumab, pembrolizumab, 
nivolumab and atezolizumab showed modest benefits, with low response rates of 3.6% 
to 4.7%, median PFS between 2.6 and 3.1 months, and mOS between 7.6 and 14 
months 40,41,177 Different authors have tried to identify predictive biomarkers of response 
to systemic therapy, but until now, none is used in the clinical practice. 178,179 
In manuscript number 4, we reported the survival outcomes of uveal melanoma patients 
treated with PD-1 plus CTLA-4 in a multicenter study. 39 Our results showed an overall 
response rate to of 15.6%, which is superior to checkpoint inhibitors monotherapy, 40,41,177 
and in line with other reports on combined immunotherapy outcomes in this population. 
180-182 The median duration of response was 25.5 months (range 9.0–65.0). Stable dis-





duration of the clinical benefit of 28.0 months (range 7.0–65.0). The median PFS was 
3.0 months (95% CI 2.4–3.6) and the median OS was estimated to be 16.1 months (95% 
CI 12.9–19.3), also superior to previous reports with monotherapy. Altogether, our study 
implies that combined checkpoint blockade represents the hitherto most effective treat-
ment option available for metastatic uveal melanoma available outside of clinical trials, 
with an expected overall response rate of 15–17%. Considering the data available so far, 
we conclude that the increased overall response rate of combined immunotherapy ver-
sus PD-1 inhibition alone amounts to approximately 10%.  
The results of this multicentric study have been used by the UM Cure 2020 group, which 
includes Portuguese investigators, to inform therapeutic options in countries where com-
bined immunotherapy is not available or is not reimbursed. 183 Clinical trials investigating 
immune checkpoint inhibitors in combination with other systemic or local therapies in the 
metastatic setting, and targeted therapies is the adjuvant setting are ongoing or have 
recently been reported. 184-188 The results are not better than the ones we reported, and, 
therefore, there is no SOC for stage IV uveal melanoma. The European effort for boost-
ing the investigation in this area is definitely to be commended, as only a multicentric 
and multinational approach can lead to a leap forward in the investigation on this area of 
particular need. 
 
7.5. Systemic and local treatment of melanoma brain metas-
tases 
Patients with MBM have a particular dismal prognosis acknowledged by a new subgroup 
– M1d - in the 8th AJCC classification. 44 Approximately half of the patients with advanced 
melanoma develop brain metastases and more than 90% will also have extracerebral 
disease. 189 These percentages highlight the necessity of performing a complete staging 





brain metastasis leads to a later diagnosis, and potentially to a worse outcome, as the 
tumor burden might be higher. 191 The follow up of the response to local and systemic 
therapy should be performed using MRI, as the brain CT scans have lower acuity in this 
setting. 189 In the ESMO Guidelines there are, however, no specific recommendations for 
follow-up in patients with MBM. 191  
Prognostic factors in MBM include the number, extent and localization of brain metasta-
ses, the presence and extent of extracerebral disease, baseline LDH, age, tumor burden, 
and ECOG PS.192-194 
Four clinical trials have specifically evaluated systemic therapy in MBM – the ABC trial, 
the Checkmate 204 trial, the COMBI-MB trial and the BREAK-MB trial. 106-109 The two 
first ones evaluated PD-1 based immunotherapy in treatment naïve patients. The 
COMBI-MB study evaluated targeted therapy with dabrafenib and trametinib in three dif-
ferent cohorts of patients that included patients treated or not treated with local therapy. 
The BREAK-MB study evaluated dabrafenib monotherapy in patients with melanoma 
brain metastases with or without previous local therapy. 
Manuscripts 5 and 6 evaluated the outcomes of these same therapies in two different 
cohorts. 112,123 In total, these two publications accessed the survival outcomes of 543 
patients. Our results showed that PD-1 based immunotherapy and BRAF/MEK inhibitors 
are effective in patients with MBM treated in a real-world setting, similar to what has been 
shown in clinical trials.  
The main finding in manuscript number 5 was the considerable impact of immunotherapy 
in OS, particularly in combination with local therapy (stereotactic radiosurgery or sur-
gery). Combination of local therapy with immunotherapy, targeted therapy or chemother-
apy resulted in a mOS of 25 months, 14 months and 11 months, respectively (95% CI: 
14.6–35.4 and 12.1-15.9 and 8.4-13.6). In our collective the 1-y OS rate in the group 





This is probably explained by the fact that in our collective a significant percentage of 
patients received PD-1 plus CTLA-4 and local therapy, while the other studies evaluated 
CTLA-4 or PD-1 monotherapy in combination with local therapy. In patients treated only 
with systemic therapy, the 1-y OS rate of the group treated with targeted therapy was 
particularly lower when compared to results the COMBI-MB study - 29.5% versus 46% 
(95% CI: 16-43 and 33-58, respectively), 108 highlighting the need for further investiga-
tions involving this subgroup of patients. 
We extensively debated the fact that no survival benefit was seen in patients treated with 
whole brain irradiation. The mOS was only 5 months (95% CI: 3.9-6.1), not so different 
from what our group reported in 2011. 199 Since effective targeted and immunotherapies 
are available in clinical practice, and achieve good results also when used alone, treat-
ment with whole brain radiation should be judged critically, as the toxicity is also higher 
compared to stereotactic radiosurgery. 200 In our center and others, this therapy is re-
served for symptomatic patients without local or systemic therapeutic options, in line with 
the recommendations from the European guidelines. 201 However, the definition of mul-
tiple brain metastases is foggy, and depends, in the majority of the cases, on the exper-
tise of the treating center. A clearer definition of multiple brain metastases is needed, as 
we see that in some centers radiosurgery of single brain metastases is offered to patients 
with up to twelve brain metastases, while in others, the patient is classified as having 
multiple brain metastases when 4 or more metastases are present. 202 This inevitably 
leads to a potential bias and might explain the difference in terms of outcomes between 
retrospective series. 
In manuscript number 6, we focused on the survival outcomes of patients with MBM 
treated with nivolumab plus ipilimumab in 23 centers. We confirmed that nivolumab plus 
ipilimumab improves survival in this subgroup, comparable to other stage IV patients. 





Moreover, the reported 1-y and 2- y OS rates (69% and 41%) are comparable to those 
of the ABC trial (1-y and 2-y OS rate of 63%) and Checkmate 204 trial (1-y OS rate 
81.5%). The minor differences can be explained by the different collectives evaluated in 
each study. Compared with the ABC and the Checkmate 204 trials, which included pa-
tients with asymptomatic MBM and treatment-naïve BRAF wild-type patients, 31% 
(60/193) of the patients in our study had symptomatic MBM, and 20% of the BRAF wild-
type patients were pretreated. In the Checkmate 204 trial, 17% of the patients had re-
ceived previous systemic therapy for MBM and 52% had only one MBM, compared with 
34% pretreated patients and 53% patients with more than three MBM in our cohort.  
The survival outcomes from combining local therapy and systemic therapy were in line 
with what we have shown in manuscript number 5, and favored the combination of local 
plus systemic therapy (p=0.009). Receiving local therapy upfront or later had no statisti-
cally significant impact in survival, but a trend was seen favoring local therapy upfront, 
confirming data previously reported by us and other groups. 121,122 Currently, several 
centers use the “treatment on demand” approach, i. e., patients receive local therapy 
only for the progressing brain metastasis, while the same systemic therapy is continued, 
if the extracerebral disease is stable.  
In our cohort of patients treated with checkpoint inhibition first-line or later, in the sub-
group of patients with BRAFV60 mutated melanoma we found no differences in terms of 
OS when receiving first-line either BRAF and MEK inhibitors or nivolumab plus ipili-
mumab (p=0.085). Based on our results we cannot produce a definitive conclusion 
whether BRAFV600 mutated patients should be treated upfront with targeted or immu-
notherapy, as we did not include the patients that only received targeted therapy. How-
ever, results from trials evaluating systemic therapy in stage IV melanoma, showed a 





mutated melanoma.78 In BRAF wild-type patients, we saw no difference in OS when re-
ceiving nivolumab plus ipilimumab in first-line or later (p=0.996).  
 
7.6. Safety profile of immune checkpoint inhibitors and 
BRAF/MEK inhibitors 
Targeted and immunotherapies have different safety profiles. This aspect has not been 
extensively addressed in any of the publications generated by this thesis. Yet, we have 
presented data on the toxicity induced by PD-1 based immunotherapy in patients treated 
in our center and others, and a publication is in preparation addressing toxicity associ-
ated with BRAF/MEK inhibitors, particularly cardiovascular toxicity. 203  
Table 2 and Table 3 refer to the different toxicity in the most important clinical trials. 
Figure 4 and Figure 5 illustrate the potential mechanism associated with immune-re-
lated adverse events (irAE) and propose an algorithm to managing irAE. 204 In clinical 
trials, we see no significant differences between the toxicity from nivolumab and pem-
brolizumab, and choosing one or the other has more to do with the patients’ and treating 
physician preferences, and the frequency of the cycles – every 2 or 4 weeks for 
nivolumab, and every 3 or 6 weeks for pembrolizumab.  
For the combination of nivolumab plus ipilimumab versus nivolumab and ipilimumab 
alone, the differences are related not only to the frequency of the AE but also to their 
severity. The combination induces a higher percentage and more severe AE than both 
monotherapies isolated. 78 For ipilimumab, the onset of AE is normally between week 2 
and 8, but later onset of AE has been documented. The most frequent AE reported for 
PD-1 monotherapy was fatigue, and grade 3 and 4 AE are less common with PD-1 mon-
otherapy than with ipilimumab. With the combination of nivolumab plus ipilimumab, al-





were CTCAE grade 3 or higher. 90 These toxicities may develop earlier, and be apparent 
over a longer period of time. 205 
Regarding targeted therapy, the frequency of AE between the three combinations avail-
able is similar. 157 However, the type of AE is different, and this aspect is the one that 
frequently leads to choosing one or the other combination. Dabrafenib induces almost 
no photosensitivity compared to vemurafenib (41%). It also induces fewer kera-
toacanthomas and squamous cell carcinomas (7% versus 20-30%). Arthralgia (56%), 
fatigue (46%) and rash (41%) were commonly reported with vemurafenib treatment. 95 
On the other hand, pyrexia is the most common problem associated with dabrafenib 
treatment, with almost 50% of the patients reporting pyrexia that leads to treatment in-
terruption. 157 As for encorafenib plus binimetinib, the most frequent AE were gastro-
intestinal (28% to 40%). The cutaneous AE were manageable, and in a percentage be-
tween 3% to 13%, similar to dabrafenib plus trametinib and lower than for vemurafenib 
plus cobimetinib. 103 Finally, MEK inhibitors are associated with ophthalmological toxicity, 
which is a class effect and normally requires treatment delay. Patients with previous his-
tory of ophthalmological issues should be evaluated before treatment start. 206 
As always, patients’ collaboration is the backbone for a successful management of tox-
icity. A structured first appointment, experienced nurses and medical doctors, as well as 
a dedicated ambulatory support, is one of the reasons why CTACE grade 3 and 4 AE 






Figure 4: Mechanism of immune-related adverse events associated with immune check-
point inhibition 
The mechanisms of irAE associated with ICI depend on the type of ICI, i.e., anti-PD-1/PD-L1 or anti- CTLA-
4. CTLA-4 inhibitors are able to induce as T cell activation and proliferation, impaired CD4+CD25+ regulatory 
T cell (Treg cell) survival, and increased counts of type 17 T helper cells. CTLAS-4 inhibitors are also able 
to induce cross-reactivity between anti-tumor T cells and antigens on normal cells, as well as autoantibody 
production. PD-1 and PD-L1 inhibitors are able to reduce Treg cell survival and Treg cell inhibitory function. 
They also increase cytokine production. TCR, T cell receptor; TNF tumor necrosis factor. From Ramos-
Casals et al. 204 
who received combination immunotherapy (CTLA-4 
and PD-1 inhibitors) with fatal myocarditis had robust 
T!cell infiltration and clonal expansion with shared T!cell 
receptors in both the myocardium and the tumour60. 
In one of th  patients, a tenfold increase in expression 
of PD- L1 was demonstrated in affected cardiac tissue 
compared with non- diseased muscle tissue60.
B cell- mediated autoantibody production
Owing to increased T!cell activation with ICIs, aug-
mented T!cell–B cell interactions can result in autoan-
tibody production. Indeed, interactions between 
follicular T!cells and B cells in germinal centres are vital 
for humoral immunity and abnormal interactions have 
been associated with autoimmunity61. The production 
of autoantibodies in mouse models of anti- CTLA-
4- induced irAEs is common62. Indeed, wild- type mice 
administered with repeated injections of anti- CTLA-4 
antibodies develop anti- pituitary antibodies, and hypo-
physitis (inflammation of the pituitary gland) is an irAE 
commonly observed with ipilimumab but not with PD-1 
and PD- L1 inhibitors62. Further evidence supporting a 
potential role for B cells in immunotoxicity comes from 
recent data showing that patients treated with ICIs had 
B cell changes after a single dose, including reduced 
numbers of circulating B cells and increased numbers 
of CD21low B cells and plasmablasts. These early changes 
were strong predictors of subsequent irAEs63.
The detection of autoantibodies during an adverse 
event would support an immune- mediated aetiology 
and could assist in guiding specific therapeutic interven-
tion. To this end, several autoantibodies have been iden-
tified in some patients with specific irAEs, although their 
































Fig. 2 | Mechanism of immune-related adverse events. The mechanisms of immune- related adverse events owing to 
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Figure 5: Proposed therapeutic algorithm for the management of immune related ad-
verse events  
The first-line therapy for patients who develop irAE while receiving treatment with ICI is glucocorticoids, 
except for adverse events affecting the endocrine system. Other therapies can be considered for severe or 
refractory cases, including other immunosuppressive therapies, intravenous immunoglobulin, plasma ex-
change and monoclonal antibodies. These therapeutic suggestions are based on official guidelines, retro-
spective analysis, published case reports, and the authors personal experience. 
a) Avoid etanercept owing to the risk of autoimmune inflammatory colitis. b) Consider abatacept or 
alemtuzumab. c) Consider infliximab or tocilizumab. AIHA/ITP, autoimmune hemolytic anemia/immune 
thrombocytopenic purpura; ILD, interstitial lung disease; SAD, systemic autoimmune diseases; TNF, tumor 
necrosis factor. From Ramos-Casals et al. 204 
 
  
inhibitors and increased survival, providing clinically 
feasible strategies to dissociate efficacy and toxicity in 
human trials177. Before administering TNF inhibitors, 
tests to identify infectious disease, such as a tuberculo-
sis spot test, should be performed as TNF inhibitors can 
increase the risk of reactivation of certain infections89,174.
Vedolizumab (a monoclonal antibody to the integrin 
!4"7 that inhibits the migration of T#cells into inflamed 
gastrointestinal mu osa) can be used instead of inflix-
imab for immune- related colitis178. The theoretical 
advantage of using vedolizumab is that the immunosup-
pression would be limited to the gastrointestinal tract 
and, therefore, spares the systemic immune suppression. 
In a retrospective study of patients refractory to ster-
oids (n = 19) and infliximab (n = 9) who received vedol-
izumab, 86% achieved a sustained clinical remission and 
54% achieved an endoscopic remission179.
Tocilizumab (an anti- IL-6 antibody) has been sug-
gested for the management of some steroid- refractory 
irAEs180. One study in patients with nivolumab- 
associated grades 3–4 irAEs (n = 34; predominantly 
pneumonitis, serum sickness and systemic inflammatory 
response syndrome or cerebritis) reported a clinical 
improvement in 80% of those who received tocilizumab, 
which, in most cases, required only 1–2 doses to cause 
clinical improvement181. Another study has reported 
the effective use of tocilizumab in three cases of severe 
polyarthritis56.
Other monoclonal antibodies have also shown some 
promise for the treatment of some steroid- refractory 
irAEs. R tuximab has shown efficacy for the treat ent 
of glucocorticoid- refractory cases of severe enceph-
alitis182, autoimmune cytopenias183 or severe bullous 
skin disease184. In addition, two cases of successful 
response to abatacept185 or alemtuzumab186 have been 
reported in patients with steroid- refractory autoimmune 
myocarditis.
Despite the benefits of monoclonal antibodies for the 
treatment of steroid- refractory irAEs, they are associated 
with specific adverse effects that may preclude their use 
for some irAEs (FIG.!5). For example, anti- TNF antibodies 
should be used with caution for treating pneumonitis 
because there is a risk of exacerbating interstitial lung 









































































Fig. 5 | Suggested therapeutic algorithm for the organ-by-organ management of irAEs.9JGPCU[UVGOKEVJGTCR[KU
considered in patients presenting with immune- related adverse events (irAEs) owing to immune checkpoint inhibitors,  
the first- line treatment is glucocorticoids with an exception for adverse events that affect the endocrine syste . Other 
VJGTCRKGUVQDGEQPUKFGTGFKPUGXGTGTGHTCEVQT[ECUGUFGRGPFQPVJGCHHGEVGFQTICPU[UVGODWVECPKPENWFGU[PVJGVKE
immunosuppressants, intravenous immunoglobulin, plasma exchange and monoclonal antibodies. These therapeutic 
suggestions are based on recommendations included in official guidelines, data from some retrospective studies, isolated 
published cases and personal experience of the authors. aAvoid etanercept owing to the risk of autoimmune inflammatory 
colitis. bConsider abatacept or alemtuzumab. c%QPUKFGTKPHNKZKOCDQTVQEKNK\WOCD#+*#+62CWVQKOOWPGJCGOQN[VKE
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8. Limitations and conclusions 
The limitations of this study were extensively described and discussed in the respective 
publications. They include the observational nature of the data, the absence of a popu-
lation-based sample, the potential referral bias to the centers from which patients were 
included, the monocentric analysis in three publications, and the potentially limited fol-
low-up time.  
Nonetheless, we provided insights on patterns of care in distinctive centers in Germany, 
that might be different from those in other European countries, namely Portugal. This 
can be explained by the earlier availability of the new systemic therapies, compared to 
other countries, and the elevated number of German patients included in clinical trials. 
By using observational data, we were able to inform on the reproducibility of clinical trials’ 
survival data in a real-world setting. Observational data can further advise on the best 
strategy to be used in the design of future clinical trials.  
Finally, we highlighted the need of having a well-designed and continuously updated 
population-based and therapy-based registry. Data derived from such registries enable 
clinicians and investigators to examine regional and international differences with an ed-
ucated opinion on the potential causes of these disparities, and facilitate discussions on 
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